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Small cell lung cancer (SCLC) is a highly aggressive malignancy with extreme 
mortality and morbidity. Although initially chemo- and radio-sensitive, almost 
inevitable recurrence and resistance occurs. SCLC patients often present with 
metastases, making surgery not feasible. Current therapies, rationally designed on 
underlying pathogenesis, produce in vitro results, however, these have failed to 
translate into satisfactory clinical outcomes. Recently, research into cancer stem cells 
(CSCs) has gained momentum and form an attractive target for novel therapies. 
Based on this concept, CSCs are the cause of neoplastic tissue development that are 
inherently resistant to chemotherapy, explaining why conventional therapies can 
shrink the tumour but are unable to eliminate the tumour completely, leading to 
eventual recurrence. 
 
Here I demonstrate that SCLC H345 and H69 cell lines contain a subset of cells 
expressing CD133, a known CSC marker. CD133+ SCLC sub-population maintained 
their stem cell-like phenotype over a prolonged period of culture, differentiated in 
appropriate conditions and expressed the embryonic stem cell marker Oct-4 
indicating their stem-like phenotype. Additionally, these cells displayed augmented 
clonogenic efficacy, were chemoresistant and tumorigenic in vivo, distinct from the 
CD133- cells. Thus, the SCLC CD133 expressing cells fulfil most criteria of CSC-
like definition. 
 
The molecular mechanisms associated with CD133+ SCLC chemoresistance and 
growth is unknown. Up-regulated Akt activity, a known promoter of resistance with 
survival advantage, was observed in CD133+ SCLC cells. Likewise, these cells 
demonstrated elevated expression of Bcl-2, an anti-apoptotic protein compared to 
their negative counterpart explaining CD133+ cell chemoresistance phenotype. 
Additionally, CD133+ cells revealed greater expression of neuropeptide receptors, 
gastrin releasing peptide (GRP) and V1A receptors compared to the CD133- cells. 
III 
 
Addition of exogenous GRP and arginine vasopressin (AVP) to CD133+ SCLC cells 
promoted their clonogenic growth in semi-solid medium, illustrating for the first time 
neuropeptide dependent growth of these cells.  
 
A novel peptide (peptide-1) was designed based on the known structure of the 
substance P analogues that have shown benefit in animal models and in early clinical 
trials. This compound inhibited the growth of SCLC cells in in vitro with improved 
potency and stability compared to previous analogues and reduced tumorigenicity in 
vivo. Interestingly, peptide-1 was more effective in CD133+ cells due to increased 
expression of neuropeptide receptors on these cells.  
 
In conclusion, my results show that SCLC cells retain a sub-population of cells that 
demonstrate CSC-like phenotype. Preferential activation of Akt and Bcl-2 survival 
pathways and enhanced expression of neuropeptide receptors contribute to CD133+ 
SCLC chemoresistance and growth. Therefore, it can be proposed that CD133+ cells 
are the possible cause of SCLC development, treatment resistance and disease 
recurrence. Despite being chemoresistant, CD133+ cells demonstrated sensitivity to 
peptide-1. The identification of such new analogue that demonstrates efficacy 
towards resistant CD133+ SCLC cells is a very exciting step forward in the 
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Figure 1: Stem cell hierarchy model  
Stem cells via asymmetrical division can self-renew and generate 
progenitor cells. Progenitor cells have limited proliferation potential 
and ultimately divide into terminally differentiated cells. 
Self-renew 
Tumour type CSC marker % of tumour cells 




CD44+ CD24-/low 11-35 
ALDH1+ 3-10 
19-29 CD133 




EpCAM+ CD44+ 0.03-38 
Lung CD133 0.32-22 
Melanoma ABCB5 1.6-20 
ALDH, aldehyde dehydrogenase; CSC, cancer stem cell; EpCAM, epithelial cell 
adhesion molecule, HCC, hepatocellular carcinoma. Data obtained from [73]. 
HCC CD133 1-32 
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Figure 2: Membrane topology of CD133 
CD133 is predicted to consist of an 85 aa N-terminal extracellular 
domain, five transmembrane domains (TM 1-5) with two large 
glycosylated extracellular loops containing 255 aa and 290 aa, and 
two small cytoplasmic loops, both containing 30 aa and an 50 aa C-
terminal domain. Potential glycosylation sites are indicated as  
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Figure 3A: Schematic representation of GPCR 
GPCR receptor consists of a single polypeptide chain containing 7 
hydrophobic α-halicase creating 7 TM (TM1-7) domains, three 
extracellular loops (Exloop) and four cytoplasmic loops (Cyloop). The 
receptor contains an extracellular N-terminal and an intracellular C-
terminal. 
Figure 3B: Ternary complex model of GPCR activation 
GPCRs exists in an equilibrium between active (R*) and inactive (R) 
state. Binding of an agonist (A) stabilises R* stimulating interaction 
with G-proteins (G) whereas binding of an antagonist (Ant) stabilises 











Figure 4: Schematic representation of the activation of G-proteins 
via activated GPCRs 
(A) In the absence of agonist, the receptor favours no interaction with 
the G-proteins and the α-subunit contains bound GDP with α and βγ-
subunit association. (B) Binding of an agonist induces GPCRs 
conformational changes exposing residues to G-protein, therefore 
promoting G-protein receptor coupling. (C) Binding of activated 
GPCRs to G-proteins triggers exchange of GTP for GDP with α and βγ 
subunit dissociation. (D) The intrinsic hydrolyte activity of α-subunit 






























Figure 5: Neuropeptide analogue mediated signal transduction 
pathways  
See text for details and abbreviations. 
Substance P analogue 
% of growth inhibition 
at 25 µM 
Table 3: Structure and the inhibitory affect of substance P 
analogues on the growth of H69 SCLC cells in liquid culture on 














(a) Substance P 
(b) SP-G 
(c) SP-D  
(d) SP-A 
 
Cell lines IC50 (µM) 
Table 4: Growth inhibitory by SP-G (IC50) in a panel of cell lines 
(adapted from [65]). 
H69 (SCLC)   10.5 
H510 (SCLC)   29    
W X330 (SCLC)  42 
NX002 (NSCLC)  33.5 
HT29 (Colorectal)  18 
HRT18 (Colorectal)  37 
HCT116 (Colorectal)  129 
PEO4 (Ovarian)  31 
PANC1 (Pancreatic)  58 
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R*2 R R*1 
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Gα12 Gαq 
Figure 6: Biased agonist theory for receptor activation by 
neuropeptide antagonists 
Adapted from [223] 
A receptor is in an equilibrium of two or more active conformation 
states (R*1 and R*2) and one more energetically inactive state R. R*1, 
represents conformation state of GPCR that activates Gαq and R*2, 
represents conformation state of GPCR that activates Gα12. Upon 
binding of an agonist (A), both active state of the receptor is stabilised. 
An antagonist (AA) binds to all three states competing with the 
agonist. This interaction may or may not stabilise the active state. If 
the binding of the antagonist stabilises the active state of the receptor it 
is termed as partial agonist. Binding of an inverse agonist (IA) 
stabilises the inactive state of the receptor. A biased agonist (BA) 
preferentially binds to one of the active state and stabilises it, therefore 
activates one set of signal transduction events without activating 
others. 
Table 5:  Characteristics of H345 and H69 cell lines 
Cell line H345 H69 
Sex 
Prior Treatment  
Source  
M M 
Chemotherapy  Chemotherapy  
BM PE  
Class  C C 
DDC u/mg  
CK-BB /mg  
98 240 
2.2 5.8 
NSE ng/mg  817 4075 
BLI pmol/mg  1.7 4.7 
Abbreviations: PE, pleural effusion; BM, bone marrow; C, classical; DDC, L-dopa 
decarboxylase (elevated > 1.0 u/mg; CK-BB, creatine kinase brain isoenzyme 
(elevated > 0.4 g/mg); NSE, neurone specific enolase (elevated > 100 ng/mg); 
BLI, bombesin-like immunoreactivity (elevated > 0.1 pmol/mg). 
Figure 7: Representative images of H345 cells stained EB/AO for 
detection of apoptotic cells 
(A) SCLC cells cultured in SITA medium for 72 hours. (B) SCLC cells 
cultured in SITA medium plus etoposide 100 g/ml for 72 hours. 1l of 
ethidium bromide (1mg/ml) and 1l acridine orange (1mg/ml) was added 
to the wells, and the cells were viewed by fluorescent microscopy. 
Apoptotic cells are small and either green (early apoptosis) or orange 




Figure 8: Representative images of H345 cells stained May-
Grunwald-Giemsa for detection of apoptotic cells 
(A and A1) SCLC cells cultured in SITA for 72 hours. (B and B1) SCLC 
cells cultured in SITA plus etoposide 100 g/ml for 72 hours. Cells were 
cytocentrifuge onto glass cover slips, air dried, and fixed in methanol for 
2 minutes and stained with May-Grunwald-Giemsa. Cell morphology 
was examined using light microscopy. Apoptotic cells were shrunken 
cells with dense nuclei. (   ) represents apoptotic cell. Images A and B 
were taken with 10× magnification and images A1 and A2 were taken 
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Figure 9: Schematic figure of S9 liver preparation 
Livers from female C57BL/6 mice were removed and washed twice 
with cold potassium phosphate buffer 0.1 M. Liver tissue was 
homogenised using a glass Teflon homogeniser in the buffer to give a 
final homogenate consisting of 25% w/v tissue. Samples were spun at 
9000 × g for 20 minutes at 4°C and the supernatant was stored on ice. 
The stability of SP-G and peptide-1 was assessed in the S9 liver preps 
at 37°C and data was analysed using HPLC. The HPLC presented is a 
representative figure, demonstrating the degradation of parent peptide-




Figure 10: SCLC cell line characteristics 
(A) SCLC cells grow as cellular aggregates in tissue culture. Images 
were taken with 20× magnification with light microscope. (B) H345 
and H69 cells were treated with etoposide (1-100 µg/ml). After 72 
hours, MTT was added and cell viability was determined. Data 
represents the mean ± SEM of three independent experiments 
performed in triplicates. (C) Cells were cultured in SITA medium 
containing 0.3 % agarose and were layered over a semi-solid base of 
0.5% agarose. After 21 days colonies (>16 cells) were counted using 
light microscope. Results are expressed as percentage of number of 
cells seeded. Data represents the mean of three independent 
























































 Figure 11: SCLC cell lines express stem cell markers 
 (A) Expression of CD133 and Oct-4 proteins demonstrated by western 
blot. A band of ~120 kDa and ~48 kDa represents CD133 and Oct-4 
protein expression, respectively. β-actin was used as loading control. 
Images are representative of three independent experiments. (B and C) 
ALDH enzyme activity was measured by ALDEFLUOR® kit and data 
was analyzed by flow cytometry. See text for more details. Cells treated 
with DEAB were used as negative control and ALDH activity was 
calculated relative to negative control. B1 and C1, represents histograms 
of H345 and H69 cells stained with Aldefluor in the presence of DEAB, 
respectively. B2 and C2 represents histograms of H345 and H69 cells 
stained with Aldefluor in the absence of DEAB, respectively. B3 and C3 
are overlay histograms of H345 and H69 cells in the presence (dashed 
histogram) and absence (grey histogram) of DEAB respectively. Data is 
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Figure 12: ALDEFLUOR assay schematic 
ALDEFLUOR® is used to identify cells with elevated ALDH1 
activity. The Fluorescent ALDH-substrate, BODIPY-
aminoacetaldehyde (BAAA) freely diffuses into cells. In the presence 
of ALDH enzyme, BAAA converts to BODIPY-aminoacetate (BAA) 
which is negatively charged and is therefore, retained in the cells. 
Additionally the Aldefluor buffer provided with the kit also contains 
ABC transporter inhibitors further blocking BAA efflux from the cells. 
 The degree of fluorescent ALDH reaction produced directly correlated 
with the amount of ALDH activity. DEAB is an ALDH inhibitor, thus 
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Figure 13: CD133-1 expressing H345 cells are positive for CD133-2 
H345 cells were stained with monoclonal antibodies CD133-1-APC 
and/or CD133-2-PE. Cells stained with APC-conjugated and/or PE-
conjugated isotype-matched mouse IgG were used as negative control. 
A1 demonstrates expression of CD133-1 according to its negative 
control, A. B1 displays expression of CD133-2 according to its 
negative control, B. C1 demonstrates co-expression of CD133-1 and 
CD133-2 on H345 according to its negative control, C. As shown, all 
H345 cells positive for CD133-1 are positive for CD133-2. Data is 
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Figure 14: CD133-1 expressing H69 cells are positive for CD133-2 
H69 cells were stained with monoclonal antibodies CD133-1-APC 
and/or CD133-2-PE. Cells stained with APC-conjugated and/or PE-
conjugated isotype-matched mouse IgG were used as negative control. 
A1 demonstrates expression of CD133-1 according to its negative 
control, A. B1 displays expression of CD133-2 according to its 
negative control, B. C1 demonstrates co-expression of CD133-1 and 
CD133-2 on H69 according to its negative control, C. As shown, all 
H69 cells positive for CD133-1 are positive for CD133-2. Data is 















Figure 15: Flow cytometric analysis of CD133 expression on H345 
and H69 cells 
Cells were stained with CD133-1-APC monoclonal antibody and were 
analysed by flow cytometry. Cells stained with APC-conjugated, 
isotype-matched mouse IgG were used as isotype control. Percentage 
of CD133+ cells were calculated relative to isotype control. CD133 
expression demonstrated a gaussian expression pattern on H345 and 
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 Figure 16: H345 CD133+ and CD133- cells isolated by MicroBeads 
kit demonstrated poor purity as analysed by flow cytometry 
 The purity of CD133+ and CD133- isolated cells using MicroBeads kit 
was analysed based on CD133-2 expression by flow cytometry. A1 
represents CD133 expression on the negatively selected population. 
A2 represents CD133 expression on the positively selected population. 
A3 is an overlay histogram demonstrating CD133-2 expression on 
CD133+ and CD133- isolated populations with their respective isotype 
controls. As shown in the figure, no difference in the fluorescent 
intensity between the two populations could be observed, indicating 
CD133 MicroBead Kit did not select a pure populations. Data is 























Figure 17: Schematic image of fluorescent activated cell sorting 
Labelled cell suspension is directed into a thin stream of fluid which 
leads the cells to pass in a single file. The stream merges from a 
vibrating nozzle, breaking the stream into discrete droplets. A laser 
beam is directed at the stream and the scattered light and emitted 
fluorescence is captured by a number of detectors. The signals 
captured by the detectors are then processed by analysing the 
fluctuation in brightness at each detector which then allow to obtain 
various information regarding the cell of interest. If the signals from 
the detectors match the criteria set for size, shape and fluorescence, a 
positive or negative electrical charge is given to the fluidic stream. 
The stream of droplets is then directed through a pair of charged 
plates so that the charged droplets containing cells are deflected and 
collected. 
Electromagnets 
Figure 18: Fluorescent activated cell sorting in H345 cells 
(A) Based on the forward and side scatter distribution of H345 cells, two 
populations were detected, population-1 and population-2. The viability of 
cells within the population-1 (B1) and -2 (B2) was evaluated based on PI 
exclusion. In contrast to population-1, most cells within population-2 were 
viable. (C) Single cells within the population-2 were selected by their 
Height (FSC-H) and FSC-Area (FSC-A) distribution. (D) After single cell 
selection within the population-2, viable cells within that population were 
gated based on PI exclusion. (E) demonstrates CD133 distribution on 
single, viable cells within population-2. Dashed histogram represents 
isotype control and gray histogram presents CD133 expression. Since 
CD133 exhibits a Gaussian expression pattern, the top ~7% of the cells 
with high expression of CD133 and the bottom ~7% of the cells with 

































 Figure 19: CD133+ and CD133- H345 cells isolated by fluorescent 
activated cell sorting are pure  
  A1 represents CD133-1 expression on the parent cells relative to isotype 
control. A2 is an overlay histogram of CD133-1 expression on CD133- 
and CD133+ cells. A3 is an overlay histogram of CD133-1 expression on 
the parent, CD133- and CD133+ cells. CD133+ cells exhibited the 
highest geometric mean (GM) while CD133- cells demonstrated the 
lowest GM indicating CD133+ cells have greater expression levels of 
CD133-1 compared to CD133- and parent cell, therefore pure and 
enriched isolation. B1 exhibits CD133-2 expression on the parent cells 
relative to isotype control. B2 is an overlay histogram of CD133-2 
expression on CD133- and CD133+ populations. B3 is an overlay 
histogram of CD133-2 expression on the parent, CD133- and CD133+ 
cells. Likewise, isolated CD133+ cells demonstrated the highest GM in 
while CD133- showed the lowest GM, further supporting the purity of 
cell isolation. Data are representative of three independent experiments. 
CD133-1 
Parent CD133- CD133+ Parent CD133- CD133+ 
A1 A2 A3 
Parent CD133- CD133+ Parent CD133- CD133+ 
B1 B2 B3 
CD133-2 
Figure 20: Purity of FACS sorted CD133+ and CD133- H345 cells 
was confirmed by western blot 
The purity of sorted populations was analysed by CD133 protein levels 
in the sorted and parent cells by western blot. No band could be detected 
in CD133- isolated cells, whereas a band of ~120 kDa was 
representative of CD133 expression in the CD133+ isolated and parent 
cells confirming sort purity. β-actin was used as loading control. Images 
are representative of three independent experiments. 
CD133 
β-actin 
- + P 
H69 H345 
- + P 
CD133+ 
CD133- 
Figure 21: CD133+ and CD133- cells are similar in cellular size and 
illustrate similar tissue culture appearance 
(A) The size of CD133+ and CD133- H345 cells were compared based 
on their Forward Scatter distribution (FSC) on flow cytometer. As 
shown, CD133+ and CD133- are similar in size. (B) Three days post-
sorted cells cultured in SITA were cytocentrifuged onto glass cover 
slips and were stained with May-Grunwald-Giemsa. Isolated cells from 
both cell lines demonstrated similar morphology judged by light 
microscopy. (C) Tissue culture appearance of three days post-sorted 
cells cultured in SITA medium were observed under light microscopy. 
In both cell lines, CD133+ and  CD133- cells grew as floating 
aggregates with no differences in the shape or size of the cellular 
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Figure 22: FACS does not effect the cell viability of isolated cells 
The viability of sorted and unsorted H345 and H69 cells was measured by 
staining isolated cells with May-Grunwald-Giemsa and Ethidium 
bromide/acridine orange (EB/AO). A is a representative image of cells 
stained with May-Grunwald-Giemsa. Apoptotic cells appeared as shrunken 
cells with dense nuclei. B is a representative image of cells stained with 
EB/AO in which cells can be distinguished based on their nuclear 
morphology and fluorescence (viable cells, green nucleus, late apoptotic 
cells, shrunken cells with orange nucleus). No significant differences 
between the viability of sorted and parent H345 and H69 cells stained with 
either May-Grunwald-Giemsa (C1 and C2) or EB/AO (D1 and D2) could 





















































































Figure 23: CD133+ are more proliferative than CD133- cells 
Proliferation of sorted CD133+ and CD133- cells was evaluated by 
culturing 1 × 104 sorted cells/well in SITA medium and counting the 
viable cells by NucleoCounter NC-100 every two days over 24 days. In 
both H345 (A) and in H69 (B) cell lines, CD133+ cells were 
significantly more proliferative than CD133- cells. Data represents the 
mean ± SEM of three independent experiments performed in 











Figure 24: CD133+ cells are clonogenic 
Cells were cultured in SITA medium containing 0.3% agarose and 
were layered on the same medium containing 0.5% agarose. Colonies 
(>16 cells) formed were scored after 21 days using standard light 
microscopy. Data is presented as percentage of the cells seeded 
(cloning efficiency). A, is a representative image of tissue culture dish 
containing CD133-, CD133+, and parent H345 cells in semi-solid 
medium after 21 days post-culturing. In contrast to the wells 
containing CD133+ and parent cells, no colonies within the well 
containing CD133- cells could be detected. In both H345 (B) and 
H69 (C) cells, CD133+ cells were more clonogenic than the CD133- 
and parent cells. Data represents the mean of three independent 
experiments ± SEM. (* P=0.04 and **, P=0.006). 
* 
** 
A CD133- Parent CD133+ 


































Figure 25: CD133+ cells are a heterogeneous population  
To examine the heterogeneity within the CD133+ cells, H345 
(unsorted) cells were evaluated for CD133-1 expression (A and A1), 
ALDH activity (B and B1), and co-expression of both markers (C and 
C1). Low percentage of cells co-expressing CD133 and ALDH 
indicates, CD133+ cells are a heterogeneous population of cells 
comprising of CD133+ ALDH+ and CD133+ ALDH- cells. Data is 
representative of three independent experiments. D, is a schematic 















































Figure 26: CD133+ cells express embryonic stem cell marker Oct-4 
The presence of Oct-4 in the sorted and unsorted cells was examined by 
evaluating their protein levels by western blotting. A protein band of 
~48 kDa in both CD133+ and parent cells indicated the presence of Oct-
4 whereas no band could be detected in the CD133- cell lysates. β-actin 
was used as loading control. (-) represents CD133- cells, (+) represents 
CD133+ cells and (P) represents parent cells. Image is representative of 










Figure 27: CD133+ cells maintain CD133 expression during 
prolonged periods of culturing 
Sorted and unsorted H345 cells were cultured in serum-free SITA 
medium and the expression of CD133-2 was evaluated on day 0 (day 
when cells were cultured) and 30 days post-culture by flow cytometry. 
Data presented is a representative flow cytometry histogram showing the 
expression of CD133 on the parent (A1, day 0 and B1, day 30), CD133- 
(A2, day 0 and B2, day 30) and CD133+ cells (A3, day 0 and B3, day 
30). In each histogram, CD133 expression was compared with its 
corresponding isotype control. Histograms A4 and B4 are overlay 
histograms of CD133-, CD133+ and parent cells on day 0 and on day 30 
respectively. CD133+ cells demonstrated the highest GM compared to 
CD133- and parent cells on day 0 and day 30. Therefore, CD133+ were 
able to maintained the expression of the stem cell marker, CD133 during 
the prolonged periods of culturing. Data is representative of five 
independent experiments. 
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Figure 28: CD133+ cells maintain their high clonogenic potential 
over prolonged periods of culturing 
To confirm CD133+ H345 cells retain their stem cell-like features over 
long periods of culturing, the clonogenicity of 30 days post-sorted 
CD133+, CD133-, and parent H345 cells was evaluated in semi-solid 
medium. Sorted cells were cultured for 30 days in SITA medium. After 
this period 104 cells were transferred into SITA medium containing 0.3% 
agarose and were layered on the same medium containing 0.5% agarose. 
SITA medium was used to inhibit possible cellular differentiation. 
Colonies were scored after 21 days using standard light microscopy. Data 
is presented as cloning efficiency. Despite long periods of culturing, 
CD133+ cells retained their clonogenic potential and were more 
clonogenic than CD133- and parent cells indicating that CD133+ cells 
are possibly capable of self-renewing. CD133- did not form colonies. 
Data represents the mean of five independent experiments ± SEM. (**, 
P=0.006) 
Day 0 
A1       Parent A2      CD133- A3      CD133+ 
Day 30 
B1        Parent B2       CD133- B3      CD133+ 
CD133-2 
CD133-2 
Figure 29: CD133+ cells differentiate in appropriate culture 
condition 
Sorted H345 cells were cultured in serum containing medium (RPMI 
complete medium) and the expression of CD133 was evaluated on day 0 
(day when cells were cultured) and 30 days post-culture by flow 
cytometry. Data presented is a representative flow cytometry histogram 
showing the expression of CD133 on the parent (A1, day 0 and B1, day 
30), CD133- (A2, day 0 and B2, day 30) and CD133+ cells (A3, day 0 
and B3, day 30). In each histogram, CD133 expression was compared 
with its corresponding isotype control. Histograms A4 and B4 are overlay 
histograms of CD133-, CD133+ and parent cells on day 0 and on day 30, 
respectively. In serum-containing medium CD133+ cells differentiated to 
generate a heterogeneous population similar to parent cells. Data is 
representative of five independent experiments.  
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Figure 30: CD133+ cells on differentiation lose their stem cell-like 
phenotype 
The proliferation and clonogenicity of differentiated CD133+ cells were 
evaluated in serum containing liquid culture and semi-solid medium 
respectively. (A) Sorted H345 cells were cultured in in RPMI complete 
medium for 30 days. After this period, 1 × 104 cells/well were transferred 
into fresh RPMI complete medium and the number of viable cells was 
counted every 2 days by NucleoCounter NC-100 over 24 days. 
Differentiated CD133+ cells grew at the same rate as the CD133- cells 
with no significant difference in their growth potentials. (B) 104 viable 
cells which were previously cultured for 30 days in RPMI complete 
medium were transferred into fresh differentiating medium containing 
0.3% agarose and were layered on the same medium containing 0.5% 
agarose. Colonies were scored after 21 days using standard light 
microscopy. Data is presented as cloning efficiency. CD133+ 
differentiated cells demonstrated similar clonogenicity as the parent cells. 
Data represents the mean of five independent experiments ± SEM.  
A 
B 
Figure 31: CD133+ cells are tumorigenic in vivo  
Various cell numbers (5 × 105, 1 × 105, and 1 × 104) of sorted CD133+ and 
CD133- H345 cells in growth factor reduced Matrigel (1:1 volume of 
cells:Matrigel mixed at 4ºC, total volume of 100 µl) were implanted 
subcutaneously in contralateral flanks of the nude/nude mice (n=4). Same 
numbers of unsorted H345 cells under the same conditions were implanted 
subcutaneously in the right flank of nude/nude mice (n=4). Tumour size 
was assessed with callipers every 3-4 days. (A) CD133+ cells were 
significantly more tumorigenic than CD133- and parent cells. B, is a 
representative H and E staining of sections taken from tumours developed 
from injecting CD133+ and parent cells. CD133+ cells consistently 
generated tumours with histological features closely resembling the 
tumours initiated by parent cells. Images were taken with 10× 
magnification. C, is a representative image of mice with subcutaneous 
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Figure 32: Mice injected with CD133+ cells exhibit enlarged inguinal 
and axillary lymph nodes  
(A) Representative image of a control nude/nude mouse axillary (AX) 
lymph node. Mice lymph nodes are small and difficult to identify in 
physiological conditions. (B) Image of axillary lymph node in nude/nude 
mouse that was subject to CD133+ cell implantation. 
AX 
NCAM CD45 
Figure 33: IHC staining of CD133+ primary tumour  
Primary tumour (directly generated by implantation of CD133+ cells in 
mouse) was subject to IHC for detection of NCAM+ cells (representative 
of SCLC cells) and CD45+ cells (representative of mouse leukocyte 
cells). Sample was visualised using Tyramide signal amplification (TSA) 
plus fluorescent kit (NCAM, green; CD45, red) as described in materials 
and methods. DAPI (0.1 µg/ml) was added to stain the nuclei. Sections 
were mounted with PermaFluor Aqueous Mounting Medium. Samples 
were analysed by Confocal microscopy. (A) Almost all cells within the 
primary tumour were NCAM+. Some CD45+ NCAM- cells could be 
detected on the border of the tumour. Image was taken by 4× 
magnification. B, is a magnified image of the tumour region presenting 
DAPI staining. C, is a magnified image of the tumour region presenting 
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Figure 34: IHC staining of inguinal and axillary lymph nodes excised 
from nude/nude mouse with subcutaneous implantation of CD133+ 
cells 
The four lymph nodes presented were excised from the inguinal and 
axillary regions of a mouse subject to CD133+ implantation. Lymph 
nodes were subject to IHC for detection of NCAM+ cells (representative 
of SCLC cells) and CD45+ cells (representative of mouse leukocyte 
cells). Sample was visualised using Tyramide signal amplification (TSA) 
plus fluorescent kit (NCAM, green; CD45, red) as described in materials 
and methods. DAPI (0.1 µg/ml) was added to stain the nuclei. Sections 
were mounted with PermaFluor Aqueous Mounting Medium. Samples 
were analysed by Confocal microscopy. (A) Almost all cells within the 
lymph nodes were CD45+. Few NCAM+ CD45- cells were also detected 
within all four lymph nodes. Image was taken by 4× magnification. B, is 
a magnified image of the lymph node region presenting DAPI staining. 
C, is a magnified image of the lymph node region presenting CD45 and 





Figure 35: IHC staining of spleen from nude/nude mouse unexposed 
to human SCLC cells 
Control nude/nude mouse spleen was subject to IHC for identification of 
NCAM+ cells (representative of SCLC cells) and CD45+ cells 
(representative of mouse leukocyte cells). Sample was visualised using 
Tyramide signal amplification (TSA) plus fluorescent kit (NCAM, green; 
CD45, red) as described in materials and methods. DAPI (0.1 µg/ml) was 
added to stain the nuclei. Sections were mounted with PermaFluor 
Aqueous Mounting Medium. Samples were analysed by Confocal 
microscopy. (A) Almost all cells within the spleen were CD45+. Some 
NCAM+ CD45- cells could be detected. Image was taken by 4× 
magnification. B, is a magnified image of the spleen region presenting 
DAPI staining. C, is a magnified image of the spleen region presenting 



























Figure 36: CD133+ cells are enriched by therapy due to their 
resistant phenotype 
Unsorted (parent) H345 and H69 were treated with 3 or 30 µg/ml 
etoposide for 72 hours. After this period, the percentage of CD133+ cells 
was assessed  by flow cytometry. Untreated cells were used as control. In 
both H345 (A) and H69 (B) cells, increasing concentration of etoposide 
was associated with greater enrichment of CD133+ cells. Data represents  
the mean of three independent experiments ± SEM. To confirm the 
resistant phenotype of CD133+ cells, cells were treated with increasing 
concentration (1-100 µg/ml) of etoposide and cell viability was 
determined after 72 hours by MTT assay. Untreated cells were used as 
control, and data is presented as percentage of control. In both H345 (C) 
and H69 (D) cells, CD133+ cells were most resistant to etoposide 
compared to CD133- and parent cells. Data represents the mean of three 


















































16.97 ± 1.2 
20.18 ± 2.2 




22.34 ± 1 
28.98 ± 3.1  
35.78 ± 1.7 
Table 6: Percentage of CD133+ cells in SCLC cell lines following 
etoposide treatment 
Data represents the mean of three independent experiments ± SEM. 
A1  CD133+ A2  CD133- 
B1  CD133+ B2  CD133- 
Figure 37: Representative images of CD133+ and  CD133- H345 cells 
treated with etoposide and stained with May-Grunwald-Giemsa and 
EB/AO for detection of apoptotic cells 
Sorted CD133+ and CD133- H345 cells were exposed to 30 µg/ml 
etoposide for 72 hours. After this period, the percentage of apoptosis by 
May-Grunwald-Giemsa and EB/AO staining method was calculated. A1 
and A2 represent samples stained with May-Grunwald-Giemsa. 
Apoptotic cells appeared as shrunken cells with dense nuclei analysed by 
light microscopy. B1 and B2 represent samples stained with EB/AO in 
which apoptotic cells were shrunken cells with green nucleus (early 
apoptotic) or shrunken cells with orange nucleus (late apoptotic cells) 
analysed by fluorescent microscopy. In both staining method, CD133+ 
cells were significantly more resistant to etoposide treatment than 
CD133- cells. (   ) represents apoptotic cells. Images were taken with 20× 
magnification. 
Etoposide concentration (µg/ml) 

























Figure 38: CD133+ H345 cells are resistant to apoptosis induced by 
etoposide 
Sorted CD133+ and CD133- H345 cells were exposed to three different 
concentrations of etoposide (3, 10, and 30 µg/ml) for 72 hours. After this 
period, the percentage of apoptosis by May-Grunwald-Giemsa and 
EB/AO staining was calculated. In both May-Grunwald-Giemsa (A) or 
EB/AO staining (B), CD133+ cells were significantly more resistant to 
etoposide treatment than CD133- cells. Data represents the mean of three 















10.37 ± 1.6 
12.48 ± 0.6 




11.1 ± 1.57 
20.52 ± 1.36 
31.3 ± 1.66 
Table 7A: Percentage of apoptosis induced by etoposide in CD133+ 
and CD133- H345 cells measured by May-Grunwald-Giemsa 
staining  
30 23.3 ± 1.3 
30 38.63 ± 2.9 






15.76 ± 2.54 
17.11 ± 1.59 




16.13 ± 2.17 
27.77 ± 2.72 
36.29 ± 3.07 
Table 7B: Percentage of apoptosis induced by etoposide in CD133+ 
and CD133- H345 cells measured by EB/AO staining  
 
30 26.86 ± 2.3 
30 45.9 ± 3.47 
Data represents the mean of three independent experiments ± SEM. 
Data represents the mean of three independent experiments ± SEM. 
Etoposide concentration (µg/ml) 

























Figure 39: CD133+ H69 cells are resistant to apoptosis induced by 
etoposide 
Sorted CD133+ and CD133- H69 cells were exposed to three different 
concentrations of etoposide (3, 10, and 30 µg/ml) for 72 hours. After this 
period, the percentage of apoptosis by May-Grunwald-Giemsa and 
EB/AO staining was calculated. In both May-Grunwald-Giemsa (A) or 
EB/AO staining (B), CD133+ cells were significantly more resistant to 
etoposide treatment than CD133- cells. Data represents the mean of three 















12.31 ± 2.11 
12.91 ± 2.89 




12.28 ± 0.99 
25.26 ± 1.38 
39.75 ± 1.94 
30 30.25 ± 3.07 
30 52.09 ± 1.56 






20.32 ± 1.42 
21.74 ± 1.17 




18.18 ± 1.58 
28.8 ± 1.73 
42.02 ± 3.14 
30 42.28 ± 3.26 
30 58.72 ± 3.48 
Table 8A: Percentage of apoptosis induced by etoposide in CD133+ 
and CD133- H69 cells measured by May-Grunwald-Giemsa 
staining  
Table 8B: Percentage of apoptosis induced by etoposide in CD133+ 
and CD133- H69 cells measured by EB/AO staining  
 
Data represents the mean of three independent experiments ± SEM. 






CD133- CD133+ Parent 
Figure 40: CD133+ are resistant to apoptosis due to preferential 
expression of proteins involved in survival pathways 
Endogenous expression of activated Akt (phosphorylated at Ser473), or 
Bcl-2 proteins were evaluated in CD133+, CD133- and parent H345 cell 
lysates by western blotting. CD133+ cells demonstrated significantly 
elevated levels of pAktSer473and Bcl-2 compared to CD133- cells. 
Elevated expression of phosphoserine-specific Akt in CD133+ H345 
cells was not a result of an increase in total Akt protein levels. β-actin 
was used as a control for equal loading. Data is representative of three 
independent experiments. 
Control CD133 
Figure 41: Human SCLC tissue sections retain high levels of 
CD133+ cells 
The expression of CD133 was evaluated in primary SCLC tissues by 
IHC. IHC was performed using a DAKO Envision kit (for more detail 
see materials and methods). CD133 antibody was diluted 1:100 in 
antibody diluent. Sections were labelled with biotinylated donkey anti-
rabbit IgG (H+L) secondary antibody (diluted 1:200 in antibody diluent) 
and were counterstained with Mayers haematoxylin. In each 
experiment, negative controls of secondary antibody only was used. A1 
and A2 are negative controls (A2 is a magnified image of a region 
within A1). B1 and B2 are images of a SCLC section stained with 
CD133 (B2 is a magnified image of a region within B1). High levels of 
CD133 expression was detected in SCLC biopsy samples judged by 
light microscopy. Images are representative of three independent 
experiments. A1 and B1 are images taken with 5× magnification and A2 











Figure 42: Schematic illustration of origin of cancer stem cells 
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Figure 43: CD133+ cells express higher levels of neuropeptide 
receptors compared to the CD133- cells 
(A1) mRNA encoding GRP-R in H345 cells or (A2) mRNA encoding 
V1A-R in H69 cells was measured by quantitative q-PCR. 18s mRNA 
was used as internal control. Graphs show fold increase relative to 
external calibrator which was a pool of experimental cDNA. In both 
cell lines, CD133+ cells expressed significantly higher levels of GRP-R 
or V1A-R compared to CD133- and parent populations. Results 
represent the mean ± SEM of five independent experiments. (B1) 
Protein levels of GRP-R in H345 cells or (B2) V1A-R in H69 cells was 
evaluated by western blotting. Lysates of G6A cells (GRP-R expressing 
CHO cells), and V3B cells (V1A-R expressing CHO cells) were used as 
positive control. β-actin was used as loading control. Results represent 






















































Figure 44: Exogenous neuropeptides enhance the colony formation      
of CD133+ cells  
The effect of exogenously added neuropeptide on the clonogenicity of 
CD133+ and parent cells was evaluated by seeding cells in semi-solid 
SITA medium in the presence/absence of GRP or AVP. The number of 
colonies was evaluated after 21 days using a light microscope. (A) 
Addition of GRP enhanced clonogenicity in a dose-dependent manner 
in both CD133+ and parent H345 cells. However, the affect of this 
neuorpeptide on the clonogenicity of CD133+ cells was significantly 
enhanced. (B) AVP enhanced the colony formation of both CD133+ and 
parent H69 cells, however, its affect on the clonogenicity of CD133+ 
H69 cells was significantly higher. Results represent the mean ± SEM 







Figure 45: SP-G is more effective in chemoresistant cells  
Figure taken from [65] 
(A) mRNA encoding GRP-R in three human SCLC cell lines, GCL14, 
16 and 19 was evaluated by semi-quantitative RT-PCR. β-actin mRNA 
levels was used as internal control. Increased mRNA levels of GRP-R 
was in line with progression of resistant phenotype in the SCLC cell 
lines. (B) The inhibitory effect of SP-G on the cell growth of GLC16 
and GLC19 was evaluated by culturing cells in SITA medium in the 
presence or absence of SP-G. SP-G was a more effective inhibitor of 
cell growth in GLC19 cells than GLC16 cells. (C) The inhibitory effect 
of SP-G on colony forming ability of GLC16 and GLC19 cells was 
evaluated by plating cells in SITA medium containing 0.3% agarose in 
the presence or absence of SP-G layered on a base of 0.5% agarose in 
culture medium. After 21 days, number of colonies formed were 
counted using light microscopy. SP-G was more potent inhibitor of 
colony formation in GLC19 cells than GLC16 cells. Each point 
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Figure 46: Peptide-1 is a more potent inhibitor of cell viability than 
SPG 
H345 and H69 cells were cultured in SITA medium in the presence or 
absence of SP-G or peptide-1 (1-100 µM). After 72 hours MTT was added 
and cell viability was assessed. Untreated cells were used as control. Data 
is presented as percentage of control. (A) In H345 cells and (B) in H69 
cells, peptide-1 was significantly more potent in inhibiting SCLC cell 
viability than SP-G Results represent the mean ± SEM of three 
independent experiments.  
H345 

























































Figure 47: Representative tracing of intracellular calcium 
mobilisation 
(A) Represents tracing of intracellular calcium mobilisation in G6A cells 
exposed to 10 nM GRP. (B) Represents tracing of calcium mobilisation 










































Figure 48: Peptide-1 inhibits [Ca2+]i mobilisation stimulated by 
neuropeptides 
Quiescent G6A (GRP-R expressing CHO cells) and V3B (V1A-R 
expressing CHO cells) were incubated with FURA-2AM for 20 min at 
37°C and ratiometric fluorescence was monitored at 37°C. Intracellular 
calcium mobilisation was observed in a dose-dependent manner in (A) 
G6A exposed to GRP and (B) V3B cells exposed to AVP. The inhibitory 
affect of peptide-1 on [Ca2+]i mobilisation induced by neuropeptides, was 
evaluated initially by pre-treating the samples with various 
concentrations of peptide-1 (1-100 µM) for 2 minutes at 37°C before 
adding 10 nM GRP for G6A cells or AVP for V3B cells. Peptide-1 
inhibited [Ca2+]i stimulated by GRP in G6A (C) and by AVP in V3B cells 
(D). Results represent the mean ±SEM of five experiments. 
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Figure 49: Peptide-1 is a more potent inhibitor of cellular growth 
than SP-G  
H345 and H69 cell proliferation was evaluated in SITA medium in the 
presence of 1-100 µM concentration of SP-G or peptide-1. Cell number 
was evaluated by counting cells using the NucleoCounter for 24 days. 
Untreated cells were used as control and data is presented as percentage 
of control on day 24. (A) In H345 cells as well as (B) in H69 cells, 
peptide-1 was more potent inhibitor of cellular proliferation than SP-G. 
Each point represents the mean ± SEM of three independent experiments 











































Figure 50: Peptide-1 inhibits basal and neuropeptide stimulated 
colony formation 
Cells were cultured in SITA medium containing 0.3% agarose in the 
presence or absence of 10 nM GRP or AVP and/or 10 µM peptide-1 or 
combination of neuropeptide and peptide-1 were cultured over solid SITA 
medium with 0.5% agarose. After 21 days colonies of >16 cells were 
counted under microscope. (A) In H345 cells as well as (B) in H69 cells, 
peptide-1 inhibited the basal and neuropeptide stimulated clonal growth 
of SCLC cells in semi-solid medium. The data represent the mean ± SEM 





































































Figure 51: Peptide-1 is a more potent inducer of apoptosis than SP-G 
H345 and H69 cells cultured in SITA medium were treated with two 
different concentrations of SP-G or peptide-1 (1 µM and 10 µM) for 72 
hours. After this period, apoptosis was determined by cytocentrifuging 
cells onto glass cover slips and staining with May-Grunwald-Giemsa. 
Images were taken with 40× magnification. (A) Representative image of 
control and 10µM peptide-1 treated H345 cells. Apoptotic cells appeared 
as shrunken cells with dense nuclei and are presented by (   ). (B) In H345 
cells and (C) in H69 cells, peptide-1 induced apoptosis and its effect was 
significantly greater than SP-G. Untreated cells were used as control. The 
data represent the mean ± SEM of four independent experiments 
performed in duplicate. 
SP-G 
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Figure 52: Representative image of a HPLC tracing 
(A) Represents the presence of peptide-1 at time point 0 (the time 
which immediately after addition of peptide-1 to S9 liver 
preparation an aliquot of sample was removed for HPLC analysis). 
(B), (C), and (D) traces demonstrate the degradation of peptide-1 
and production of metabolites 1 and 2 after 20, 80 and 130 minutes 
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Figure 53: Peptide-1 is more stable than SP-G 
The stability of SP-G and peptide-1 (0.1 mg/ml) was evaluated in mouse 
S9 liver preparation. Samples were incubated at 37°C for 130 minutes 
and aliquots were removed at appropriate time points for HPLC analysis. 
The figure indicates the percentage of non-metabolised SP-G and 
peptide-1 present in the sample with time. Peptide-1 was approximately 
four times more stable than SP-G. Each point represents the mean ± SEM 
of three independent experiments. 









Figure 54: Peptide-1 significantly inhibits H345 growth in vivo 
15 × 106 H345 cells suspended in growth factor reduced Matrigel (1:1 
vol of cells : Matrigel mixed at 4ºC, total volume of 100 µl) were 
implanted subcutaneously in the right flank of nude/nude mice. H345 
xenografts were palpable 3 days post injection. Treatment started on day 
7 and animals were treated once a day for 5 consecutive days. Peptide-1 
was dissolved in sterile distilled H2O and was administered by 
subcutaneous injection at 25 mg/kg. Etoposide was dissolved in sterile 
distilled H2O and was administered by subcutaneous injection at 15 
mg/kg. Controls received the same dose schedule of vehicle (H2O). As 
shown in figure, peptide-1 administered alone profoundly reduced 
growth of SCLC xenograft and was as efficacious as etoposide alone. 





































Figure 55: Peptide-1 is more potent in CD133+ cells than in CD133- 
cells 
Sorted H345 cells and unsorted parent cells were treated with different 
concentrations of  peptide-1 (1-100 µM) for 72 hours and cytotoxicity 
was evaluated by MTT assay. CD133+ H345 cells were more sensitive 
to peptide-1 than CD133- and parent cells. Each point represents the 
mean ± SEM of three independent experiments performed in triplicates. 
H345 





































Figure 56: Mouse SCLC cell lines express CD133 and Oct-4 
The presence of CD133 and Oct-4 in JC9574 and JC9569 cell lysates 
were examined by evaluating their protein levels by western blotting. A 
band of ~120 kDa and a band of ~48 kDa in both cell lines were 
indicative of presence of CD133 and Oct-4 proteins in these cell lines. 
β-actin was used as loading control. Image is representative of three 
independent experiments. 





Lung cancer is a lethal malignancy with high tendency for relapse. It is histologically 
classified into two main groups of small cell lung cancer (SCLC) and non small cell 
lung cancer (NSCLC) [1]. The classification has important implication for clinical 
management and prognosis. NSCLC accounts for about 80% of lung cancers in the 
UK which have comparatively better prognosis than SCLC. NSCLC include 
adenocarcinoma (30%-40%), squamous cell carcinoma (25%-35%) and large cell 
carcinoma (10%) [2, 3]. 
 
Long term exposure to tobacco smoke is the principle cause of lung cancer, in 
particular SCLC. SCLC accounts for 15-20% of all lung cancers and over two thirds 
of patients on presentation have metastasis [4, 5]. Resection is rarely an effective 
treatment strategy for SCLC and although initially chemo-radio-sensitive, recurrence 
and resistance is almost inevitable [6, 7]. Thus, overall prognosis is unsatisfactory 
with a 5-year survival rate less than 5%. These figures have unfortunately not 
improved significantly in the past two decades despite advances in diagnosis and 
treatment [8]. Therefore, urgent research focus on SCLC is required for development 




Lung cancer is the most frequently encountered malignancy in the world, accounting 
for 1 in every 8 new cancer cases [9]. In the United Kingdome (UK), pulmonary 
cancer is the second most common malignancy in men accounting for 14% of all 
new cancer cases in male and the third most common cancer in women accounting 
for more than 11% of all new cancer cases in females [10]. A decline in SCLC 
incidence (11%-13%) world wide including UK over the past few decades has been 
addressed [2, 3]. This may be due to increase abstinence from smoking, change to 
low tar filter cigarettes, and possibly by the revision of the pathological classification 
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where by a few SCLCs are now classified as NSCLCs with neuroendocrine features 
[11, 12].  
 
Lung cancer is rarely seen before the age of 40 and most SCLC cases diagnosed are 
above 65 years old. The disease is more common in men than women. However, the 
male/female ratio has declined in the past fifty years from 6:1 to approximately 7:5 
due to increase in smoking habits in women [3].  
 
Smoking is the main risk factor for lung cancer with SCLC having the clearest 
association with tobacco consumption. More than 95% of SCLC cases are 
attributable to tobacco smoking [13]. Therefore, the future trends in lung cancer, and 
particularly SCLC, will be shaped by the increase in female smokers and the higher 
prevalence of tobacco use in lower socio-economic groups [14]. Other risk factors 
include atmospheric pollution, industrial exposure to carcinogens and chronic lung 
disease [15]. Unfortunately, it is clear that SCLC will continue to be a significant 
health burden for the foreseeable future. 
 
1.2 Genetic alteration associated with SCLC 
 
SCLC early lesions are rare making access to sequence of genetic alteration that 
leads to disease development unclear. Commonly encountered chromosomal 
abnormality is, deletion of the short arm of chromosome 3 (3p) at distinct areas 
(3p(14-25)) [16, 17]. Deletion of this region is observed in 90% of SCLC cases and 
is mostly loci for tumour suppressor genes including, RASSF1A, FUS1, and Fragile 
histidine triad (FHIT). Other common chromosomal aberrations include loss of 5q, 
13q, and 17p [18]. The latter two are loci with tumour suppressor genes Rb and p53 
and deletion or inactivating mutations are observed in 90% of SCLCs. Gain of 1p, 
2p, 3q, 5p, 8q and 19p which encode oncogenes including, Myc and K-ras are also 
commonly detected [19, 20]. Despite numerous studies, the contribution of each 
genetic alteration promoting SCLC is unknown. 
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1.3 Clinical features, diagnosis and staging of SCLC 
 
1.3.1 Clinical features 
 
SCLC is the most aggressive form of lung cancer [21]. In addition to cachexia, 
symptoms can be due to local growth of tumour (persistent cough, obstructive 
pneumonia, hemoptysis), and involvement of adjacent structures (superior vena cava 
obstruction syndrome, hoarseness, dysphagia). Extrathoracic metastasis to bone 
(19%-38%), liver (17%-34%), adrenal glands (10%-17%) and brain (up to 14%) may 
present with features of the involved organ [22]. Mediastinal and metastatic 
complications are frequently encountered. 
 
Several paraneoplastic syndromes are associated with SCLC. These are broadly 
divided into endocrine and neurological syndromes [23]. Endocrine syndromes 
associated with SCLC include, hyponatraemia seen in syndrome of inappropriate 
antidiuretic hormone (SIADH) [24, 25] due to ectopic release of arginine vasopressin 
(AVP) and Cushing’s syndrome (hypercortisolism) which is associated with release 
of adrenocorticotropic hormone or corticotropin releasing factor [25, 26]. The best 
described neurological syndromes associated with SCLC is Lambert-Eaton 
myasthenic syndrome (LEMs) observed in 50-60% of SCLC patients and features 
proximal muscle weakness and autonomic dysfunction with significant serum levels 




Radiological findings usually demonstrate SCLC as tumours with hilar (84%) or 
mediastinal (92%) lymphadenopathy [22]. Computer tomography (CT) of the chest 
and upper abdomen determines intra-thoracic and distal organ involvement. 
Magnetic resonance imaging (MRI) of the brain and radionuclide bone scan 
additionally searches for possible metastasis. MRI is usually utilised to resolve 
ambiguous CT findings [27, 28].  
 
CHAPTER 1                                                                                                               4 
 
Diagnosis of SCLC is primarily based on histopathology of samples obtained by 
bronchoscopy or percutaneous needle aspiration/core biopsies. Typically, SCLC 
tumour cells are small, round or spindle shaped with scant cytoplasm and minimal or 
absent nucleoli. High mitotic count and large areas of necrosis are frequently 
observed [21]. In addition to tumour cell morphology, immunohistochemical stains 
are often helpful in the diagnosis of SCLC using markers including chromogranin, 




SCLC is classified as either limited disease (LD) or extensive disease (ED) as 
recommended by the Veterans’ Administration Lung Study Group (VALSG) [25]. 
LD stage is defined for tumours confined to one hemi-thorax (including ipsilateral 
supraclavicular lymph nodes) that can be encompassed within a tolerable radiation 
field. ED spreads beyond these boundaries including bilateral pulmonary lesion, 
malignant pericardial and pleural effusion and extrathoracic involvement where 
radiation required would be too large with toxicity [25, 29]. Tumour, node, 
metastases (TNM) staging, a fundamental system for classification of NSCLC, 
requires accurate surgical lymph node and secondary sampling, making most patients 
with SCLC inappropriate candidates [30]. Accurate staging is fundamental to select 
an appropriate treatment for individual patients.  
 
1.4 Treatment of SCLC 
 
SCLC usually presents as inoperable centrally located lung lesions with loco-
regional and distant metastasis. Thus, chemo-radiation forms the cornerstone for its 




SCLCs show initial chemo-sensitivity to cytotoxic agents. In the 1970’s, 
monotherapy with cyclophosphamide [33], other alkylating agents, and platinum 
based treatments were replaced by combination of multiple therapies [30]. 
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Combination regimes achieved a response rate of 57% as against 12% with 
monotherapy. Likewise, the survival curve for combination regimes was significantly 
higher (P=0.012) [34].  
 
Over the last 30 years, the standard first line therapy for SCLC has comprised of 
etoposide with a platinum-based drug administered in 4-6 cycles. Etoposide plus 
cisplatin (EP) is active in both LD and ED SCLC with 85% objective response rates 
(ORR) and 50%-60% complete response (CR) in LD SCLC, and 50%-60% ORR and 
7%-10% CR in ED SCLC [35-37]. Despite initial sensitivity to first-line 
chemotherapy, 80% of LD SCLC patients and almost all ED SCLC patients relapse 
making them candidates for second-line treatment [38].  
 
1.4.2 Second-line therapy 
 
Efficiency of second-line chemotherapy in SCLC patients is lower with objective 
response rate of 18-24% however it can significantly provide prolongation of 
survival [39]. Response to second-line therapy is influenced by physical status (PS), 
disease stage and relapsed or refractory disease. Disease relapse after 3 months of 
completion of first-line therapy is considered chemosensitive disease. Relapse in less 
than 3 months or limited or no response to first-line therapy is described as 
chemoresistant disease [40]. 25% response is observed in chemosensitive as against 
10% in chemoresistant group. For relapse after 6 months, a repeat of the initial 
regime instead of monotherapy is applied [41]. Agents used as second-line therapy 
for SCLC include, topotecan and irinotecan which are camptothecin derivatives and 
topoisomerase I inhibitors [39, 42-44], paclitaxel, a cell cycle inhibitor by stabilising 
microtubules [45, 46], and amrubicin, a topoisomerase II inhibitor [47, 48].  
 
Although some promising results have been obtained for SCLC treatment, however, 
a gain of only a few months in survival have been achieved and SCLC remains an 
incurable disease. Thus, the need for novel, more effective therapeutics with minimal 
toxicity is urgently required. 
 




SCLC cells are initially highly radio-sensitive. Since the 1990’s, combination of 
chemotherapy and radiotherapy has been considered as standard therapy for SCLC 
confined to one hemithorax [49, 50]. Chemoradiation schedules include concurrent, 
sequential, or alternating therapy [51]. Concurrent approach shortened duration of 
treatment and increased overall survival rate with improved 2-, 3-, and 5-year 
survival rates by 54.4%, 29.8% and 23.7%, respectively [52]. Optimal dose of 
thoracic irradiation (TR) TR is debatable with some favouring dose intensification. 
In a randomised phase II trial, twice daily TR at a dose of 45 Gray (Gy) concurrent 
with EP improved 5-year overall survival rates and is currently considered as 
standard therapy in LD SCLC [53]. 
 
TR is not yet been considered as a standard therapy in ED SCLC. Although, in a 
randomised study by Jeremic et al. [54], TR as consolidation treatment for ED SCLC 
showed promising results with a 5 year survival rate of 9%, the data obtained was 
from a single study and requires confirmation [54].  
 
1.4.4 Prophylactic cranial irradiation 
 
Brain metastasis (BM) is common in SCLC patients. Half of LD SCLC in complete 
remission after standard chemotherapy regimes will develop brain metastasis [55] 
making prophylactic cranial irradiation (PCI) mandatory. A meta-analysis of 987 
SCLC patients in complete remission showed at three years, a 25.3% decreased 
incidence of BM and ~5% improvement in survival with the addition of PCI [56]. 
Currently, the standard doses used is 24-30 Gy, administered over 8-10 fractions. 
 
PCI offers convincing results in ED SCLC. PCI in ED SCLC reduced BM at 1 year 
by 26% and increased 1 year survival rate by 27% in PCI group versus 13% in 
control group [57]. PCI is now considered as a standard therapy in ED patients with 
complete or partial response to chemotherapy.  
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Despite years of research in the field of chemo-radiation, dramatic initial response 
was often followed by recurrence and resistance. Thus, a shift in therapeutic 
approach is needed. With better understanding of SCLC, several molecular targets 
have been identified in various preclinical studies. 
 
1.4.5 Novel targeted therapies in SCLC 
 
Targeted therapies have been rationally designed on current analysis of SCLC 
biology. Therapies used to target apoptosis resistance, unrestrained growth, and drug 
efflux in SCLC will be described in the following section. 
 
1.4.5.1 Inhibitors of cell survival pathways  
 
Circumventing apoptosis underpins cancer cell survival and promotes chemo- and 
radio-resistance. Bcl-2, a central regulator of apoptosis, is over-expressed in 80% of 
SCLC and serves as a promising target for SCLC therapy [58]. Small molecule 
inhibitors of Bcl-2 family proteins (ABT-737 and ABT-263) have been developed 
for SCLC treatment [59, 60]. ABT-263 has recently entered clinical trials, posing as 
a promising agent for the treatment of SCLC.  
 
PI3K/AKT/mTOR pathways are critical for SCLC cell survival [61]. Both 
temsirolimus and everolimus have been used as mTOR inhibitors in ED SCLC 
patients. However, in phase II clinical trials, these agents did not show improved 
median survival [62, 63].  
 
1.4.5.2 Growth and proliferation pathway inhibitors 
 
Multiple neuropeptides via autocrine and paracrine loops fuel unrestrained SCLC 









]-substance-P (6-11) function as broad spectrum antagonist, inhibiting 
SCLC growth in vitro and in nude mice xenograft models [64]. Interestingly, SP-G 
has proven to be more effective in chemoresistant cells suggesting its implication in 
recurrent and resistant SCLCs [65]. SP-G has completed a phase I clinical trial with 
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minimal toxicity at therapeutic plasma concentrations [66]. Neuropeptide antagonists 
and their implication in SCLC treatment will be detailed in section 1.6.6. 
 
SCLC cells express a range of RTKs which also regulate SCLC growth and 
proliferation. High expression of c-Kit and its ligand, SCF, has been associated with 
SCLC pathogenesis [67]. Imatinib is a broad spectrum RTK inhibitor [67]. The 
efficiency of imatinib as a monotherapy or in combination with chemotherapy, tested 
in two phase II clinical trials for relapsed SCLC patients, demonstrated poor 
efficiency [68, 69]. 
 
1.4.5.3 Inhibition of efflux pump 
 
Active efflux pumps that expel cytotoxic agents are logical targets for chemo-
sensitisation. However, biricodar that blocks the action of efflux pump P-gp and 
MDRP when combined with chemotherapy produced poor response along with 
significant toxicity which resulted in early termination of the trail [70].   
 
Despite advances in unveiling pathogenesis of SCLC, so far the methods to 
circumvent resistance have not been successful in clinical practice. These failures 
could possibly result from treating tumour mass but failing to eliminate a sub-
population within the tumour that may trigger relapse and resistance. In this regard, 
cancer stem cells (CSCs) may be particularly relevant in SCLC. 
 
1.5 Cancer stem cells 
 
Cancer cells exhibit broad spectrum of heterogeneity in their cellular morphology 
and functional properties. Evidences indicate that cells within tumour lesion may 
differ in their proliferation index, therapeutic response and tumorigenicity [71]. 
Southam was the first to demonstrate tumour cell heterogeneity [72]. Tumour cell 
heterogeneity may be due to the presence of cancer stem cells (CSCs) within the 
neoplasm, a sub-population of cells with similar characteristics to normal stem cells 
(reviewed in [73]). Stem cells are specialised cells found in multicellular organs. 
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They have the potential to self-renew as well as to differentiate, thus replenishing 
adult tissue. Self-renewal is defined as the ability to undergo unlimited cycles of cell 
division while still maintaining its undifferentiated state. The classical stem cell 
hierarchy model is illustrated in Figure 1. Transformed stem cells are the suggested 
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Evidence of CSC was initially observed in myeloid leukaemia where in only a small 
subset of cells (0.01%-1% of the total population) initiated the disease when 
transplanted into severe combined immune deficient (SCID) mice [74]. Numerous 
studies support the existence of CSCs in various malignancies including solid 
tumours [75-78] such as lung cancer [79]. These cells are chemoresistant [80-82] and 
their presence in clinical specimens is associated with poor survival [83-85]. Based 
on these observations, it has been proposed that conventional therapies target tumour 
bulk, sparing the chemoresistant CSCs. The surviving cells, with their stem cell-like 
phenotype, are speculated to regenerate the tumour leading to disease recurrence. 
Thus, identification and characterization of CSCs may improve strategies for better 
clinical outcomes.     
 
1.5.1 Origin of lung cancer stem cells 
 
In lung cancer, it is debatable whether lung CSCs arise from lung stem cells that 
have acquired oncogenic mutations or from differentiated lung cells that have 
acquired mutations including re-programming with acquisition of stem cell-like 
properties. In this section the presence of stem cells in adult lung tissue and the role 
of stem and more differentiated cells in pulmonary epithelial repair and lung cancer 
development will be described.  
 
1.5.1.1 Lung stem cells  
 
It has become increasingly accepted that in adult organisms, stem cell populations 
exist and serve to maintain tissue homeostasis. Presence of stem cells have been well 
characterised in organs with fast cell turnover including, skin, hematopoietic system, 
and the small intestine where a classic model of a stem cell hierarchy is observed 
[86, 87].  
 
In contrast, the cell turnover rate is significantly slower in the lung. However, in 
stress conditions such as lung injury, increased pulmonary cell proliferation is 
observed. Along the respiratory system, stem cells as well as differentiated 
pulmonary epithelial cells are involved in tissue maintenance and repair [88]. 
CHAPTER 1                                                                                                               12 
 
Giangreco et al. [89] proposed that in normal lungs, after mild to moderate 
pulmonary injury, tissue repair is undertaken by resident pulmonary progenitor cell 
activation. However, with extensive pulmonary injury, respiratory stem cells are 
mobilised. Thus, the classic stem cell hierarchical model has to be redefined in the 
lung [86, 90]. Injury models that mimic lung damage inflicted by environmental 
conditions or infectious disease are most frequently employed to elicit repair 
programmes by surviving stem/progenitor cells. 
 
1.5.1.2 Lung epithelial injury and stem/progenitor cell repair 
 
Adult lung is a complex organ that features major differences in its cell composition 
from proximal to distal axis. The proximal lung contains ciliated and Clara-like cells. 
A few sub-mucosal glands present in this region contain mucous-producing cells. 
The more distal lung is composed of Clara cells and neuroendocrine cells. The distal 
pulmonary system is organised into a complex system of alveoli and the epithelium 
consists of, alveolar type 1 (AT1) and 2 (AT2) cells. The origin of the progenitor 
cells present in the proximal region of the lung is different from those of the distal 
lung. The function of different pools of lung progenitor cells is restricted to their 
regional specificities in both proximal and distal airway during lung development 
and repair (reviewed in [91]).  
 
Injury models project the properties of stem/progenitor cells in lung repair. The most 
common injury model is treatment of mice with naphthalene to ablate Clara cells [92, 
93]. After naphthalene injury, Clara cell repopulation depends on the region of the 
lung. In the proximal airway, basal cells function as stem cells replenishing the Clara 
cells [94]. This was evident by genetic lineage labelling approach in mouse with 
inducible Cre-recombinase controlled by a cytokeratin K14 promoter that is 
selectively active in basal cells. The K14
+
 featuring basal cells were able to self-
renew and reconstitute both Clara and ciliated cells upon injury, displaying stem cell 
characteristics [94].  
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In the distal airway system, after naphthalene injury, Clara cells are restored by a rare 
population of naphthalene resistant Clara cells known as variant Clara (vClara) cells 
[95] [96]. Clusters of vClara cells are localised in specialised niches including 
neuroendocrine bodies (NEB) in the bronchi/bronchioles or at the broncho-alveolar 
duct junctions (BADJs) [95, 97]. NEB associated vClara cell express Clara cell 
marker CC10 also known as CCSP, CCA, or secretoglobin Scgb1a1 and appear to 
function as stem cells after pulmonary injury.  
 
Kim et al, 2005 [98] demonstrated that vClara cells that reside at the BADJ exhibit 
stem cell phenotype. These cells, termed bronchoalveolar stem cells (BASCs), co-
express both the alveolar type II cell marker, surfactant protein-C (SPC), and the 









 isolated BASCs expanded in culture and gave rise to 
cells that expressed markers for Clara and alveolar cells in vitro. Although BASCs 
self-renewal and differentiation potential in vivo has not be proven, recent cell-
tracing studies have suggested that these cells are involved in the maintenance and 
repair of the proximal pulmonary system, but not the alveolar epithelium [89, 99]. 
Therefore, both lung progenitors and stem cells repair pulmonary tissue injury. 
However, it needs to be noted that both vClara cells and BASCs differ from classical 
stem cells as they express proteins that are present in fully differentiated lung cells 
[96]. 
 
1.5.1.3 Lung cancer stem cells in mouse 
 
BASC as the origin of adenocarcinoma has been addressed in several mouse models. 
Kras mutation is commonly observed in NSCLC [100]. Thus, transgenic mice 
expressing activation variants of Kras, (for example Kras-G12D), serve as an ideal 
tool for lung CSC study. The importance of BASCs as the cell of origin in Kras-
G12D induced adenocarcinoma has been pointed out in several studies that showed: 
(1) In these transgenic mice, an outgrowth of BASCs was observed which was 
associated with atypical adenomous hyperplasia, a precursor lung adenocarcinoma 
lesion [98, 101], (2) The transgenic BASCs were highly proliferative and multipotent 
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in colony assay, (3) Exposure of these transgenic mice to naphthalene enhanced 
tumour growth (~11 fold) compared to control animals [98, 101]. In line with these 
observations, Ventura et al, 2007 [102], demonstrated that inducible p38 knockout 
mice were more prone to Kras-G12D induced adenocarcinoma. P38 positively 
regulates differentiation and inhibits the proliferation of BASCs. Therefore, based on 
the above data it can be suggested that transformed BASCs are the CSCs leading to 
adenocarcinoma development. However, to support this concept the ability of 
transformed BASCs to develop tumours during serial transplantation in mice is 
necessary.  
 
Unipotent progenitors PNEC, subject to oncogenic mutations are suggested 
forerunners of SCLC. Both PNECs and SCLC are co-located at the midlevel 
bronchioles and express similar neuroendocrine markers including calcitonin-gene 
related peptide (CGRP) and NCAM [103, 104]. Mutations in the tumour suppressor 
genes, retinoblastoma (Rb) and p53 are common genetic abnormality associated with 
SCLC [105]. Mouse models with Rb depletion and p53 knockout, formed SCLC-like 
hyperplastic foci that corresponded to NEB microenvironment. More recently, using 
an inducible lung-specific Rb knockout strategy, PNEC hyperplasia was exclusively 
observed despite Rb deficiency in other cell types along the lung [106]. Conditional 
inactivation of both Rb and p53 in mouse lung epithelial cells resulted in pulmonary 
neoplasm with striking similarities to human SCLC [103]. Importantly, these 
tumours gave rise to extrapulmonary metastasis closely resembling its human 
counterpart. Despite wide spread conditional mutation along the respiratory tree, 
only PNECs responded. These observations imply the crucial role of transformed 
PNECs cells in SCLC tumorigenesis.  
 
Evidence that common signalling pathways are activated in NEB associated PNECs 
and SCLC cells further emphasises PNECs as SCLC cells of origin. Hedgehog (Hh) 
signalling, an embryonic pathway essential for lung development, is elevated in NEB 
during lung repair, while elevated expression of Patched (Ptc) Hh receptor in PNECs 
is observed during pulmonary repair [107]. Similarly, Hh activation with increased 
sonic hedghog (Shh) receptor and ligand is observed in SCLC [107]. Inhibition of 
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Shh ligand activity in SCLC cell lines using monoclonal antibodies was associated 
with inhibition of SCLC growth in vitro [108]. Likewise, Notch signalling involved 
in NEB growth and SCLC progression is indicative of common signalling pathways 
[109]. Concluding, co-location of PNEC and SCLC along the airway system, similar 
neuroendocrine phenotype and signalling pathways, makes transformed PNECs 
putative SCLC CSC candidates.  
 
1.5.2 Cancer stem cell markers 
 
The identification of reliable markers for the study and isolation of cancer stem cells 
has been the main challenge facing researchers in this area, but a number of 
candidates have been hypothesised such as CD133, expression of drug efflux pumps 
and, enhanced aldehyde dehydrogenase (ALDH) enzyme activity. Table 1 
summarises key markers employed for isolation of prospective CSCs in solid 
tumours. It is apparent that common markers, in particular CD133, have been used to 
detect CSCs in diverse solid tumours. To be noted, none of these markers are 
exclusively expressed by the CSCs, indicating the need for more specific or the use 
of combination of markers. In this section I will be focusing on CD133, ALDH and 




















































 CD133 (prominin-1 in mice), a cholesterol-binding protein, in humans was initially 
detected in hematopoietic stem and progenitor cells [110]. The protein is selectively 
associated with plasma membrane protrusions and due to this intrinsic preference, it 
inherits the name ‘prominin’ (from the Latin word prominere, to be prominent) [111, 
112]. Glycosylated form of CD133 epitopes select for stem and CSCs. Most 
commonly used antibodies for detection of glycosylated epitopes of CD133 antigen 
include, monoclonal CD133-1-APC (clone AC131) antibody which recognises 
eptiope-1 of the CD133 antigen, and monoclonal CD133-2-PE (clone AC141) 
antibody that detects epitope-2 of the same antigen [110, 113, 114]. Both antibodies 
are commercially available from Miltenyi Biotec, Germany. Although CD133-2 has 
been used for isolation of hematopoietic stem cells (HSC), due to cross reactivity of 
the antibody with cytokeratin-18 [115], it is not commonly employed for CSC 
selection.   
 
CD133 expression is detected in several stem cells [116, 117] and CSCs [76-79]. The 
prognostic value of CD133 expression has been documented in various malignancies 
[85, 118] [119-121], making this marker a valuable tool to develop future therapies 
towards identifying CSCs. The development of such therapies would require clearer 
understanding of the characteristics and molecular mechanisms that regulate the 
behaviour of CD133 expressing cells. 
 
1.5.2.1.1 CD133 structure 
 
The Prominin-1 gene is located on chromosome 4 (locus p15.33) in humans and on 
chromosome 5 (locus 5B3) in mice. The genomic organisation in both species is 
similar consisting of 37 (human) and 34 (mice) exons spanning approximately 160 
kb. In human it is under control of five alternative promoters [122]. Mouse and 
human prominin-1 share approximately 60% homology. To date several spliced 
variants affecting the open reading frame have been identified in mice and in human 
several of which exhibit distinct C-terminal domains explaining the diverse 
cytoplasmic protein interactions [122]. 
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Human Prominin-1 (CD133) consists of 865 amino acids (aa) with a predicted 
molecular weight of 95 kDa and apparent molecular mass of 120 kDa due to 
glycosylation [114]. CD133 displays a membrane topology consisting of an 85 aa N-
terminal extracellular domain, five transmembrane domains with two large 
extracellular loops, and an 50 aa C-terminal domain (Figure 2). Analysis of this 
protein has revealed eight potential N-glycosylation sites: five on the first 
extracellular loop and three on the second, conserved cysteine-rich region located in 
the transition of the first transmembrane domain and the first cytoplasmic loop and 
leucine zipper-like motifs in the extracellular loops. This unique protein does not 
share sequence homology to other known proteins, making it challenging to resolve 
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1.5.2.1.2 CD133 function 
 
The function of CD133 is not fully understood. Numerous studies indicate the stem 
cell-like phenotype of CD133 expressing cells. Hematopoietic stem cells (HSC) 
expressing CD133 were multipotent when compared with CD34+/CD133- cells 
[123]. During self-renewing of HSCs via asymmetric cell division, CD133 was 
transferred to daughter cells with stem cell phenotype [124]. Similar observations 
were made in lung cancer cells. DNA co-segregation is a mechanism by which the 
cellular components are divided asymmetrically during mitosis in intestinal, muscle 
and neural cells. Interestingly, Pine et al., [125] showed during asymmetric division 
in lung cancer cell lines and primary tissues, CD133 co-segregated with the template 
DNA, while the differentiation markers such as prosurfactant protein-C and pan-
cytokeratins were transferred to the more differentiated cells. The above data imply 
that CD133 expression may be associated with stem cell phenotype. 
 
Differentiation of neuroepithelial cells to neuron-generating progenitors upon 
neurogenesis is associated with budding of CD133-containing membrane particles 
known as prominosomes [126]. Release of prominosomes from differentiating stem 
cells could be a mechanism of intracellular communication and/or removal of 
proteins that regulate stem cell phenotype, further emphasizing the possible role of 
CD133 in maintaining the “stemness” of a cell. In line with these observations, stable 
knockdown of CD133 by lentivirus mediated shRNA in neuroblastoma cells was 
associated with loss of anchorage independent colony formation and in vivo 
tumorigenicity in contrast to wild type cells [127], characteristic of CSCs. Although 
CD133 expression appears critical for stem cell-like phenotype, it is at present not 
possible to draw solid conclusions on the molecular function of CD133 in stem and 
CSCs. 
 
1.5.2.1.3 CD133, somatic stem and progenitor cell marker  
 
The human HSCs were initially identified as CD34+ cells. However, recently CD133 
has attracted greater attention as an alternative maker for HSC. CD133 expressing 
CD34+ HSCs regenerated the entire immune system in NOD/SCID mice in contrast 
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to CD34+ CD133- sub-population [128]. Additionally, CD133+ cells ably 
differentiated into endothelial and neuronal cells and myoblasts in specific culture 
conditions [117, 129, 130], underlining the plasticity of the CD133+ cells in 
comparison to the CD34+ cells. Large-scale immunomagnetic selection of CD133+ 
HSCs from healthy mobilised adult donors has allowed enrichment of sufficient 
numbers of cells for transplantation [116]. In a study by Koehl, et al, [131] 
engraftment of CD133 selected autologous progenitor cells (2.5 × 10
6
 cells/kg) in a 
pediatric patient with meningeal relapse of CD34+ CD133- Precursor B-Cell 
Lymphoblastic Leukemia-Lymphoma led to complete remission. Thus, these data 
emphasise the essential role of CD133 in selection of HSC. 
 
CD133 is also an ideal marker for selection of somatic stem cells/progenitors in adult 
tissues including kidneys, muscle, skin and prostate [117, 132-134]. CD133+ cells 
from adult human kidneys were capable of self-renewal and differentiation into 
epithelial or endothelial cells, both ex-vivo and in vivo. Interestingly, in SCID mice 
with glycerol-induced tubulonecrosis, CD133+ cells contributed to the renal tissue 
regeneration [132]. Likewise, CD133 identified a rare population (~1%) of 
progenitors located in the basal layer of human prostate. These cells possessed high 
proliferative potential in vitro and when engrafted in immunocompromised mice, 
reconstitute prostatic-like acini [134].  
 
1.5.2.1.4 CD133, cancer stem cell marker 
 
The expression of CD133 has been addressed in various malignancies including 
brain, lung, prostate and colon carcinomas [76, 78, 79, 135]. CD133 expression is 
proven to select for self-renewing with differentiation potential, chemoresistant and 
tumorigenic cells. Characterising these aggressive cells could possibly allow 
explaining the tumour initiation and chemoresistance after therapy. In this section I 
will provide data regarding the role of CD133 expression in tumorigenesis, 
chemoresistance and prognosis of colorectal, brain, hepatocellular carcinoma, and 
lung cancers. 
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1.5.2.1.4.1 Colorectal cancer 
 
The presence of colon CSCs was first described in 2007 [136]. In contrast to CD133- 
cells, injection of CD133+ cells under the renal capsule of NOD/SCID mice resulted 
in generation of tumours retaining their parental tumour morphology even after serial 
transplantation in mice [136]. Similar observations were made by Ricci-Vitiani et al., 
[77] where 3000 CD133+ cells engrafted successfully in mice while 10
5
 CD133- 
were not tumorigenic. Differentiation of CD133+ cells in the presence of serum was 
associated with loss of CD133 expression and tumorigenicity in vivo [77]. In HT29 
colorectal cancer cell line, CD133+ selected the chemoresistant population. CD133 
knockdown enhanced sensitivity to staurosporine and reduced cell motility [137]. 
The importance of CD133 as marker in colorectal cancer has also been clinically 
proven. Higher CD133 expression levels (≥55%) in 104 stage IIIB colon cancers, 
strongly suggested lower 5-year survival rates [138]. These data demonstrate that 
CD133 expression identifies the stem cell-like, chemoresistant colorectal CSCs and 
the association of its expression with poorer prognosis in colon cancer patients 
implies its contribution in tumour progression.  
 
1.5.2.1.4.2 Brain cancer stem cells 
 
CD133+ glioma cells exhibit tumorigenity in mice. Culturing dissociated tumour 
samples of 14 pediatric patients with brain tumours led to formation of neurospheres 
similar to normal neural stem cells which expressed CD133. Injection of 100 
CD133+ cells into NOD/SCID mice produced tumours with exact phenocopies of the 
original tumour, where as 10,000 CD133- cells were not tumorigenic in vivo [78]. In 
addition to the tumour initiating potential, CD133+ glioma cells were also more 
resistant to radiotherapy than the CD133- population and were enriched after 
exposure to radiation [139]. CD133 expression was assessed in a cohort of 95 glioma 
samples where the frequencies of CD133+ cells correlated with tumour grade [120]. 
Therefore, CD133 serves as an ideal marker to detect the aggressive, chemoresistant 
brain cancer cells. 
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1.5.2.1.4.3 CD133 and hepatocellular carcinoma (HCC) 
 
Various studies have demonstrated the importance of CD133 as HCC CSCs marker. 
Sorted CD133+ cells had higher cloning efficiency and proliferation in vitro and 
significantly more tumorigenicity in vivo [140-142]. HCC CD133+ cells expressed 
Oct-4 and Nanog in contrast to CD133- cells, further confirming that CD133 selects 
for stem cell-like cells in HCC [140]. Exposure of HCC tumours to doxorubicin and 
fluorouracil in vivo resulted in the enrichment of CD133+ cells in a dose-dependent 
manner [141] indicating, conventional chemotherapy is ineffective and increase 
doses and cycles of therapy only add to the toxicity. Clinical significance of CD133 
expression in HCC has also been addressed. Analysis of 63 HCC tissue specimens 
revealed increased CD133 expression correlated with increased tumour grade and 
advance stage, indicating poor prognosis [143]. 
 
1.5.2.1.4.4 CD133 and lung cancer stem cells 
 
The presence of a stem cell-like sub-population in SCLC and NSCLC specimens was 
addressed in 1980’s by Carney et al., [144]. Since then, various studies have 
successfully isolated chemoresistant, stem cell-like lung pulmonary from primary 
tissue and cell lines [79, 145, 146]. Eramo and colleagues in 2008 [79], demonstrated 
that CD133+ lung cells expanded in growth factor containing serum-free cultures as 
self-renewing tumour spheres and differentiated into CD133- in the presence of 
serum. These cells were highly tumorigenic in vivo and generated tumours that 
mimic the histology of the primary tumour. Co-expression of embryonic stem cells 
markers such as Oct-4 and Nanog, further confirmed the stem cell nature of CD133-
expressing cells. Thus, in vitro and in vivo studies suggest CD133+ cells as putative 
lung CSCs that initiate and propagate the malignant neoplasm. 
 
Lung cancer CD133+ cells are resistant to most conventional chemotherapy, 
emphasising the urgent need of alternative therapies [79, 84]. In vitro treatment of 
NSCLC cells with cisplatin resulted in enrichment of CD133+ sub-population both 
after acute cytotoxic exposure and in cells with stable cisplatin-resistant phenotype 
[84]. Likewise, treatment of lung cancer cell lines with doxorubicin, cisplatin, or 
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etoposide enriched CSCs which expressed CD133 [82]. The exact mechanism of 
lung cancer CD133+ chemoresistance is unknown. Understanding underlying 
mechanisms of chemoresistance is critical for an appropriate approach. 
 
The importance of CD133 as a marker for predicting chemo-response and disease 
prognosis has also been addressed by several studies. The expression of CD133 was 
associated with shorter progression-free survival in NSCLC candidates treated with 
platinum-based regimens [79, 84]. A recent study assessed the value of CD133 
expression and its association with disease recurrence in 117 samples from patients 
with stage I adenocarcinoma. Patients expressing higher CD133 had greater risk of 
recurrence than those with low CD133 expression; 5-year disease-free survival rate 
was 77.2% versus 95.1% (P=0.004) [118]. In another study, the association of CSC 
marker expression with overall survival rate in 50 NSCLC candidates undergoing 
induction chemo-radiotherapy was evaluated. These patients had received docetaxel 
and cisplatin concurrently with thoracic radiation followed by surgery. Patients 
positive for CD133 and ALDH exhibited worse 5-year overall survival rate than 
patients with both CD133 and ALDH negative expression (44.9% versus 90.0%, 
respectively) [85].  
 
These findings infer that, CD133 expression identifies the stem cell-like, 
tumorigenic, chemoresistance cells and is a valuable prognostic marker for lung 
cancer.  
 
1.5.2.2 Aldehyde Dehydrogenase 
 
Certain isoenzymes of aldehyde dehydrogenase (ALDH) superfamily are shown to 
be creditable for selection of CSCs. Antibodies are commercially available for 
detection of ALDH enzymes however, most studies have used ALDEFLUOR® kit 




CHAPTER 1                                                                                                               25 
 
1.5.2.2.1 The Human Aldehyde Dehydrogenase superfamily 
 
Human ALDH represents a superfamily currently consisting of 19 genes, sub-divided 
in 11 families and 4 sub-families, which differ in their chromosomal locations [147, 
148]. At sub-cellular levels, ALDH enzymes can be found in the nucleus, cytosol, 
mitochondria and endoplasmic reticulum and have wide tissue distribution [147, 
148]. These cognate proteins are NAD (P)
+
-dependent enzymes involved in 
converting aldehydes into weak acids, a reaction associated with resistance to 
alkylating chemotherapeutic agents in CSCs [147-149]. Sub-family of ALDH 
enzyme catalyse the final and irreversible step in the conversion of retinol to retinoic 
acid, essential for embryogenesis [150]. From the ALDH super-family, those 
involved in stem cells as well as CSCs are shown in Table 2. ALDH1 is commonly 
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1.5.2.2.2 ALDH in CSCs 
 
The ALDH activity has been employed as a functional marker to identify and isolate 
CSCs in various malignancies including breast, prostate, colon as well as lung 
cancers (reviewed in [151]). In breast cancer, 500 ALDH+ cells were tumorigenic in 
nude mice whereas the same number of ALDH- cells and even higher (50,000) were 
not sufficient to generate tumours in animals [83]. In lung cancer cell lines, ALDH+ 
cells were clonogenic, tumorigenic and resistant to the chemotherapeutic agents 
commonly used as first-line therapy [152]. The importance of ALDH as a marker has 
also been clinically demonstrated. In a study of 303 NSCLC candidates, expression 
of ALDH1 in early-stage lung cancer was associated with poor prognosis [152].  
 
ALDH1A1 and ALDH3A1 expression, due to their intrinsic ability to oxidise 
alkylating agents to weak acids, have been associated with chemoresistance [151]. 
Knock-down of ALDH1A1 and ALDH3A1 by siRNA in NSCLC resulted in loss of 
clonogenecity and increase sensitivity to 4-hydroperoxycyclophosphamide (4-HC) 
[153]. Treatment of acute myeloid leukemia cell line resistant to cyclophosphamide 
with ALDH1 inhibitor, DEAB, restored sensitivity to 4-HC [154]. Therefore, 
targeting ALDH1 could be a strategy for re-sensitising chemoresistant disease.  
 
These data indicate that ALDH1 can be used as a marker for identifying and isolating 




Oct-4 or octomer binding transcription factor 4 is a protein of the POU domain 
family. Expression is restricted to pluripotent cells with decrease in levels on cell 
differentiation and loss of pluripotency [155]. The protein is a key regulator of self-
renewal and differentiation in embryonic stem (ES) cells. Oct-4 has been shown to 
increase the malignant potentials of ES cells in a dose dependent manner, indicative 
of possible oncogenic role [156]. Oct-4 transcripts have been consistently detected in 
embryonic carcinoma cells, testicular germ cells tumours, seminomas and bladder 
cancers [157, 158].  
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With regards to CSCs, the expression of this gene correlates with tumorigenesis, with 
particular emphasis on tumour recurrence and treatment resistance [157]. Its 
expression in mammary CSCs suggested self-renewal and tumorigenesis [159]. 
Likewise, Chen et. al., [158] demonstrated that Oct-4 maintained the stem-like 
properties of lung cancer CD133+ cells. Knockdown of Oc-4 in CD133+ cells was 
associated with differentiation of these cells to CD133- cells accompanied by loss of 
clonogenicity in vitro and tumorigenicity in vivo. Additionally, Oct-4 knockdown 
significantly sensitised cells to anti-cancer therapy including chemotherapy, 
radiotherapy or combined treatment. In the same study the author demonstrated that 
increased incidences of Oct-4 expression positively correlated with advanced stage 
of lung cancer. Thus, Oct-4 may serve as an important marker for CSCs. 
 
1.5.3 Targeting CSCs 
 
Conventional therapeutic approaches eradicate cells that form tumour bulk but spare 
the CSC sub-population. These surviving cells with stem cell-like phenotype are the 
proposed cause of tumour recurrence or relapse after therapy. Targeting CSCs may 
lead to improvement in long-term outcomes.  
 
Embryonic signalling pathways such as Wnt, Notch and Hedgehog signalling 
involved in self-renewal, proliferation and differentiation of normal stem cells, are 
also active in CSCs. Novel drugs have been designed that specifically target CSCs in 
glioblastoma, multiple myeloma, and leukaemia [160-163]. These studies 
demonstrate reduction in CSC population, inhibition of sphere formation, 
proliferation and colony formation, indicating the pivotal role of these pathways in 
CSC stemness. Clinical trials using agents against Wnt (PRI-724), Notch 
(RO4929097, BMS-906024, MK0752), and Hedgehog pathways (GDC-0449, PF-
04449913, BMS-833923, IPI-926, TAK-441) have begun, however their effects on 
the CSCs in patients remains to be assessed [164]. 
 
As mentioned earlier, CSCs are resistant to conventional chemotherapy. Sensitisation 
of these aggressive cells to treatment is also a promising strategy. Levina et al., [165]  
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demonstrated that lung CSC growth is mediated by autocrine loop that activates the 
c-Kit receptors. Blocking c-Kit by imatinib (Gleevec) combined with cisplatin was 
sufficient to increase sensitivity, thereby inhibiting tumour cell growth [165]. 
Similarly inhibiting interleukin 4, which increases the chemoresistance of colon 
CSCs via autocrine and paracrine signalling, was associated with chemosensitivity 
[166].  
 
Differentiation of CSCs results in loss of stemness. Recently, the novel compound 
salinomycin, by induction of epithelial cell differentiation in breast CSCs, inhibited 
in vitro and in vivo growth [167]. Likewise, treatment of multiple myeloma cells with 
interferon-alpha, a pleotropic cytokine, induced terminal differentiation of the CSCs 
with loss of cellular proliferation and clonogenic growth [168]. These data provide 
the rationale for clinical differentiation therapy for the treatment of resistant cancers. 
 
In summary, if CSCs are the principle cause of treatment resistance and cancer 
relapse, targeted strategies against these aggressive cells in combination with 
conventional treatment would be a promising avenue. This would not only eradicate 
most non-tumorigenic cells within the tumours but also eliminate the root cells 
considered as the source of malignancy. SCLCs are neuroendocrine tumours with 
extensive neuropeptide network which through autocrine and paracrine signalling 
fuel SCLC growth and are associated with their chemoresistance [65, 169-171]. 
Primary findings have demonstrated the involvement of expression of neuropeptide 
receptor in expansion of the brain CSCs in vitro [172]. Similar findings in SCLC 
putative CSCs may be speculated. Below, the role of neuropeptides in SCLC growth 




The regulation of cellular growth and proliferation is essential for various 
physiological processes including embryogenesis, development and tissue repair. 
Cancerous cells escape the regulatory signals from their environment and acquire 
independence from mitogenic controls. For example, various malignancies produce 
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growth factors such as neuropeptides that trigger unrestrained growth via autocrine 
(receptors present on the same cell) or paracrine signalling (receptors on adjacent 
cells) [171]. This is illustrated by the observation that, in contrast to normal tissue 
cells, cancer cells can proliferate in serum free medium [169]. These cells can evade 
physiological growth controls by alerting the number or the structure of growth 
receptors and by changes in the activity of post-receptor signalling pathways [65, 
171]. 
 
Small regulatory peptides or neuropeptides are structurally diverse group of 
hormones and neurotransmitters. In the nervous system, they serve as 
neurotransmitters, while in the peripheral neuroendocrine cells they act 
systematically as circulating hormones and locally via autocrine and paracrine loops 
[170]. Expression of neuropeptides and their receptors have been implicated in 
several diseases including inflammatory and cardiovascular diseases and 
malignancies such as breast, prostate, colon, pancreatic, renal, gastric carcinoma and 
SCLC [173]. In SCLC, neuropeptides are the principle driving force that promotes 
SCLC cell growth in vivo and in vitro [169]. Neuropeptides that act as growth factors 
include, bombesin/gastrin-releasing peptide (GRP), vasopressin, neurotensin, 
bradykanin, cholecyctokinin, and galanin [64, 169]. Modulating neuropeptide 
induced signalling may serve as a promising strategy for treatment of malignancies 
with neuroendocrine phenotype.   
 
1.6.1 G-protein coupled receptors 
 
Neuropeptides exert cell proliferation by binding to surface receptors known as G-
protein coupled receptors (GPCRs). The GPCRs are the largest group of integral 
membrane proteins involved in signal transduction. These receptors bind to, and 
transduce signals via heterotrimetic GTP binding proteins (G-proteins). GPCRs 
possess 7 membrane spanning α-helices referred to as transmembrane domains (TM) 
1-7 in addition to extracellular amino termini and cytoplasmic carboxyl termini 
(Figure 3A) [174]. Sequence homology among the GPCRs is mainly observed in the 
7 TM regions. A single conserved cysteine residue on the first two extracellular 
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loops is believed to form a disulphate bond which maintains the active form of the 
protein. Proline residues located in TM 4, 5, 6, and 7 are suggested to be essential for 
formation of binding pocket. Ligand binds to GPCRs via receptor binding pocket 
which is created by its three dimensional arrangement within the plasma membrane 
[174, 175]. 
 
GPCRs in the absence of ligand are maintained in an inactive conformation by 
stabilising intramolecular interactions. Receptor interaction with ligand leads to 
release of these constrains causing the key sequences of GPCRs to be exposed to 
various G-proteins. There are several theories explaining GPCRs activation. The 
ternary complex model, the most widely accepted theory, explains the active 
/inactive state of GPCR (Figure 3B) [176]. Inactive ‘R’ state indicates no reaction 
with G-proteins, whereas active ‘R*’ state indicates G-protein activation with 
subsequent signalling. In the absence of neuropeptide ligand, basal receptor activity 
is determined by the equilibrium between R and R*. Agonist binds to and stabilises 
R*, promoting interaction with G-proteins, whereas antagonist binds to and stabilises 
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Altered GPCR signalling has been documented in several cancers making these 
receptors the largest class of drug discovery targets (reviewed in [177]). A single 
GPCR can activate more than one G-protein, thus it is possible to design selective 
pathway antagonist which inactivate a selective subset of responses triggered by the 
receptor. Such ligand-dependence theoretically offers a completely new dimension to 
ligand-induced receptor signal control in that they have the potential to allow 
beneficial signalling to continue while blocking signalling due to pathology. This is 
useful in cancers which demonstrate inappropriate GPCR signalling due to elevated 
receptor expression or mutations causing constitutive activity leading to cellular 




G-proteins are a large family of highly homogenous heterotrimeric proteins that 
comprises of α, β, and γ subunits. At least 18 different human Gα exists which are 
divided into 4 families based upon sequence similarity: Gαs, Gαi/Gαo, Gαq/Gα11, and 
Gα12/Gα13 [178]. Similarly, at least five Gβ types and 11 Gγ types are present. 
Members of the G-proteins can stimulate multiple down-stream pathways [178]. The 
Gαs family of the G-protein stimulate adenylate cyclase, resulting in increase in the 
intracellular cAMP concentration. The G-proteins of the Gαi/Gαo family are 
ubiquitously expressed and Gi proteins are identified as inhibitory regulators of 
various types of adenylyl cyclases. In addition, recently Gi proteins are demonstrated 
to be activators of mitogen activated protein kinase (MAPK) and tyrosine kinase 
pathways. The G-proteins of the Gαq/Gα11 family are also ubiquitously expressed and 
couple receptors to β-isoforms of phospholipase C. Indirect studies indicated 
Gα12/Gα13 role in activation of phospholipase A2 and c-jun NH2-terminal kinase. In 
addition to α-subunit of the Gi proteins, dissociated βγ-complex from the α-subunit 
can also mediate multiple effectors including regulation of ion channels, specific 
isoforms of adenylyl cyclase and phospholipase C, as well as of phosphoinositide-3-
kinase isoforms [179, 180]. 
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Transfer of signals from activated receptor to effectors, requires G-proteins to 
undergo an active-inactive cycle (Figure 4). In basal state, the α-subunit contains 
bound GDP with α and βγ-subunit association. Binding of activated GPCRs to G-
proteins triggers exchange of GTP for GDP with α and βγ subunit dissociation. Thus, 
two potential pathways, the α-GTP and the βγ-subunit are generated for downstream 
signalling. The intrinsic hydrolyte activity of α-subunit finally converts GTP to GDP 
with return of G-protein to its inactive state [179, 181].  
 
Despite the importance of G-proteins in regulation of cell growth, some G-proteins 
can induce cellular transformation. Various G-protein α-subunits due to GTPase 
inactivating mutations lead to cellular transformation by protein constitutive activity 
[182]. Constitutive activity of members of α-subunit has been detected in human 
cancers such as, activated Gαs in 30% of thyroid adenomas, active mutant of Gαi in 
adrenal cortical tumours as well as in human ovarian sex cord stromal tumours [183], 
and activated Gα12 as an oncogene present in soft tissue sarcoma [184]. Despite 
transforming mutations of Gαq/Gα11 has not been detected in human tumours, 
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1.6.3 Bombesin/GRP and its receptors 
 
Bombesin, a 14-amino acid bioactive peptide, was initially isolated from frog skin 
[185]. GRP, a mammalian homologue, consists of 27 amino acids and is closely 
related to bombesin [186]. The GRP gene is located on chromosome 18 at 18q21 
[186]. It functions as a neuro-transmitter as well as an intestinal, adrenal and pituitary 
hormone [187]. In lungs, GRP is a potent mitogen for both normal bronchial 
epithelial and malignant SCLC cells [188-190]. Studies on Swiss 3T3 cells have 
shown that this neuropeptide stimulates colony formation in semi-solid medium and 
can induce DNA synthesis and cellular proliferation. 
 
Three structurally and pharmacologically distinct bombesin receptors have been 
identified which belong to the super-family of GPCRs. These include the GRP-R, 
neuromedin B receptor (NMB-R) and bombesin receptor subtype-3 (BRS-3) that 
display different affinity for ligand GRP and NMB. These receptors are expressed in 
an overlapping subset of human lung cancer cell lines [191]. 
 
1.6.4 Vasopressin and its receptors 
 
Arginine vasopressin (AVP) is a cyclic nonapeptide and its expression is mainly 
restricted to the hypothalamus in physiological conditions [192]. Two main types of 
vasopressin receptors have been identified, V1 and V2 receptor [192]. V1 receptor, 
sub-divided into V1a and V1b, is involved in multiple physiological processes 
including vasoconstriction, liver glycogenolysis and various brain functions. V2 
receptor expression is mainly identified in the renal system, and its activation is 
associated with reabsorption of H2O [193]. 
 
V1 receptors via activation of inositol phosphate turnover regulate vascular and 
hepatic functions stimulated by AVP. V2 receptors couple to adenylate cyclase and 
regulate antidiuretic responses. Like bombesin/GRP, in Swiss 3T3 cells, AVP results 
in Ca
2+
 mobilisation and PKC production mediated by G-protein linked transduction 
pathway leading to cellular proliferation in liquid culture and increased clonogenicity 
in semi-solid medium (reviewed in [170]).  
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1.6.5 Neuropeptide mediated signal transduction 
 
Neuropeptides, including GRP and vasopressin are principle mitogenic stimuli for 
SCLC cells which activate the heterotrimeric G-proteins, namely Gq/11, Gi/o, and G12 
(Figure 5) [194]. Predominantly, receptors couple to Gq to elicit phospholipase C-β 
(PLCβ) activation with subsequent production of diacylglycerol (DAG) and 
phosphatidylinositol 1, 4, 5-triposphate (IP3), triggering protein kinase C (PKC) 
activation and Ca
2+
 mobilisation,  respectively [195, 196]. The resultant Ca
2+
 induced 
extracellular signal regulated kinase (ERK) activation is essential for the anchorage-
independent phenotype and SCLC proliferation [197]. PKC activation by 
neuropeptides is involved in cell cycle regulation through Ras/Raf/ERK cascade in 
several cell types. Additionally, neuropeptide activated PKC results in activation of 
protein kinase D (PKD), a novel kinase cascade downstream of PKC. In Swiss 3T3 
cells, neuropeptide activated PKC with subsequent PKD activation leads to DNA 
synthesis and cell proliferation raising the possibility of the PKC/PKD pathway in 
SCLC growth [198]. 
 
These peptides also activate Gi and G12 (Figure 5). Receptors coupled to Gi family 
regulate cellular proliferation through both αi and βγ subunits. The βγ subunits via 
direct stimulation of PI3K activate the Ras/Raf/MEK/ERK cascade. ERK activation 
can be mediated by Gαi subunit independent of βγ subunits and PI3K Ras activation 
[199]. Therefore, ERK activation via Gi protein is by both α and βγ subunits. 
Neuropeptide receptors couple to G12 to elicit activation of Rho family of small 
GTPase which are involved in the regulation of cytoskeleton and contribute to C-Jun 
N-terminal Kinase (JNK) cascade activation [200]. Activation of G12/13 proteins in 
SCLC cell is associated with maintenance of cellular morphology but does not have 
any impact in SCLC proliferation. Rho family by regulating the dynamics of 
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1.6.6 Neuropeptides and SCLC 
 
SCLC cells express and secrete various neuropeptides that mediate uncontrolled 
growth of the malignancy [169, 201]. The concept was supported by colony assay in 
which multiple neuropeptides stimulated clonal growth of SCLC cell lines in serum-
free semi-solid medium. In this section the effects of GRP and vasopressin on SCLC 
cell growth will be discussed. 
 
1.6.6.1 Gastrin releasing peptide and SCLC  
 
GRP regulates growth of normal human bronchial epithelium as well as SCLC cells 
[188, 189]. In the embryonic lung, expression of bombesin is associated with 





]-bombesin [188]. In the adult lung, GRP is secreted by lung 
neuroendocrine cells as a response to change in lung oxygen levels as observed in 
lung diseases including chronic obstructive airway diseases which causes reduced 
lung oxygenation [202]. Elevation in GRP secretion in adult lung is associated with 
lung neuroendocrine hyperplasia and increased expression of GRP has been 
documented in smokers [203].  
 
GRP stimulates SCLC growth in vitro and in vivo. Treatment of 10 SCLC cell lines 
with GRP increased colony formation up to 150-fold in 9/10 cell lines [204]. In 
another study, addition of GRP was associated with increased DNA synthesis in 
SCLC cell lines [205]. The mitogenic effect of this neuropeptide was also confirmed 
in vivo. Treatment of NCI-H69 xenograft with GRP three times daily IP injections, 
increased tumour growth by 77% when compared with untreated controls [206].  
 
1.6.6.2 Vasopressin and SCLC 
 
Vasopressin is mitogen for SCLC. Both vasopressin and its receptor expression in 
SCLC indicate that the neuropeptide is an autocrine growth factor for the malignancy 
enhancing transcription, cell proliferation and augmenting cell survival [64, 171]. 
67% of SCLCs show immunoreactivity to AVP [207]. All three receptors of 
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vasopressin, namely V1a, V1b, and V2 are present in SCLC cells [208]. The 
expression of AVP and its receptor serve as a diagnostic tool to differentiate SCLC 
from NSCLC which are devoid of the hormone and its receptors [209]. The ectopic 
expression produces clinical syndrome known as SIADH, as seen in SCLC patients 
[24]. Targeting this growth factor could benefit SCLC patients.  
 
1.6.7 Blocking growth factor action as a therapy for neuroendocrine 
cancers 
 
Current chemotherapeutic agents target rapidly dividing malignant cells. However, 
normal tissue cells are also exposed to cytotoxic insults, producing adverse effects. 
Targeting neuropeptide autocrine and paracrine loops in SCLC and other 
neuroendocrine cancers by neutralising ligand or inhibiting its interaction with its 
receptors are promising interventional strategies that would block mitogenic effects 
on neoplastic cells. 
 
Several groups have designed specific bombesin antagonist aimed at inhibiting its 
mitogenic effect on cancer cells. Bombesin monoclonal antibody, 2A11, was used to 
retard SCLC cell growth in vitro and in nude mice xenografts [190]. The antibody 
entered phase I clinical trial with no limiting toxicity [210]. However, antibodies 
may be antigenic, are costly to manufacture and its large size makes tissue 
penetration ineffective compared to small peptide drugs. Alternatively, peptide 




] bombesin that readily 
inhibited Ca
2+
 mobilisation and clonal growth in Swiss 3T3 cells was introduced 
[211]. However, these receptor antagonists are effective in malignancies selectively 
expressing bombesin receptors and are expected to have poor clinical outcome in 
cancers with multi-neuropeptide receptor expression including SCLC. This 
necessitated the introduction of broad spectrum Substance P analogues that are able 
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1.6.7.1 Broad spectrum neuropeptide antagonists as novel SCLC therapy 
 
Substance P (SP) is an 11-amino acid neuropeptide (Arg-Pro-Lys-Pro-Gln-Gln-Phe-
Phe-Gly-Leu-Met-NH2) that functions as neurotransmitters and neuromodulators 
[212]. Synthetic analogues of SP proved to be antagonists of various SP mediated 
cellular effects as well as other neuropeptide activities. Some of these analogues are 
shown in table (Table 3). In SCLC cells, SP analogues inhibited [Ca
2+
]i mobilisation 
stimulated by multiple neuropeptides including bombesin, vasopressin, bradykinin, 
gastrin, galanin, cholecystokinin, and neurotensin [64, 213, 214]. Based on this 
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Set backs encountered with SP analogues are their relatively low potency (M 
range). Additionally, easy inactivation of antagonists by serum peptidases makes 
systemic delivery difficult and often impossible. Thus, chemical modifications for 
augmentation of affinity and stability have been suggested. Victor Hruby et al., [215] 
demonstrated improved stability with D-amino acid substitution. Substitution of 
glutamine in position 5 by D-phenylalanine (DPhe) in a SP analogue spantide 
(DArg-DPro-Lys-Pro-Gln-Gln-DTrp-Phe-DTrp-Leu-Leu-NH2) resulted in 5-10 fold 
increased potency to inhibit neuropeptide mediated growth of the new analogue, 
DArg-DPro-Lys-Pro-DPhe-Gln-DTrp-Phe-DTrp-Leu-Leu-NH2 (SP-D). 
Additionally, the replacement of position 5 DPhe by D-tryptophan (DTrp) in SP-D 
produced even greater inhibitory potency of the new analogue, DArg-DPro-Lys-Pro-










) substance P (6-11) is a broad spectrum neuropeptide 
antagonist. It functions as an antagonist to multiple neuropeptide mitogens including 
GRP, vasopressin, bradykinin, and endothelin [213, 218]. This analogue inhibited the 
growth of SCLC cell lines in liquid and semi-solid media with IC50 values of 
approximately 20 µM [213, 214]. SP-G has also demonstrated dramatic inhibitory 
effect on SCLC cell cloning efficiency in the absence of exogenously added 
neuropeptide (basal colony formation) [219]. The knowledge that SP-G inhibits basal 
and stimulated clonal growth of SCLC cells regardless of positivity for bombesin 
receptors strongly suggest that, it could be a more effective anticancer drug than 
ligand specific growth factor antagonists. 
 
In addition to in vitro inhibitory effect, SP-G effectively inhibited in vivo growth of 





produced complete inhibition with effects extending beyond the period of 




 for 7 days likewise 
produced significant growth inhibition in WX322 xenograft [220]. The growth 
inhibitory effect of SP-G has been shown to be at least partly due to apoptosis. In 
SCLC cell lines, this analogue has proven to induce apoptosis at similar 
concentrations that causes growth inhibition [221]. 
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SP-G inhibited growth of various other neuroendocrine tumours including colorectal, 
pancreatic and ovarian cancers [65]. The growth inhibitory effects of SP-G (IC50) in 
a panel of cell lines are demonstrated in Table 4. According to unpublished data from 
my laboratory, SP-G retarded the tumour growth of colorectal cancer cell lines, 
HT29 and ovarian cancer cell line, PE04 in vivo indicating the analogue could 
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The exact mechanism by which these analogues induce their cytotoxic effect is 
subject to considerable debate. SP analogues can reversibly inhibit the binding of 
multiple neuropeptides to their receptor subsequently retarding signalling pathways 
stimulated by these growth factors. This observation suggested that SP analogues 
function as competitive antagonists of ligand binding. However, even in the presence 
of high concentrations of exogenous neuropeptides, the growth inhibitory and pro-
apoptotic effect of SP analogues are not reversible indicating these analogues 
function via a mechanism distinct from or in addition to competitive neuropeptide 
antagonism [221]. One theory is that SP analogues may also insert cell membrane 
and induce their cytotoxic effect by directly modulating G-proteins [222]. However, 









] substance P, abolishes the signal transduction 







] demonstrated inhibitory effect against vasopressin but 
was ineffective against bombesin suggesting that SP analogues induce their effect at 
receptor level. 
 
Multiple studies have recently demonstrated that SP analogues function in a more 
complex manner than data documented previously. Jarpe et al., [223] demonstrated 
that SP-D, similar to neuropeptides, via G12 activate JNK thus, demonstrating agonist 
activity. However, in contrast to neuropeptides, SP-D via Gq inhibited Ca
2+
 
mobilisation demonstrating antagonist activity. Similar observation was made in my 
laboratory. SP-D administered to block bombesin stimulated Ca
2+
 release via Gq 
protein, additionally caused sustained activation of JNK and ERK [224]. Likewise, at 
V1A vasopressin receptor, SP-G via Gi led to sustained activation of ERK alongside 
Gq inhibition [225]. Thus, SP analogues are able to activate and inactivate different 
arms of signal transduction pathways at single receptors. Based on these observations 
the terminology of “biased agonism” was proposed to define SP analogue 
mechanism of action (Figure 6) [223]. Based on this theory, SP analogues 
preferentially stabilise R*2 than R*1. Discordant signalling induced by sustained 
activation of JNK and ERK along inhibition of [Ca
2+
]i mobilisation is the proposed 
cause of induction of apoptosis and inhibition of tumour growth upon SP analogue 
exposure. 
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The most exciting property of SP-G is that it is more effective in resistant disease 
[65, 171, 226]. Waters et al, [65] demonstrated that chemoresistance in SCLC cell 
lines was associated with increase expression of neuropeptide receptors. This was 
evaluated by quantifying the expression levels of GRP-R by semi-quantitative RT–
PCR in three human SCLC cell lines (GLC14, 16 and 19) established from the same 
patient during longitudinal follow-up [227, 228]. During therapy, the patients’ 
tumour progressively changed from chemosensitive to resistant. GLC14 was 
established before treatment, GLC16 was derived from tumour recurrence after 
chemotherapy and GLC19 was derived from tumour recurrence after chemo- and 
radio-therapy. Increase expression of GRP-R on the drug resistant cells was 
subsequently associated with enhanced responsiveness to SP-G. Treatment with SP-
G inhibited the growth and the cloning efficiency of GLC14, 16 and 19, but the 
analogue was most efficient in the GLC19 cell line (IC50 for the GLC14, 16 and 19 
SCLC cells was 25, 25 and 15 µM, respectively, for liquid culture, and 25, 25 and 5 
µM, respectively, for cloning efficiency) [65]. Similarly, in ovarian, colorectal and 
pancreatic cancer cell lines, sensitivity to SP-G positively correlated to the 
expression of GRP-R expression in these cell lines [65]. Moreover, transfection of 
GRP-R into rat-1A fibroblast significantly increased their sensitivity to SP-G [65]. 
Thus, targeting resilient malignant cells with SP-G and other novel analogues may 
opened a new horizon for cancer management. 
 
SP-G has completed a phase I clinical trial where in patients on consent received 6 
hour infusion of the peptide every three weeks for up to 12 cycles [66]. 
Pharmacokinetic analysis of patient plasma demonstrated that the mean plasma 
concentration at maximum dose was 40 µM, well within the range for in vitro growth 
inhibition. No dose limiting toxicity was observed. This analogue did not enter phase 
II clinical trail due to its major set back with in vivo rapid degradation. Plasma 
concentration of the antagonist was brief on discontinuation of the drug [66]. Such 
short exposure of an agent cumulates into unsatisfactory therapeutic outcomes. Rapid 
antagonist clearance implicates larger doses. Thus, continuous protracted infusions 
were required making therapy not feasible.  
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Together these data suggest that the post-chemotherapy, clinically aggressive, 
resilient SCLCs might display a more extensive network of neuropeptide regulation. 
On the other hand, SP-G may be more beneficial in chemoresistant disease and can 
sensitise SCLC to chemotherapy. With the concept of CSCs, the pathogenesis of 
SCLC should be revised. These cells are the proposed cause of chemoresistance in 
cancer. Thus, targeting resilient malignant cells with analogues similar to SP-G but 






























Despite advances in chemotherapy and radiotherapy regimes there has been little 
impact on the long-term survival in SCLC patients. The presence of CSCs which are 
stem cell-like cells with chemoresistant and tumorigenic potentials are the possible 
explanation for therapy resistance and tumour recurrence observed in these patients, 
emphasising the urgent need of alternative therapies. Based on the findings in my 
laboratory, resistance in SCLC cells is associated with increased expression of 
neuropeptide receptor expression and subsequent enhanced sensitivity to 
neuropeptide analogues. Therefore, it is hypothesised that SCLC CSCs express 
higher levels of neuropeptide receptors making these chemoresistant aggressive cells 




With the background described in the introduction the aims of this PhD were: 
 
A. Identify and characterise SCLC CSCs 
B. Investigate the expression of neuropeptide receptors on the CSCs 
C. Design more stable and potent neuropeptide antagonist for the eradication of 
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CHAPTER 2: 
Materials and Methods 
 
 
2.1 Chemotherapeutic reagents 
 
 
Etoposide was purchased from Sigma-Aldrich, UK. In collaboration with Professor 
Mark Bradley (Department of Chemistry, Kings Building, Edinburgh) a series of 
analogues were synthesised based on the structure of SP-G and SP-A. The eight 













2.2.1 Antibodies used for flow cytometry 
 
Mouse monoclonal anti-human CD133-1, APC conjugated (clone AC133), anti-
human CD133-2, PE conjugated (clone AC141), monoclonal anti-mouse IgG1, APC 
conjugated, and monoclonal anti-mouse IgG1, PE conjugated were from Miltenyi 
Biotec, Germany. 
 
2.2.2 Antibodies used for western Blotting 
 
Rabbit monoclonal anti-actin was from Sigma-Aldrich, UK. Mouse monoclonal 
anti-human CD133-1 (W6B3C1) was purchased from Miltenyi Biotec, Germany. 
Goat polyclonal anti-human Oct-3/4 (C-20) was from Santa Cruz Biotechnology, 
USA. Rabbit monoclonal anti-Protein Kinase B (Akt/PKB) [pS
473
] (193H12) 
antibody was from Cell Signalling, USA. Mouse monoclonal anti-Bcl-2 (Ab-1) was 
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from Merck Millipore, Germany. Rabbit polyclonal anti-gastrin-releasing peptide 
receptor, GRP-R was from Fisher scientific, USA. Rabbit polyclonal anti-
vasopressin receptor, V1A-R was from Enzo Life Sciences, UK. 
 
2.2.3 Antibodies used for IHC 
 
Rabbit polyclonal anti-human CD133 (ab16518) was from Abcam, UK. Biotinylated 
donkey anti-rabbit IgG (H+L) was from Vector laboratories, USA. Rabbit 
monoclonal anti-human NCAM (clone EP2567Y) was from Epitomics, USA. Rat 
monoclonal anti-mouse CD45 (clone 30-F11) was from BD Biosciences, USA. 
 
2.3 Tissue culture reagents and cell lines 
 
Tissue culture plates (6- and 96-well plates) were purchased from Life Technologies, 
UK. 20 µM pore size nylon gauze was from BD Biosciences, USA. Tissue culture 
reagents Rosewell Park Memorial Institute Medium 1640 (RPMI 1640), Dulbecco’s 





, Hanks balanced salt solution (HBSS) with/without calcium and L-glutamine, 
penicillin/streptomycin, and trypsin were from PAA, Austria. Foetal Calf Serum 
(FCS) was from Biosera, UK. Insulin-Transferrin-Sodium Selenite (SIT) media 
supplement, soya bean trypsin inhibitor, Bovine Serum Albumin (BSA) and Agarose 
were from Sigma-Aldrich, UK. 
 
Small cell lung cancer cell lines (SCLC), NCI-H69 and NCI-H345 were obtained 
from American Type Tissue Culture Collection, USA. Table 5 demonstrates the 
characteristics of cell lines used. Cells were maintained in RPMI 1640 supplemented 
with 10% (v/v) heat-inactivated FCS (heat-inactivated at 57ºC for 1h), 5 µg/ml L-
glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin (complete medium). For 





and were re-suspended in RPMI 1640 supplemented with, 
SIT media supplement consisting of, 30 nM selenium, 5 µg/ml insulin, 10 µg/ml 
transferrin and 0.25 % (w/v) BSA (SITA medium). SCLC cells were maintained in 
suspension at 1-3 × 10
6
 cells/ml and were passaged into fresh medium twice a week. 
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G6A-CHO and V1A-CHO cells are CHO-K1 cells expressing with full-length human 
GRP-receptor or human V1A-receptor, respectively by Mackinnon et al., 2005 [171] 
Both cell lines were maintained in DMEM supplemented with 10% (v/v) heat-
inactivated FBS, 5 g/ml L-glutamine, 50 U/ml penicillin and 50 g/ml 
streptomycin, 1% non-essential amino acids and 400 g/ml G418-sulphate (DMEM 
complete medium). Cell lines were maintained at 10-80% confluence and passaged 
twice a week by treatment with trypsin (0.1%). For experimental purposes, cells were 




 and were resuspended in DMEM 
supplemented with 5 g/ml L-glutamine, 50 U/ml penicillin and 50 g/ml 
streptomycin and 1% non-essential amino acids, and 0.1% FCS (DMEM quiescent 
medium). 
 
All cells were maintained in a humidified atmosphere of 5% CO2 at 37ºC and were 
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2.4 Liquid growth assay 
 
SCLC cells were centrifuged at 300 × g for 5 minutes, washed twice in PBS and re-
suspended in SITA or complete medium. Cells were gently disaggregated by 3 × 
passes through a p1000 pipette and then filtered through a 20 µm pore size nylon 
gauze. Cell viability and number was evaluated using NucleoCounter NC-100 
(ChemoMetec, Denmark) based on the manufacturer’s instruction. In brief, samples 
were treated with equal volumes of NucleoCounter reagent A100 
(lysis/disaggregation buffer) and reagent B (stabilising buffer) which causes 
disruption of plasma membrane of all cells, permitting access of propidium iodide 
(PI) to cell nucleus, and therefore allowing determination of total number of cells 
within the sample. The number of non-viable cells was determined in parallel 
samples suspended in reagent B only.  Viable cell number was calculated as total cell 
number minus non-viable cell number. Cells were plated at a density of 1 × 10
4 
cells/well, in the presence or absence of mediators in triplicate in flat bottom 96-well 
plates. Cell number was determined every 2 days for a period of 24 days using the 
NucleoCounter NC-100. Prior to counting cell clumps were disaggregated by passing 
the cell suspension gently 3 times through p1000 pipette. 
 
2.5 MTT Assay 
 
MTT assay is a colorimetric method to determine cell viability. Yellow MTT (3-(4,5- 
dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide) is reduced to purple 
formazan in the mitochondria of living cells, allowing measurement of the cytotoxic 
affect of chemotherapeutic agents on cell viability. Dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich, UK) is added to dissolve the insoluble purple formazan product into 
a coloured solution, the absorbance of which can be measured at λ570 nm on a 
spectrophotometer. Viable cells at density of 5 × 10
4
 cells/well were re-suspended in 
SITA medium and cultured in 96-well round-bottom plates. Cells were exposed to a 
series of concentrations of SP-G or neuropeptide analogues from 1 µM to 100 µM or 
etoposide from 1 µg/ml to 100 µg/ml and were incubated in 5% CO2 at 37°C. After 
72 hours, 1:10 dilution of 4 mg/ml MTT (Sigma-Aldrich, UK) solution in PBS was 
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added to each well (0.4 mg/ml final concentration) and samples were further 
incubated for 4 hours at 37°C. Plates were centrifuged at 300 × g for 5 minutes and 
supernatant was replaced by DMSO. The purple solution was transferred to a 96-well 
flat-bottom plate and absorbance was determined. Viability is expressed as a 
percentage of control. 
 
2.6 Western blot 
 
2.6.1 Cell lysis and assessment of protein concentration 
 
Cells were washed once in PBS, lysed with appropriate volume of lysis buffer at 4°C 
for 25 minutes at 4°C. Lysates were cleared by centrifugation at 13000 rpm for 10 
minutes at 4°C. Whole cell lysates were normalised for protein concentration using 
bicinchoninic acid (BCA) protein assay reagent according to the manufacturer’s 
instructions (Pierce, USA). BCA protein assay is a two-step method with an initial 
biuret reaction where cupric ion reduces to cuprous ion followed by the chelation of 
BCA with the cuprous ion, resulting in purple colour that can be measured by 
spectrophotometry. Normalised whole cell lysates were solubilised in 4 × sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer at 
95°C for 5 minutes. Samples were analysed immediately or stored at -20°C for future 
analysis.  
 
2.6.2 SDS-PAGE and western blotting 
 
Buffer ingredients are explained in detailed in sections 2.6.3. Equal amount of cell 
extract (20-80 µg/lane) were loaded onto 10-12 % SDS-PAGE gels using a vertical 
electrophoresis tank Bio-Rad Mini Protean® II system (Bio-Rad, USA). Samples 
were electrophoresed at 150 V for 1-2 hours using electrophoresis buffer. Proteins 
were transferred onto Hybond C nitrocellulose (GE Healthcare Life Sciences, UK) 
membrane in an ice-cold transfer buffer at 100 V for 60 minutes. Equal protein 
loading was confirmed by incubating blots for 5 minutes in 1% Ponceau S (AMS 
Biotechnology, UK).  Non-specific binding sites were blocked by incubating the 
membrane with 5% non-fat dried milk powder or 5% BSA in Tris-buffered saline 
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(TBS)-Tween 20 (0.1%) overnight at 4°C. Membranes were probed with appropriate 
antibodies diluted in blocking buffer, overnight at 4ºC. Membranes were washed 3 × 
5 minutes in TBS-Tween  before incubating for 1 hour at room temperature  (20-25 
°C)  with species-appropriate horseradish peroxidase (HRP) conjugated secondary 
antibody (diluted 1:2000 in blocking buffer).  Membranes were further washed in 
TBS-tween 20 (3 × 5 minute washes) and the immunoreactive bands were identified 
using enhanced chemiluminescence (ECL) (GE Healthcare Life Sciences, UK) as per 
manufacturer’s instructions.  ECL is a high resolution, non-radioactive method of 
detecting specific immobilised antigens that are conjugated (directly or indirectly) to 
HRP labelled antibodies.  Membranes were then exposed to Kodak Medical X-ray 





HEPES, PH7.4     25 mM 
NaCl     0.3 M 
MgCl2     1.5 mM 
Ethylenediaminetetraacetic acid (EDTA)     0.2 mM 
Triton X-100     0.5% (v/v) 
Sodium orthovanadate     1 mM 
Dithiothreitol (DTT)     0.5 mM 
One Complete™ protease inhibitor tablet (Roche, UK) was added per 50 ml of lysis 
buffer. 
 
4 × SDS-PAGE sample buffer 
Tris-HCl        50 mM 
SDS          2% (v/v) 
Glycerol         10% (v/v) 
Bromophenol blue        0.1% (v/v) 
β-mercaptoethanol (PH, 6.8)      10% (v/v) 
 
SDS polyacrylamide gels 
Stacking gel: 
Tris base (pH 6.8)       0.125 M  
SDS         0.1% (v/v)  
Acrylamide solution       4.5% (v/v) 
Ammonium persulphate      0.1% (v/v) 
TEMED        0.02% (v/v)  
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Separating gel:  
Tris base (pH 8.8)       0.375 M  
SDS         0.1% (v/v)  
Acrylamide solution       10-12% (v/v) 
Ammonium persulphate      0.1% (v/v) 
TEMED        0.02% (v/v)  
 
1 × Gel electrophoresis running buffer 
Tris base        50 mM 
Glycine                                                                                 250 mM 
SDS         0.1% (v/v) 
 
Blotting buffer 
Glycine        210 mM 
Tris base        24.7 mM 
Methanol        20% (v/v) 
 
TBS-Tween 20 wash buffer 
Tris HCl (pH 7.4)       20 mM 
NaCl         150 mM 
Tween-20        0.1% (v/v) 
 
2.7 Clonogenic assay 
 
SCLC cells were centrifuged at 300 × g for 5 minutes, washed twice in PBS and re-
suspended in SITA or complete medium. Cells were gently disaggregated by 3 × 
passes through a p1000 pipette and then filtered through a 20 µm pore size nylon 
gauze. Single cell suspension was judged by light microscopy. 10
4
 viable cells 
counted using the NucleoCounter NC-100, were suspended in SITA or complete 
medium containing 0.3% low melting point SeaKem agarose in the presence or 
absence of mediators, and layered over a solid base of 0.5% agarose in SITA or 
complete media, in 35 mm plastic tissue culture dishes. The cultures were incubated 
at a humidified atmosphere of 5% CO2 at 37ºC for 21 days. Colonies (>16 cells) 
were counted by light microscope. Colonies of at least 10 different random fields 
were counted for each well. Clonogenic efficiency is presented as the percentage of 
the cells seeded forming colonies and is calculated as below: 
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Step 1:  
Average of number of colonies counted × Area of the dish in which cells were 
seeded 
= Total number of colonies 
 
Step 2: 
(Total number of colonies / The number of cells seeded) ×100 
= cloning efficiency 
 
2.8 Flow cytometry 
 
Cells were centrifuged at 300 × g for 5 minutes, washed twice in PBS and re-




, 0.5% BSA, and 2 mM 
EDTA, pH 7.2). Cells were gently disaggregated by 3 time passes through a p1000 
pipette and then filtered through a 20 µm pore size nylon gauze. Single cell 
suspension was judged by light microscopy. 10
6
 viable cells were counted using a 
NucleoCounter NC-100 (ChemoMetec, Denmark) and were added to polystyrene 
FACS tubes (Becton Dickinson, UK). Cells were re-centrifuged at 300 × g for 5 
minutes and re-suspended in MACS buffer with FCR blocking reagent (1:50 
dilution, Miltenyi Biotec, Germany) and CD133-1-APC or CD133-2-PE antibodies 
(1:100 dilution) or mouse IgG1-APC or IgG1-PE isotype control (1:100 dilution). 
Samples were incubated at 4°C for 10 minutes and subsequently washed with MACS 
buffer at 300 × g for 10 minutes and re-suspended in the same buffer. Until analysis, 
all samples were kept on ice. Samples were analysed on FACSCalibur or 
LSRFortessa (BD Biosciences, USA) with Diva option. Data was analysed using 
FlowJo software (Tree Star Inc., USA). Dead cells were excluded from the analysis 
using 0.1 µg/ml 4,6 diamidino-2-phenylindole (DAPI) or propidium iodide (PI) at 
1µg/ml. 
 
2.8.1 Flow sorting 
 
Cells were stained for CD133 as described above with minor modifications. After 
CD133 staining, cells were re-suspended in RPMI 1640 supplemented with 5 g/ml 
L-glutamine, 50 U/ml penicillin and 0.1 % BSA. Addition of BSA was required to 
maintain cell viability during sorting. Before cell sorting samples were filtered again 
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through a 20 µm pore size nylon gauze. Approximately 10
8
 cells were prepared per 
sort. Samples were loaded on the machine in 3 ml volumes. This was the optimal 
volume for maintaining cell flow throughout the cell sorting. Cells were sorted with a 
100 µM nozzle on a FACSVantage (BD Biosciences, USA).  
 
2.8.2 MicroBeads isolation 
 
CD133 MicroBead Kit (Miltenyi Biotec, Germany) was used to isolate CD133+ and 
CD133- SCLC cells. The procedure of cell isolation is as described my 
manufacturer’s protocol. In brief, cells were centrifuged at 300 × g for 5 minutes, 





, 0.5% BSA, and 2 mM EDTA, pH 7.2). Cells were gently disaggregated by 3 
time passes through a p1000 pipette and then filtered through a 20 µm pore size 
nylon gauze. Single cell suspension was judged by light microscopy. 10
8
 viable cells 
were counted using a NucleoCounter NC-100 and were added to polystyrene FACS 
tubes (Becton Dickinson, UK). Samples were incubated with CD133 MicroBeads 
(magnetic nanoparticles coated with CD133 antibody provided by the kit) for 30 
minutes at 4°C and washed with 2 ml of MACS buffer at 300 × g for 10 minutes and 
re-suspended in 500 µl MACS buffer. For magnetic sorting MS MACS column 
(Miltenyi Biotec, Germany) with MiniMACS separator (Miltenyi Biotec, Germany) 
was used. The column was placed on the separator and was rinsed with 500 µl of 
buffer. Cell suspension was applied to the column and flow-through (containing 
unlabelled cells, CD133- cells) was collected. The column was washed 3 × with 500 
µl of buffer and the flow-through was discarded. To collect the CD133 labelled cells, 
the column was removed from the separator and 1 ml of buffer was added to the 
column was immediately flushed out by firmly pushing the plunger into the column. 
To increase the purity of CD133+ cells, samples were run over a second MS column 
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2.8.3 Flow sorting and MicroBeads isolation purity check 
 
 
The purity of the sorted populations was checked by evaluating the expression of 
CD133 antigen via the presence of its epitope-1 and epitope-2. CD133-1-APC 
antibody binds to epitope-1 and CD133-2-PE antibody binds to epitope-2 of this 
antigen. Cell sorting was performed using CD133-1-APC antibody. To evaluate the 
purity of sorted cells based on epitope-1 of CD133 antigen, an aliquot of the sorted 
cells was re-run on the same machine used for cell sorting (FACSVantage). 
Analysing the expression of sorted cells based on the presence of CD133-1 epitope 
(an epitope of CD133 antigen initially used for cell sorting) was carried out to 
determine whether the sorted cells would appear in the gates that they were initially 
selected, therefore confirming the purity of isolation.  
 
The purity of sorted cells (by Flow sorting or MicroBeads) was also confirmed via 
the presence of epitope-2 of CD133 antigen. An aliquot of the sorted cells were 
stained by CD133-2-PE antibody (as described in section 2.8) and were analysed on 
the flow cytometry. Evaluating the presence of CD133 antigen via a second epitope 
could further confirm that sorted cells are pure. 
 
2.9 ALDH and ALDH, CD133-1-APC double staining 
 
To identify cells with high aldehyde dehydrogenase 1 (ALDH1) enzymatic activity, 
ALDEFLUOR® kit (Stem cell Technologies, UK) was used. The protocol was based 
on the manufacturer’s instructions. In brief, H345 and H69 (1 × 10
6
 cells/ml) were 
centrifuged at 300 × g for 5 minutes and were washed once in PBS. Cells were then 
re-suspended in Aldefluor assay buffer containing fluorescent ALDH-substrate, 
BODIPY-aminoacetaldehyde (BAAA) at 1 µmol per 1 × 10
6
 cells/ml, and incubated 
in the dark for 30 minutes at 37°C. BAAA in the presence of ALDH enzyme is 
converted to fluorescent BODIPY-aminoacetate (BAA) which is negatively charged 
thus, live cells retain the product causing the cell to fluorescence. CSCs are identified 
by flow cytometry as cells with higher fluorescence due to higher levels of ALDH. 
ALDH activity was measured by LSRFortessa (BD Biosciences, USA). As a 
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negative control, an aliquot of samples were treated with ALDH inhibitor, 
diethylaminobenzaldehyde (DEAB) at a concentration of 50 mM.  
 
For double staining SCLC cells with ALDH and CD133-1-APC, samples were 
initially labelled for ALDH activity and subsequently CD133 expression. The 
staining procedure for ALDH activity and CD133 expression was as described 
above. However, after labelling cells with CD133 antibody, samples were re-
suspended and washed with Aldefluor buffer containing 0.5% BSA instead of MACS 
buffer. This was based on the knowledge that the Aldefluor assay buffer contains 
specific inhibitors necessary to maintain Aldefluor reaction products inside the cell, 
allowing detection of ALDH+ population.  Samples labelled with mouse IgG1-APC, 
DEAB, and double stained with mouse IgG1-APC and DEAB were used as negative 
controls. 
 
2.10 Self-renewal (maintaining stem cell-like phenotype) and differentiation 
 
The self-renewing potential of CD133-expressing cells was evaluated based on the 
ability of these cells to retain the expression of the stem cell marker CD133 after 30 
days of culturing in SITA medium. CD133+ and CD133- H345 sorted cells and 
parent (unsorted) cells were immediately transferred into SITA medium, a well 
characterised serum-free medium appropriate for SCLC in vitro growth. Cells were 
cultured in SITA medium for 30 days and were maintained in suspension at 1-3 × 
10
6
 cells/ml and were passaged into fresh medium twice a week. 30 days post-
culturing, 1 × 10
6
 viable cells were stained with CD133-2-PE and the expression of 
CD133 (epitope-2 of this antigen) was analysed by flow cytometry (for details of 
CD133 staining see section 2.8). 
 
The self-renewing potential of cells was also assessed by the ability of CD133+ cells 
to maintain their colony forming ability after long periods in culture. Therefore, 10
4
 
viable cells cultured for 30 days in SITA medium were transferred into semi-solid 
SITA medium (for details of colony assay see section 2.7). After 21 days the cloning 
efficiency was determined using light microscopy.  
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To assess the differentiation potential, H345 sorted and unsorted parent cells were 
immediately plated in RPMI 1640 complete medium (serum-containing medium) for 
30 days and were maintained in suspension at 1-3 × 10
6
 cells/ml and were passaged 
into fresh medium twice a week. After this period, 1 × 10
6
 viable cells were stained 
with CD133-2-PE and the expression of CD133 was analysed by flow cytometry. 
 
Additionally, to confirm differentiation, the colony forming ability and liquid growth 
potential of the sorted populations cultured in serum containing media was evaluated. 
For colony assay, 10
4
 viable cells maintained in serum-containing medium for 30 
days were transferred into semi-solid RPMI 1640 complete medium (for details of 
colony assay see section 2.7). After 21 days the cloning efficiency was determined 
using light microscopy. For liquid growth, cultured cells for prolong period in serum 
containing medium were transferred in fresh RPMI 1640 complete medium at a 
density of 1 × 10
4 
cells/well. Cell number was determined every 2 days using 
NucleoCounter NC-100 (ChemoMetec, Denmark) over 24 days (for details of liquid 
growth assay see section 2.4). 
  
2.11 Assessment of apoptosis 
 
2.11.1 Ethidium bromide/acridine orange staining 
 
SCLC cells were plated into 96-well plates at a density of 1 × 10
4 
cells/well in SITA 
medium containing test compounds and apoptosis was assessed after 72 hours 
exposure by the addition of 1l of ethidium bromide (EB) (1mg/ml) and 1l of 
acridine orange (AO) (1mg/ml) (Sigma-Aldrich, UK). Samples were mixed gently 
and after 2 minutes the percentage of apoptotic cells were determined by fluorescent 
microscopy (Olympus BH2 fluorescence microscope). The assay is based on the loss 
of plasma membrane integrity during cell death. The cationic dye, AO, can cross the 
plasma membrane of viable and apoptotic cells, which when intercalated with DNA 
can be excited and emits green fluorescence. Conversely, EB is unable to penetrate 
the intact cell membrane of viable and early apoptotic cells. With apoptosis 
membrane permeability increases and apoptotic cells stain with both EB and AO. 
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However, EB has higher intensity emission and on binding to DNA emits orange 
fluorescence on excitation, therefore, apoptotic cells appear orange. Viable cells and 
cells at different stages of apoptosis can be identified based on their fluorescence and 
their morphology (Figure 7); 
Healthy viable cells: Green nucleus 
Early apoptotic cells: Shrunken cells with green nucleus 
Late apoptotic cells: Shrunken cells with orange nucleus 
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2.11.2 Morphological assessment 
 
Apoptosis was also assessed based on the morphology of cells. Cells were 
cytocentrifuged at 300 × g for 3 minutes onto glass slides using a Cytospin 3 
(Shandon, USA). Slides were then air dried, fixed in methanol for 2 minutes and 
stained with May-Grunwald-Giemsa. Cell morphology was examined using an 
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2.12 SCLC Xenograft 
 
All animal studies were performed on six week old female CD1 nude/nude mice 
(Harland, UK) which were maintained in 12 hours light/12 hour dark cycles with free 
access to food and water. All procedures were performed in accordance with Home 
Office guidelines [Animals (Scientific procedures) Act 1986]. 
 




 H345 cells suspended in growth factor reduced Matrigel (1:1 volume of 
cells:Matrigel mixed at 4
º
C, total volume of 100 µl) were implanted subcutaneously 
in the right flank of nude/nude mice. Tumours were palpable 3 days post-injection. 
Drug exposure was initiated on day 7 and was continued once daily for 5 consecutive 
days. Peptide-1 was dissolved in sterile distilled H2O and administered by 
subcutaneous injection at a dose of 25 mg/kg. Etoposide dissolved in sterile distilled 
H2O and was administered by subcutaneous injection at 15 mg/kg. Controls received 
the same dose schedule of vehicle (H2O). Tumours were measured using callipers 




 ×  Width/2  
   
2.12.2 CD133+ tumorigenicity 
 
Various cell numbers of sorted CD133+ and CD133- H345 cells (5 × 10
5
, 1 × 10
5
, 
and 1 × 10
4
) in growth factor reduced Matrigel (BD Biosciences, USA) (1:1 volume 
of cells:Matrigel mixed at 4
º
C, total volume of 100 µl) were implanted 
subcutaneously in contralateral flanks of nude/nude mice (4 animals per condition). 
Same numbers of unsorted parent H345 cells with the same method of preparation 
were implanted subcutaneously into the right flank of nude/nude mice (4 animals per 








Immunohistochemistry (IHC) can detect and visualise antigens at cellular levels by 
using primary and secondary antibodies to indirectly identify antigens in paraffin-
embedded or frozen tissue sections. Formalin-fixed, paraffin-embedded SCLC 
resection specimens were de-waxed in xylene (Fisher Scientific, UK) for 10 minutes 
and were rehydrated through graded ethanol (100%  90%  70%, 20 seconds 
each) and rinsed in water. Tissue sections were then heated in 740 ml distilled water 
plus 7.5 ml antigen retrieval solution (Vector Laboratories, USA) which is based on a 
citric acid formula using a 750W microwave oven for 15 minutes at maximum 
power. Sections were cooled in running tap water for 15 minutes. Endogenous 
peroxidase activity was blocked in 3% hydrogen peroxide (VWR international, UK) 
(v/v in distilled water) for 15 minutes, rinsed once with TBS. After non-specific 
binding was blocked using serum free protein block and avidin/biotin blocking kit 
(Vector Laboratories, USA), the sections were incubated with the primary antibody, 
CD133 (diluted to 1:100 in antibody diluent, DAKO, UK) overnight at 4°C. After 3 
× 5 minutes washes with TBS, sections were labelled with biotinylated donkey anti-
rabbit IgG (H+L) secondary antibody (diluted 1:200 in antibody diluent) for 30 
minutes at room temperature. Slides were rinsed 3 × 5 minutes with TBS and 
incubated with 3 drops of avidin:biotinylated enzyme complex (ABC) (Vector 
Laboratories, USA) per slide for 30 minutes at room temperature and washed × 3 
with TBS. Diaminobenzidine (DAB) (DAKO, UK) solution prepared with substrate 
as per manufacturers instructions was applied for 5 minutes at room temperature. 
Slides were rinsed × 3 in TBS, counterstained for 30 seconds with Mayers 
haematoxylin (Thermo Shandon, UK) and 30 seconds in Scotts tap water (83 mM 
MgSO4, 7.1 mM NaHCO3 in tap water), dehydrated through graded ethanol (70%  
90%  100%), and cleared in xylene. Slides were mounted using Pertex mounting 
solution (CellPath Hemel Hempstead, UK). In each experiment, negative controls of 
secondary antibody only were performed. Images were acquired using a Leica DM 
LB light microscope, Leica DC 300 digital camera and Leica IM50 software. 
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For staining sections with CD45 and NCAM antibodies, IHC was performed using 
ImmPRESS™ system (Vectore Laboratories, USA) which is based on the method of 
polymerizing enzymes and attaching these polymers to antibodies. The advantage of 
this system is it provides high signal intensity with minimal background staining in 
IHC. In this study, ImmPRESS™ anti-rat Ig reagent was used for staining sections 
with CD45 antibody raised in rat, and ImmPRESS™ anti-Rabbit Ig reagent was used 
for staining sections with NCAM antibody raised in rabbit. The ImmPRESS™ anti-
rat Ig, and anti-rabbit Ig reagents contain a “micropolymer” of an active peroxidase 
coupled to affinity-purifies anti-rat IgG (H+L) secondary antibody and affinity-
purifies anti-rabbit IgG (H+L) secondary antibody, respectively. The method used 
was performed as manufacturers’ protocol. In brief, formalin-fixed, paraffin-
embedded SCLC resection specimens were de-waxed in xylene for 10 minutes and 
were rehydrated through graded ethanol (100%  90%  70%, 20 seconds each) 
and rinsed in water. Antigen retrieval was performed by boiling samples in 10 mM 
citrate (pH 6.0) for 5 minutes. Sections were cooled in running tap water for 15 
minutes. Endogenous peroxidase activity was blocked in 3% hydrogen peroxide (v/v 
in distilled water) for 15 minutes and subsequently rinsed once with TBS. Non-
specific binding was blocked with 3 drops of ready to use (2.5%) goat serum or horse 
serum provided by the kit for 30 minutes at room temperature (20-25°C) and rinsed 
once for 5 minutes in TBS. Both CD45 and NCAM antibodies were diluted 1:500 in 
blocking serum and incubated overnight. After washing samples 3 × 5 minutes in 
TBS, sections were incubated with 1 drop of appropriate ImmPRESS reagent for 30 
minutes in room temperature and washed again for 3 × 5 minutes with TBS.   
 
To amplify the signal of interest, samples were treated with Tyramide Signal 
Amplification (TSA) plus Cyanine-3 kit (PerkinElmer, USA) for CD45 stained 
sections or TSA plus Fluorescein kit (PerkinElmer, USA) for NCAM stained 
sections. CD45 and NCAM stained samples were treated with 1:50 dilution of the 
appropriate TSA plus amplification reagent for 10 minutes in the dark at room 
temperature. Sections were then washed 3 × 5 minutes with TBS, in the last wash 
DAPI at a concentration of 0.1 µg/ml was added to stain the nuclei. Sections were 
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mounted with PermaFluor Aqueous Mounting Medium (ThermoFisher Scientific, 
USA). Cells were analysed using Confocal microscopy (Zeiss Axiovert 100M, UK) 
 
2.14 Quantitative PCR (q-PCR) 
 
2.14.1 RNA extraction 
 
RNA was prepared from, 2 × 10
6
 H345 and H69 cells using the RNeasy Mini Kit and 
QIAshredder columns (Qiagen, Netherlands) according to the manufacturer’s 
instruction. RNA concentrations, purity and quality of the samples were determined 
using the NanoDrop 1000 spectrophotometer (Thermo Scientific, USA) and RNA 
was stored at -80°C until further use. 
 
2.14.2 DNase treatment of RNA 
 
DNase treatment of RNA was performed in a sterile eppendorf by adding 2 µl RQ1 
RNase (Promega, USA) and 2 µl 10 × reaction buffer (Promega, USA) to 2 µg RNA, 
made up to final volume of 20 µl with nuclease-free H20 (NFH2O). Samples were 
incubated for 30 minutes at 37°C and the reaction was terminated by adding 2 µl 
RQ1 DNase stop solution (Promega, USA) and incubated at 65°C for 10 minutes. 
‘Clean’ RNA was stored at -80°C until further use. 
 
2.14.3 Real-Time Reverse Transcription-PCR (Real-Time RT-PCR) 
 
Clean RNA samples were reverse transcribed to cDNA using TaqMan® reverse 
transcription reagents (Applied Biosystems, USA). The following volumes were used 











The RT-PCR reaction was performed in a PTC-100 programmable thermal controller 
(MJ Research Inc., Canada). Samples were stored at -20°C. 
 
2.14.4 Quantitative PCR 
 
Every experiment was carried out under sterile conditions using filter tips and sterile 
NFH2O. The expression levels of GRP-R and V1A-R in the isolated cells were 
quantified using the TaqMan® gene expression assay kit (Applied Biosystems, 
USA). 18S rRNA primer probe mix was purchased from (Applied Biosystems, USA) 
and was used as internal control. Volumes used per PCR reaction were, 
 
1x Reaction mix:                                                                            
TaqMan mastermix (Applied Biosystems)                            12.5 µl 
18S Probe (primer/probe)                                                       1.25 µl 
TaqMan® gene expression assay (5x)              5      µl 
NFH20                                                                                       3.75 µl 
 
 
Each reaction was prepared in triplicates containing 2.5 µl cDNA or NFH2O, giving a 
total volume of 25 µl, and transferred to Micro Amp Optical 96-well reaction plates. 
The q-PCR reaction was carried out in a 7500 fast Real-Time PCR system (Applied 
Biosystems, USA) and data was analysed using the System detection software (7500 
fast system SDS software) using the 2-∆∆ct calculation method (Applied 
Biosystems, USA). Gene expression is shown as fold increase as compared to an 
external calibrator which was a pool of experimental cDNA. Water only was used as 
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a negative control since these primer/probe kits did not amplify genomic DNA and 
would only detect gene expression. 
 
2.15 Liver S9 preparation 
 
Liver S9 fractions are sub-cellular fractions most frequently used to measure drug 
metabolism. It is defined as the supernatant fraction usually obtained from the liver 
homogenate following centrifugation at 9000 × g for 20 minutes in appropriate 
solutions. S9 fraction is rich in drug-metabolizing enzymes including the 
cytochromes P450, flavin monooxygenases, and UDP glucuronyl transferases [232, 
233]. Livers from female C57BL/6 mice were removed and washed twice with cold 
potassium phosphate buffer 0.1 M (50 mM KCl, 5 mM EDTA, pH ~7.4).  Liver 
tissue was homogenised using a glass Teflon homogeniser in phosphate buffer to 
give a final homogenate consisting of 25 % w/v tissue (Figure 9). Samples were 
centrifuged at 9000 × g for 20 minutes at 4°C and the supernatant was stored on ice. 
Protein concentration was determined using BCA protein assay reagent (Pierce, 
USA).  
 
The metabolism of SP-G and peptide-1 was studied by adding the drugs at a final 
concentration of 0.1 mg/ml into 2 ml of incubation mixture containing the S9 liver 
prep (equivalent to 4 mg of protein) and PBS. Reactions were incubated at 37°C with 
a continuous gentle shake. In order to stop the reactions, at appropriate time points, 
100 μl of the incubation mixture was removed and added to 200 μl of eluting buffer 
(methanol:1M ammonium acetate (90:10 v/v)) followed by vigorous vortexing. 
Samples were then centrifuged at 1300 × g for 3 minutes and the supernatant was 













































HPLC analysis was kindly conducted by Doctor Nikolaos Avlonitis in Professor 
Mark Bradley’s laboratory, Institute of Chemistry, Edinburgh University. HPLC was 
carried out on liquid chromatograph consisting of a Model 500 solvent delivery 
system, a Model 680 controller, a Wisp autosampler (all from Waters, UK), a Model 
5100A coulochem electrochemical detector with pre-colum Model 5020 guard cell 
and a twin electrode (D1 and D2) Model 5011 high sensitivity analytical cell (ESA 
inc). The stationary phase was μ-Bondpack C18 packed in a 30 cm x 3.9 mm I.D. 
stainless steel column (Waters, UK) and the mobile phase consisted of 0.15% TFA in 
10 mM ammonium acetate (PH 2.75)-acetonitrile: 60:40 (v/v). 
 




Intracellular calcium concentration was measured using Fura-2 (Invitrogen, UK), a 
UV-excited chemical indicator. Fura-2 was chosen for the Ca
2+
 studies based on its 
features including, the ability to exhibit high fluorescence which allows 
measurements at intracellular concentrations, low Ca
2+
 affinity, and favourable 
spectral properties, including shift in absorption upon binding to Ca
2+
. Additionally, 
Fura-2 allows ratiometric measurements by computing the ratio of the fluorescence 
at two wavelengths thus, considerably reducing the effects of photobleaching, 
leakage of dye, and uneven dye loading, as well as problems associated with 
measuring Ca
2+
 in cells of unequal thickness [234, 235]. 
 
G6A and V3B cells were grown to 50-70% confluence in DMEM complete medium, 
washed twice with PBS and quiesced overnight in DMEM quiescent medium (for 
details of culture medium used see section 2.3). Cells were then trypsinised, and to 
subsequently inhibit the affect of trypsin 1mg/ml soya bean trypsin inhibitor was 
added to the cell suspension. Cells were centrifuged at 300 × g for 5 min and the cell 
pellets were re-suspended in hanks buffered salt solution (HBSS) without calcium at 
5 × 10
6
 cells/ml and were transferred into 2 ml eppendorf. 1µM FURA-2-
tetraacetoxymethylester AME (FURA-2-AM) (Merck Millipore, Germany) was 
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added and samples were incubated at 37°C for 20 minutes. The cell suspension was 
centrifuged at 300 × g for 5 minutes and re-suspended in 2 ml of HBSS with 
calcium, transferred to a cuvette and stirred continuously at 37°C. Fluorescence was 
recorded in a Model F2000 fluorescence spectrophotometer (Hitachi, Japan). 
Alternate dual wavelength excitation at 380 nm and 410 nm allowed ratiometric 
analysis of bound and unbound FURA-2AM when measured at 505 nm. Intracellular 
Ca
2+ 




] = K(F-Fmin)/(Fmax-F),  
 
F is the ratio of the unknown sample, Fmax is the ratio after the addition of 0.1% triton 
X-100 causing cell membrane fracturing therefore release of all intracellular calcium, 
and Fmin is the ratio after Ca
2+ 
chelation with 10 mM EGTA. K is the dissociation 
constant for Fura-2, which is 224 nM.   
 
2.18 Statistical analysis 
 
Results are reported as pooled data from a series of separate experiments and 
presented as mean ± standard error mean (SEM). Statistical significance was mainly 
analysed by two-tailed Student’s t test and in the other cases by two-way analysis of 
variance (ANOVA) (Prism Software). Statistical significance was assigned to data 
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CHAPTER 3: 
Human SCLC cell lines are clonogenic and chemoresistant and a sub-
population of these cells express stem cell markers which can be isolated by 




Rapid growth, highly invasive and metastatic potentials and almost inevitable 
recurrence despite initial chemo- and radiosensitivity has made SCLC one of the 
most challenging diseases to cure. Despite a multitude of studies in unveiling the 
pathogenesis of resistance in SCLC, so far methods to circumvent resistance have not 
been successful in clinical practice. The presence of chemoresistant cells with a stem 
cell-like phenotype known as cancer stem cells (CSCs) is the proposed cause of 
treatment resistance in cancer patients with tumour recurrence after therapy. Thus, 
novel interventional strategies based on CSC elimination should be designed. 
 
An accurate detection and pure isolation of CSCs is essential for their 
characterisation. Lung CSC identification is commonly based on the expression of 
surface proteins such CD133 and cellular characteristics including high ALDH 
enzyme activity and the ability to form tumour spheres [79, 236]. CD133 is one of 
the most commonly used markers for lung CSC detection [79, 84, 118, 158, 236, 
237]. Cells expressing CD133 are chemoresistant, tumorigenic and exhibit stem cell-
like features such as the expression of Oct-4, and the ability to self-renew and 
differentiate [79, 82, 158]. Common methods for isolation of CSCs include 
magnetic-activated cell sorting (MACS®), fluorescent-activated cell sorting (FACS) 
and selection of tumour spheres. FACS has been routinely used for the study of 
CSCs. This method enables simultaneous multi-parametric analysis of physical 
and/or chemical characteristic of viable cells with high performance and accuracy as 
well as isolation of cells of interest on the basis of specific marker expression or 
functional characteristics [238].  
 
As SCLC tumours are rarely resected and fresh specimens are often inaccessible, in 
the present study two human SCLC cell lines, H345 and H69 were utilised and the 
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expression of CD133, Oct-4 and ALDH activity was evaluated. To characterise 
prospective SCLC CSCs, two methods of isolation were used, MACS and FACS. If 
the presence of a CSC sub-population within tumours is the proposed cause of 
tumour resistance to therapy and recurrence, therefore, characterisation of such cells 





3.2.1 Human SCLC cell lines, H345 and H69 are chemoresistant and 
clonogenic 
 
Human SCLC cell lines, H345 and H69 were established from patients who had 
relapsed after initial therapy. Both cell lines were derived from metastatic sites - 
H345 cells from bone marrow and H69 cells from pleural effusion [239]. As shown 
previously [239], these cells grow in suspension as cellular aggregates (Figure 10A), 
indicative of their anchorage-independent growth and subsequently their possible 
tumorigenic and metastatic potentials in vivo. The sensitivity of the cells to 
chemotherapy was assessed by MTT assay (Figure 10B). H345 and H69 cells were 
treated with etoposide, the most commonly used chemotherapeutic agent for SCLC 
treatment, and cytotoxity was determined after 72 hours. Results are expressed as 
percentage of untreated cells and the potency. Even high doses of 100 µg/ml of 
etoposide were relatively insufficient to inhibit 50% of the H345 and H69 cell 
viability (Figure 10B). This confirmed the chemoresistant phenotype of both SCLC 
cells and correlated with the knowledge that these cells were isolated from patients 
who were already resistant to chemotherapy. 
 
Colony assay reflects the ability of a single cell to survive anchorage-independent 
growth and its stem cell-like feature to undergo unlimited division [144, 240, 241]. 
This assay is the gold standard in vitro method that reflects the tumorigenic potential 
of cells in vivo [241, 242]. In this study, a colony was defined to consist of >16 cells. 
The cloning efficiency of H345 and H69 was 1.8 ± 0.25% and 3.23 ± 0.36%, 
respectively (Figure 10C). Despite the ability of these cells to form colonies in the 
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semi-solid medium, not all cells cultured were clonogenic indicative of cellular 
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3.2.2 H345 and H69 SCLC cell lines express stem cell markers 
 
The protein levels of CSC markers CD133 and Oct-4 were examined in H345 and 
H69 cell lines by western blotting. A band of ~120 kDa and ~48 kDa were 
representative of presence of CD133 and Oct-4 proteins, respectively (Figure 11A). 
β-actin, a housekeeping gene and a major component of the cytoskeleton was used as 
a loading control [243]. Therefore, the human SCLC cells retain a population of cells 
expressing stem cells markers. 
 
Increased ALDH enzyme activity has proven to be a reliable marker for the selection 
of CSCs [151, 236]. The ‘gold standard’ of studying the activity of ALDH is using 
the commercial reagent ALDEFLUOR® (STEMCELL™ technologies, Canada) 
which allows the assessment of functional activity of ALDH1 in viable cells (Figure 
12). In this method, the uncharged ADLFLUOR substrate, BODIPY 
aminoacetaldehyde (BAAA) in viable cells is taken up by passive diffusion. In the 





 is fluorescent and is retained inside the cell 
due to its negative charge in addition to the presence of ABC-transporter inhibitors in 
the assay buffer which inhibits compound efflux, causing the cells with high ALDH 
activity (ALDH+) to become highly fluorescent. Using appropriate sorting gates 
(review section 3.2.4 for selection of gates for flow cytometry analyses) the ALDH+ 
can be identified and isolated by flow cytometry. Diethylaminobenzaldehyde 
(DEAB), and ALDH inhibitor was used as a negative control. In the present study 
16.3 ± 0.23% of H345 cells (Figure 11B1-B3) and 19.56 ± 0.5% of H69 cells (Figure 
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3.2.3 H345 and H69 SCLC cell lines express CD133 
 
CD133 is the most commonly used CSC marker and has consistently selected the 
stem cell-like, chemoresistant and tumorigenic lung cancer cells [79, 82, 84, 118, 
158, 237, 244]. Therefore, CD133 expression was chosen as a maker to identify and 
isolated putative SCLC CSCs. Two monoclonal antibodies, CD133-1-APC (clone 
AC131) and CD133-2-PE (clone AC141), commercially available from Miltenyi 
Biotec, Germany, have been commonly used for the detection of CD133 expressing 
cells. CD133-1-APC binds to glycosylated epitope-1 of the CD133 antigen and 
CD133-2-PE binds to glycosylated epitope-2 of this antigen. Due to the cross 
reactivity of the CD133-2-PE antibody with cytokeratin-18 [115], in the present 
study, CD133-1-APC was utilised for the identification of CD133 expressing SCLC 
cells and CD133-2-PE antibody was used to confirm the purity of cells isolated based 
on the epitope-1. 
 
To confirm all cells positive for CD133 epitope-1 are also positive for CD133 
epitope-2, H345 and H69 were double stained with CD133-1-APC and CD133-2-PE. 
Cells stained with APC-conjugated or PE-conjugated isotype-matched mouse IgG 
were used as negative controls (isotype control). The gate for the isotype control was 
chosen so that the value in the gate would be >1% for the isotype control. As shown 
in Figure 13A-A1, 13.1% of H345 cells were positive for epitope-1 and as shown in 
Figure 13B-B1, 86.4% of H345 cells were positive for epitope-2. Higher percentage 
of cells expressing epitope-2 could be associated with cross-reactivity of the 
monoclonal antibody. Interestingly, when analysing cells co-stained with both 
antibodies (Figure 13C-C1), 13.1% of H345 cells were double positive (note the 
similarity in the percentage between cells positive for eptiope-1 and cells double 
positive for epitope-1 and -2, both show ~13% positivity), 68.4% of cells were 
epitope-2+ and very low levels were epitope-1+ (0.03%), indicating that most cells 
expressing the CD133 epitope-1 also express CD133 epitope-2, but not all epitope-
2+ cells are epitope-1+. 
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Similar observation was made in H69 cells (Figure 14). In these cells, 23.9% of cells 
were epitope-1+ (Figure 14A-A1) and 88.9% of cells were epitope-2+ (Figure 14B-
B1). When co-staining H69 cells for both antibodies (Figure 14C-C1), 23.3% of cells 
were double positive for both epitopes whereas very few epitope-1+ cells did not 
express the CD133 epitope-2 (0.061%) indicating almost all epitope-1+ cells also 
express the CD133 epitope-2. These data indicate that epitope-1 of the CD133 
antigen is ideal for selection of cells expressing CD133. Therefore, in this study the 
presence of CD133 antigen will be evaluated based on the presence of its epitope-1 
using CD133-1-APC antibody. Positivity of CD133 expressing cells will be 
confirmed using CD133-2-PE which detects epitope-2 of the antigen. In this thesis, 
cells expressing the CD133 epitope-1 will be termed as CD133-1 cells and cells 
expressing epitope-2 will be termed as CD133-2. To be noted, despite the primary 
selection of cells has been based on CD133-1-APC antibody and CD133-2-PE 
antibody has been utilised for the confirmation of CD133 expression post cell 
sorting, in order to discard the possibility that CD133-2 positivity is a consequence 
of cross-reactivity with cytokeratine-18, in future experiments using CD133-2-PE 
antibody should be repeated using the CD133-1-APC antibody.    
 
Figure 15, is a representative histogram of CD133-1 expression on H345 and H69 
cells. In H345 cells 18 ± 1.24% and in H69 cells 22 ± 1.76% of the population was 
CD133+, relative to isotype control. The expression pattern of CD133 was 
continuous rather than showing discrete positive and negative populations. This data 
is consistent with previous observations where a gaussian rather than a bimodal 
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3.2.4 Fluorescent activated cell sorting produces pure isolation of CD133+ 
and CD133- cells 
 
CD133+ and CD133- H345 cells were isolated by the MACS® method using the 
CD133 MicroBead Kit (Miltenyi Biotec, Germany). This kit is designed for the 
positive selection of CD133+ cells (for more details see materials and methods). The 
principle of the MACS® separation is that cells positive for the CD133 antigen are 
magnetically labelled with CD133 MicroBeads (magnetic nanoparticles coated with 
CD133 antibody). The cell suspension is then loaded on to the appropriate MACS® 
Column which is placed onto the MACS Separator unit that contains a magnetic 
field. The magnetically labelled CD133+ cells will be trapped in the column and the 
unlabelled cells will run through, thereby, positively selecting for the CD133+ 
population. The positive population can be retained by removing the column from 
the magnetic field and flushing the column with 1 ml of buffer. To increase the 
purity of the isolated population, both cell fractions, the positively selected and the 
negatively selected cells, were passed over a second column. The purity of the 
isolated cells was evaluated by flow cytometry, by staining cells with CD133-2-PE 
(recommended by the protocol) to determine the efficiency of the separation (Figure 
16). To compare the expression levels of CD133-2 between the isolated populations, 
Geometric mean (GM) value was calculated. No difference in GM values of CD133- 
(Figure 16A1) and CD133+ (Figure 16A2) selected populations could be observed, 
indicating CD133 MicroBead Kit did not select a pure populations. Therefore, 
CD133 MicroBeads was not suitable for isolation of CD133 expressing cells in 
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FACS is the most common method for selection of CSCs [78-80]. In the present 
study, this method allowed isolation of cells of interest based on the expression of 
CD133-1. In brief, a cell suspension labelled with APC conjugated CD133-1 is 
directed into a thin stream of fluid forcing cells to pass in single file (Figure 17). The 
stream of fluid by passing through a vibrating nozzle breaks into droplets. Some of 
these droplets may contain single cells. A laser beam is directed at the stream just 
before it breaks up into droplets. When a labelled cell passes through the laser beam, 
it emits light. The scattered light and the emitted fluorescence is captured by a 
number of detectors including detectors in line with the axis of the light beam 
(forward scatter, FSC), perpendiculars to axis of the beam (side scatter, SSC) and the 
fluorescence detectors. The intensity of FSC correlates with the size of cells and the 
intensity of SSC depends on the shape and intracellular complexity of the cells. If the 
signals from the detectors match the criteria set for size, shape and fluorescence, a 
positive or negative electrical charge is given to the fluidic stream. The droplets then 
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The populations of interest are chosen based on selecting specific gates. A gate in 
flow cytometry is a set of chosen boundaries that serve to select the population of 
interest from the total cell population. Before gating on the CD133+ and CD133- 
populations, single and viable cells were selected from the total population. The 
presence of cell clumps within samples could reduce the purity of the cell sorting. 
For example, if a positive event were measured at the same time as a negative event 
in a cell clump, both would be selected and isolated because the software considers it 
as a single positive event. On the other hand, dead cells could bind non-specifically 
to the antibody causing false-positive results. Therefore, it is important to exclude the 
cell clumps and dead cells. Populations of interest were initially selected based on 
their FSC and SSC and viability judged by propidium iodide (PI) exclusion (Figure 
18A, B1, and B2). PI is membrane impermeant and generally excluded from viable 
cells. Population-2 contained the majority of the viable cells (PI positive 4.48 ± 
0.81%) (Figure 18B2) whereas most cells within the population-1 were dead (PI 
positive 94.54 ± 0.76%) or debris (particles smaller than cells) (Figure 18B1). Debris 
can be excluded based on their low FSC and SSC and dead cells can be excluded by 
their lower FSC and higher SSC compared to the living cells in addition to their 
response to PI. To increase the accuracy during the cell selection, cells within 
population-2 were gated on their FSC- Height (FSC-H) and FSC-Area (FSC-A) 
distribution to select on the single cells (Figure 18C). Using FSC-H allows 
measurement of how long a particle takes to traverse the laser beam. Cell clumps and 
doublets tend to become orientated lengthways while travelling the stream of fluid 
therefore, can be excluded on the basis of their pulse Height [245]. This was 
followed by selecting on the viable cells within the single cell gate (Figure 18D) 
based on their PI intensity. Since CD133 exhibits a gaussian expression pattern, the 
top ~7% of the cells with high expression of CD133 and the bottom ~7% of the cells 
with low/no CD133 expression (based on the isotype control distribution) were gated 
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To confirm a successful isolation, the purity of the sorted cells was evaluated based 
on the expression of CD133-1. Re-analysing sorted cells based on CD133-1 
expression (an epitope of CD133 initially selected for cell sorting) would allow 
evaluating if the sorted populations would re-appear in the same gates as they were 
initially selected. Figure 19A1-3 illustrates CD133-1 levels on H345 parent 
(unsorted) cells (Figure 19A1), overlay histogram of CD133+ and CD133- H345 
cells (Figure 19A2), and overlay histogram of all three populations (Figure 19A3). 
To compare the fluorescence on each population, GM was calculated. This permits 
comparison of the amount of antibody binding to the CD133 expressing cells; higher 
GM would correlate with higher CD133 expression. The GM of CD133+ was 22.40 
± 2.37, the GM of CD133- cells was 2.36 ± 0.32, and the GM of parent cells was 
8.98 ± 1.51. These values indicate that CD133+ cells are the most fluorescent cells 
and based on the sorting layouts, the two population of CD133+ and CD133- are 
distinct with CD133+ cells having significantly higher levels of this antigen 
(P=0.0012). The overlay histogram of 19A3 demonstrates that compared to parent 
cells, CD133+ population is enriched for cells with CD133 antigen and are therefore 
located at the top arm of parent population where the CD133+ gate for sorting was 
chosen, whereas CD133- population contains cells with no CD133 antigen 
expression and are therefore located at the lower arm of the parent cells where the 
CD133- gate for sorting was selected. This data indicates that cell sorting by FACS 
produced pure isolations. 
 
Purity of the sorted cells was further analysed using CD133-2-PE antibody that 
recognises the epitope-2 of the CD133 antigen (Figure 19B1-B3). As demonstrated 
earlier, Figures 13 and 14, SCLC cells positive for CD133-1 are also positive for 
CD133-2. Therefore assessing the presence of CD133 antigen via its epitope-2 could 
further confirm the purity of the isolated populations. Sorted cells were immediately 
stained with the CD133-2-PE antibody and were analysed by flow cytometry. To 
compare the intensity of fluorescence on each population, GM was calculated. The 
GM in the CD133+, CD133-, and parent cells were 125 ± 3.6, 3.03 ± 0.62, and 25.09 
± 1.68, respectively. Therefore, CD133-1+ cells are enriched in cells positive for 
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CD133-2 and its expression is higher than that of CD133- and parent cells further 
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The purity of sorted populations was further analysed by the CD133 protein levels in 
the sorted cells (Figure 20). This was to rule out the possibility that the cell selection 
was based on non-specific staining. CD133 is 95 kDa in length however, in line with 
previous data documented [110], this protein was detected at approximately at 120 
kDa by western blot due to glycosylation of the protein in both CD133+ and parent 
cells. No protein expression in the CD133- population could be detected. β-actin was 
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To confirm that selection of CD133+ and CD133- was not associated with their 
cellular size (bigger cells would have higher levels of CD133 antigen compared to 
smaller cells) but was associated with the levels of CD133 expression, the size of 
sorted CD133+ cells was compared with that of CD133- cells by flow cytometry and 
standard microscopy. Figure 21A is representative histogram illustrating the FSC 
distribution of CD133+ and CD133- H345 cells. As shown, no significant 
differences in cellular size between the sorted populations could be observed 
indicating that CD133+ and CD133- are similar in their size. This was further 
confirmed by microscopically evaluating the appearance of the sorted cells (Figure 
21B). Three days post sorting cells cultured in SITA medium were cytocentrifuged 
onto glass cover slips and stained with May-Grunwald-Giemsa, to visualise the cells 
as well as distinguish viable from dead cells. As illustrated in Figure 21B, in both 
cell lines, CD133+ and CD133- populations exhibited similar morphology. 
Additionally, the tissue culture appearance of the sorted population was evaluated by 
observing the three days post-sorted cells cultured in SITA medium under standard 
microscopy (Figure 21C). Similar to parent cells (unsorted cells), in both H345 and 
H69 cells, CD133- and CD133+ grew as floating aggregates with no differences in 
the shape or size of the cellular clumps. These observations indicate that CD133+ 
and CD133- cells share similar morphology and that isolation of these cells using 
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To confirm that the process of cell sorting does not effect cell viability, the 
percentage of apoptosis in CD133-, CD133+ and parent cells, 5 days post-sorting 
was evaluated by May-Grunwald-Giemsa and ethidium bromide/acridine orange 
(EB/AO) staining. Apoptotic cells in May-Grunwald-Giemsa staining appeared as 
shrunken cells with dense nuclei (Figure 22A). All three cell populations exhibited a 
similar percentage of apoptosis (Figure 22C1 and C2). In EB/AO staining, cells were 
stained with the fluorescent dyes and viability was judged based on nuclear 
morphology and fluorescence. Viable cells (green nucleus), apoptotic cells (early 
apoptotic, shrunken cells with green nucleus and late apoptotic cells, shrunken cells 
with orange nucleus) and necrotic cells (swollen cells with orange nucleus) were 
distinguished (Figure 22B). Figure 22D1 and D2 illustrates no significant differences 
in the percentage of apoptosis between the three populations. Therefore, the process 















































The results in this chapter demonstrated that the two human SCLC cells lines, H345 
and H69, were chemoresistant and clonogenic in culture and contained a population 
of cells which expressed CSC makers including CD133, Oct-4 and ALDH. CD133+ 
H345 and H69 cells could be isolated by FACS with high purity.  
 
H345 and H69 were established from patients who had relapsed after initial therapy. 
In line with their clinical chemoresistant characteristic, H345 and H69 cells were 
resistant to etoposide in vitro and even a high dose of 100 µg/ml was relatively 
insufficient to eradicate 50% of these cells. Previously, findings in my laboratory 
showed β1-integrin mediated SCLC cell interaction with extra cellular matrix (ECM) 
components leads to activation of PI3K which inhibits etoposide-induced caspase-3 
activation and therefore inhibits apoptosis [246]. Chemoresistance can also be a 
result of increased expression of anti-apoptotic proteins such as Bcl-2, increased 
expression of cell surface efflux pumps such as P-gp and/or reduced topoisomerase II 
activity [247-250].  
 
In addition to the molecular mechanism associated with treatment resistance, 
multiple studies have documented the presence of CD133+ cells as the cause of 
cancer chemoresistance [79, 82, 84, 141]. CD133+ cells, due to their resistant 
phenotype, escape therapeutic insults and are instead enriched after chemotherapy. 
SCLC cell lines used in this study were derived from relapsed patients. The presence 
of CSCs was confirmed by the expression of CD133, Oct-4 and ALDH in H345 and 
H69 cells. Therefore, it can be proposed that increased resistance to etoposide 
observed in both cell lines could be associated with enrichment of the drug resistant 
CSCs. To confirm this concept, it would be essential to evaluate the percentage of 
CSCs in cell lines derived from SCLC patients before and after treatment. 
 
Anchorage-independent proliferation is an essential hall-mark of tumour cells with 
colony forming ability in vitro and metastatic potential in vivo [240, 241]. As 
demonstrated, both cell lines not only grew as anchorage-independent aggregates in 
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liquid culture, but also formed colonies in semi-solid medium, reflecting their ability 
to escape anoikis. Despite the fundamental biological role of PI3K activation in 
cellular development, growth and survival, activation of this pathway protects 
malignant cells against anoikis therefore, promoting tumour cell migration and 
metastasis [251, 252]. Previously, in my laboratory, Moore, et al., [231] 
demonstrated that constitutive activation of PI3K pathway which results in high 
levels of basal PKB and p70s6k activity is the underlying molecular explanation of 
anchorage-independent growth in SCLC cells. 
 
Interestingly, in the present study, not all cells cultured in the semi-solid medium 
were clonogenic indicating tumour cell functional heterogeneity. Based on the CSC 
theory, not all the cells within a neoplasm are clonogenic and tumorigenic and only a 
subset of cells with stem cell-like phenotype propagate tumour development, 
metastasis and treatment resistance [74]. This observation further triggered the 
speculation that the colony forming ability observed in the H345 and H69 cells was 
due to the presence of CSC population within these cells. To evaluate this concept, it 
was necessary to isolate the putative SCLC CSCs and non-CSCs and compare the 
clonogenicity between the two populations. 
  
Expression of stem cell markers, CD133, Oct-4 and ALDH has been associated with 
the presence of CSCs in malignancies [79, 152, 157, 158]. Although CD133 
expression in lung cancer selects for chemoresistant and aggressive cells, its 
contribution to the fundamental properties of CSCs is not fully understood. In 
CD133-knock down experiments by Takenobu et al., [127] it was demonstrated that 
CD133 expression inhibits neuroblastoma cell differentiation and accelerates their 
cell proliferation and anchorage-independent growth and tumour formation in vivo. 
Additionally, treatment of colorectal tumour cell lines with the CD133 monoclonal 
antibody 6B6, which directly targets human CD133 antigen, inhibited their 
proliferation [253]. These data demonstrate the biological function of CD133 and the 
importance of this molecule in regulating the undifferentiated state and growth of 
CSCs. The importance of CD133+ cells in pulmonary cancer patients has also been 
clinically documented [85]. Fifty NSCLC patients undergoing concurrent chemo-
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radiotherapy with docetaxel, cisplatin and thoracic radiation followed by surgery 
were examined. Using IHC to evaluate the expression of CD133 and ALDH1 in 
patient’s specimens, the expression of these markers was associated with poor 
prognosis in NSCLC patients. Similarly, the CD133 expression on lung cancer cells 
predicts shorter progression-free survival of candidates treated with platinum-based 
regimens [84]. Although, to my knowledge, no study has directly evaluated the 
relation of CD133 expression with SCLC patient prognosis, however, multiple in 
vitro studies performed on SCLC cells from primary tumours and cell lines have 
illustrated the importance of this marker in selecting cells with an aggressive, 
chemoresistant and tumorigenic phenotype [79, 82, 158]. Therefore, identifying and 
characterising cells positive for CD133 could be a valuable tool for developing more 
effective treatments for SCLC. 
 
High ALDH activity is associated with CSCs in lung cancer [146, 152, 153]. ALDH 
enzyme plays a pivotal role in mediating resistance to alkylating drugs in CSCs by 
recycling aldehydes [151]. Additionally, ALDH1 by regulating the production of 
retinoic acid (RA) plays a central role in stem cell differentiation [150]. Similar to 
CD133, the expression of ALDH in lung cancer patients has a prognostic impact 
[254] making it a valuable marker for detection of CSC in SCLC. 
 
Oct-4 is a well-known stem cell and CSC marker [155, 157, 158, 255]. Targeted 
disruption of Oct-4 in mice developed embryos which were not pluripotent and were 
restricted to differentiate [255]. Thus, Oct-4 has been proposed as the main regulator 
of cell fate to be pluripotent or to be differentiated. In lung cancer, Oct-4 expression 
maintained the stem cell phenotype of CD133+ cells [158] making this transcription 
factor useful for identification of CSCs in SCLC. 
 
Based on the above data, CD133, Oct-4, and ALDH were selected as markers for 
detection of prospective SCLC CSCs. CD133 and Oct-4 protein expression in both 
SCLC cell lines was detected by western blot and the ALDH enzyme activity was 
confirmed by flow cytometry. CD133, the most commonly used marker, that 
consistently identifies the chemoresistant, clonogenic and tumorigenic CSCs [77-79, 
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84, 127], was selected for the identification of putative SCLC CSCs. Oct-4 is not an 
ideal marker for the isolation of these aggressive cells since Oct-4 is an intracellular 
protein and isolation of CSCs based on this marker would require cellular 
permeabilisation which consequently would compromise the cell viability. 
Therefore, Oct-4 was used to confirm the stem cell phenotype of the isolated cells. 
Despite ALDH enzyme activity selects for CSCs, in the present study it was not used 
as a CSC marker. However, in future it would be interesting to evaluate the 
characteristics of SCLC cells positive for ALDH activity and compare its 
characteristics with SCLC cells positive for CD133 antigen. 
 
In the present study, 18 ± 1.24% of H345 and 22 ± 1.76% of H69 cells were 
CD133+. However, the CSCs theory states CSCs to be a ‘rare’ fraction of cells 
residing within the tumour bulk. The generality of the CSC hypothesis merits some 
discussion since the frequency of CSCs appears to be highly variable between 
cancers of the same type [73]. In the study by Eramo et al., [79] 0.33-22% of lung 
cancer cells were CSCs. Variation in CSC frequency was explained by the 
differences in cancer subtypes (SCLC and NSCLC). Consistent with previous 
observations, it can be presumed that different cancers will exhibit variable 
functional differences as a result of specific oncogenic pathway activity within a 
known tumour, manipulating the CSC frequency [256]. Additionally, chemotherapy 
enriches the CSC population [80, 257]. In breast cancer patients after primary 
systemic therapy an increase in the proportion of CSCs was observed [258]. Both 
H345 and H69 cells are derived from post-chemotherapy patients, therefore, high 
percentage of CD133+ cells could be associated with enrichment of this population 
after therapy. However, it is essential to point out that the fundamental concept 
underlying the CSC hypothesis is not associated with the absolute CSC frequency; 
instead, CSC hypothesis emphasises that the basis for the functional heterogeneity 
within tumours is the result of the presence of a sub-population of cells with tumour 
initiating capacity whereas the rest of the tumour cells are devoid of it.  
 
CD133 distribution followed a gaussian rather than a bimodal pattern. Similar diffuse 
CD133 expression pattern has been observed in various other cancers [80, 111, 236, 
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259]. This observation is essential for the future studies in this thesis when 
categorising cells into CD133+ and CD133- cells (see below).  
 
Characterisation of CSCs essentially requires accurate identification and isolation of 
these cells. Various methods are employed for the selection of CD133+ cells. 
However, a successful selection of population of interest can only be confirmed by 
evaluating the purity of the isolated cells. In this study two methods were used for 
the isolation of CD133+ cells, MACS and FACS. Post-sort purity was examined by 
the expression of CD133 antigen and its protein levels in the sorted populations. 
Based on the flow cytometry analysis, isolation of SCLC cell by the CD133 
MicroBead Kit did not produce a pure selection due to technical issues. SCLC cells 
grow as cell aggregates. Thus, experimental studies would require the disruption of 
the cell clumps. This was achieved by mechanical force (gentle pipetting) 
accompanied by straining the cell suspension through a cell strainer. Although the 
majority of cells obtained were single cells, complete disruption of cell clumps was 
not possible whilst maintaining high viability. Presence of cell clumps could reduce 
the purity of the isolated cells using the CD133 MicroBead Kit. In this method, 
CD133+ cells are selected by binding of the positive cells to the magnetic 
MicroBeads and subsequent entrapment in the magnetic field. If the cell of interest is 
attached to a cell clump, the total cell clump would be selected as a positive cell. On 
the other hand, if a positive cell is surrounded by negative cells, it could hamper the 
positive cell entrapment. Additionally, the presence of dead cells could also cause 
impure selection as dead cells may bind non-specifically to MACS MicroBeads. Due 
to SCLC cell characteristics, approximately 20% of the cells are found dead in 
culture. A similar observation was made in a study by Clement et. al.,[260] in which, 
in contrast to pure isolation and enrichment of CD133 population using FACS, non-
specific binding was observed using the CD133 MicroBead in gliomas. In addition to 
the technical issues involving the CD133 MicroBead Kit, as demonstrated, CD133 
exhibits a gaussian rather than a distinct positive and negative distribution. 
Therefore, it would not be possible to select on what we consider as CD133high 
(CD133+) and CD133low (CD133-) cells. Therefore, the CD133 MicroBead Kit was 
not suitable for isolation of prospective SCLC CSCs. 
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Fluorescent activated cell sorting proved ideal for the isolation of the population of 
interest in the SCLC cell lines. This was confirmed by analysing the purity of sorted 
population. In contrast to the MACS method, by selecting specific flow cytometry 
gates it was possible to exclude cell clumps and dead cells which significantly 
contributed to sort purity. Additionally, by comparing the distribution of CD133 
expression with the isotype control, it was possible to selectively isolate cells with 
higher or lower expression of this antigen. Thus, the method was selected for 
isolation of CD133+ cells for further analysis in the present study.  
 
Despite the data in this chapter demonstrates that SCLC cells retain cells expressing 
CSC markers, it is essential to assess these cells for their CSC-like characteristics. 
CD133 was selected as the most ideal marker for the characterisation of prospective 
SCLC CSCs. Evaluation of the clonogenic, chemoresistance and tumorigenic 
features of CD133+ SCLC cells would allow us to judge if these cells could be the 
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CHAPTER 4:  
CD133+ cells are proliferative, clonogenic cells with stem cell-like phenotype 




The presence of stem cell-like cells within tumours is the suggested underlying cause 
of tumour initiation, propagation, resistance and recurrence (reviewed in [73, 261, 
262]). CD133, the most well known marker for CSCs of the epithelial origin [263], 
was selected to identify the aggressive SCLC sub-population in the present study. 
Characterisation of CD133+ cells in SCLC and dissection of molecular mechanism 
underpinning their chemoresistance could contribute to novel effective intervention. 
 
CD133+ cells demonstrated higher proliferation compared to the CD133- population 
as seen in glioblastoma, lung cancer and hepatocellular carcinoma (HCC) [80, 118, 
264]. Increased proliferation of CD133+ cells has been associated with aggressive 
phenotype. In samples taken from 44 glioblastoma candidates who had undergone 
complete or partial tumorectomy with adjuvant radiotherapy and temozolomide (an 
alkylating agent) treatment, CD133+ cells displayed high Ki-67 activity. Ki-67 is a 
nuclear protein and can be detected in all active phases of the cell cycle. Co-
expression of both markers was a poor prognostic factor [264]. Similar observations 
were made in 177 samples from patients with stage I lung adenocarcinomas. In these 
candidates, CD133 expression was an independent prognostic marker and its 
combination with proliferating activity (Ki-67 expression) demonstrated a prognostic 
value to predict postoperative recurrence in lung cancer patients. Ma et al., [80] 
demonstrated CD133+ cells were significantly more proliferative in serum-free 
medium compared to its negative counterparts. Active proliferation in these cells 
may be a result of expression of various growth factors and their cognate receptors 
promoting expansion through autocrine and paracrine signalling [82, 169]. A better 
understanding of its growth profile and the underlying mechanism of the putative 
SCLC CSCs would permit designing more effective drugs that target these 
aggressive cells. 
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Self-renewal and differentiation are the two main characteristics of CSCs. Through 
self-renewal, these cells form new stem cell-like cells with identical ability to 
proliferate indefinitely without maturing whereas by differentiation, they generate a 
heterogeneous population of cells with a more mature phenotype and limited 
proliferative ability. A gold standard method to reflect CSC self-renewal and 
differentiation potentials is serial transplantation in recipient animals [79]. The stem 
cell-like features of CSCs can also be evaluated by their ability to form tumour 
spheres in liquid cultures and colonies in semi-solid medium in serum-free 
conditions. In these assays, a single CSC is able to proliferate indefinitely and 
generate a cellular mass without losing their stem cell-like potential. In pulmonary 
malignancies, CD133 selects for cells which are able to self-renew and differentiate 
[79] indicating the utility of CD133 as a CSC marker. 
 
It is unknown if CD133 expression directly regulates a cell’s stem-like phenotype. 
However, multiple studies suggest the importance of CD133 expression on stem cells 
and CSCs. During Hematopoietic stem cell (HSC) self-renewal via asymmetric cell 
division, CD133 was transferred to daughter cells with a stem cell phenotype [124]. 
Similarly, a small fraction of lung cancer cells asymmetrically divided its template 
DNA. Interestingly, CD133 expression was preferentially enriched in the stem-like 
daughter cells, whereas the differentiation markers such as pro-surfactant protein-C 
and pan-cytokeratins were transferred to the more differentiated daughter cells [125]. 
Stable knockdown of CD133 by shRNA in neuroblastoma cells was associated with 
the loss of anchorage-independent colony formation and tumour development in vivo 
in contrast to wild type cells [127]. The association of CD133 expression with the 
immature phenotype was further supported in differentiation studies. Differentiation 
of lung cancer CD133+ cells in vitro led to loss of CD133 expression and gain of 
differentiation markers, loss of unlimited proliferation and the ability to form lung 
cancer spheres in vitro and tumorigenicity in vivo [79]. Therefore, although the 
function is unknown, CD133 is preferentially expressed on stem cells and CSCs. 
 
Embryonic signalling pathways critical for maintenance of the stem cell phenotype is 
also active in CSCs. Oct-4 is a key regulator of self-renewal and pluripotency of 
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embryonic stem cells (ESCs) [155, 265]. In addition to mouse pulmonary stem cells, 
the expression of this transcription factor has also been documented in human lung 
cancer and is associated with its stem cell-like phenotype [158]. Chen et. al., 2008 
[158] demonstrated that the expression of Oct-4 was transcriptionally and 
translationally up-regulated in CD133+ lung CSCs. Knock-down of Oct-4 expression 
using siRNA in the CD133+ cells, inhibited sphere formation and further facilitated 
differentiation with loss of CD133 expression [158]. The self-renewal and 
differentiation potential of CD133+ SCLC cells and the mechanisms associated with 
these phenotypes in SCLC have not yet been fully documented. 
 
CSCs, based on their aggressive and their stem cell phenotype, are the suggested 
cause of tumour development and metastasis. In contrast to non-CSCs, low numbers 
of CSCs are sufficient to generate tumours. In pulmonary cancer, 10
4
 lung cancer 
CD133+ cells readily generated tumour xenografts in immune-compromised mice, 
whereas 5 × 10
4 
CD133- cells did not develop tumours [79]. In breast cancer, 100 
CSCs were tumorigenic in mice where as tens of thousands of non-CSCs failed to 
generate tumours [75]. These data demonstrate the pivotal role of CSCs in tumour 
initiation making the study of CSC even more intriguing. 
  
In addition to their tumour initiation potential, CSCs confer resistance to classical 
therapeutic approaches. Instead, these therapies enrich CSC population by 
preferentially eliminating differentiated cancer cells [141, 266]. Some of the 
mechanisms associated with this resistance include efficient DNA repair, increased 
expression of membrane transporters with efflux of cytotoxic agent and resistance to 
apoptosis [139, 267] [80]. Resistance to apoptosis may be achieved by 
overamplifying antiapoptotic proteins by CSCs allowing these cells to escape the 
cytotoxic insults of treatments. This was demonstrated in hepatocellular carcinoma 
(HCC) wherein chemoresistant CD133+ cells exhibited preferential activation of 
survival pathways Akt/PKB and Bcl-2 [80]. Yet, despite a multitude of studies, the 
specific signalling pathways and mechanisms as to how CD133 CSCs are able to 
evade conventional therapies in SCLC remains largely unknown. 
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In this chapter I will examine the growth profile, stem cell nature, tumour initiating 
and chemoresistant phenotype of CD133+ SCLC cells. Despite multiple studies in 
the field of CSC, this will be the first to characterise mechanisms associated with 
CD133 SCLC chemoresistance. Characterising SCLC CSCs could be a great step 




4.2.1 SCLC CD133+ cells are proliferative in vitro 
 
Previous studies have shown that CSCs are more proliferative compared to non-
CSCs cells [78-80, 264]. The growth rates of CD133+ and CD133- in H345 and H69 
cells were evaluated by sorting the populations as described in chapter 3 and 
immediately seeding 1 × 10
4
 sorted cells/well in SITA medium and counting the 
viable cells every two days over a period of 24 days. SITA medium (RPMI 1640 
supplemented with, SIT media supplement consisting of, 30 nM selenium, 5 µg/ml 
insulin, 10 µg/ml transferrin and 0.25% (w/v) BSA) is a serum-free medium ideal for 
SCLC growth in liquid culture [268]. Serum-free medium was selected since serum 
in culture induces cellular differentiation of stem-like cells [79, 269]. Cell number 
was evaluated using the NucleoCounter NC-100 (ChemoMetec, Denmark). The 
CD133+ and CD133- H345 and H69 cells grow as cellular aggregates. Despite 
disaggregation of cells prior to cell count, residual cell aggregates could increase 
errors. NucleoCounter allows accurate counting of viable cells by analysing the light 
emitted from PI-positive dead cells. As shown in Figure 23A, in H345 cells, no 
significant difference in the growth rate between the two populations could be 
observed until day 16. From day 18 onwards, CD133+ H345 cells were significantly 
more proliferative than CD133- population (P=0.03). By the end of the study, day 
24, cell numbers of CD133+ were approximately twice than that of CD133- cells 
(CD133+ cells, 1.88 ± 0.10 × 10
6
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Similarly, in H69 cells, until day 16 no significant difference between CD133+ and 
CD133- cells was observed (Figure 23B). From day 18 onwards, CD133+ H69 cells 
were significantly more proliferative than the CD133- cells (on day 18, P=0.01). On 
day 24, CD133+ cell number had reached 2.57 × 10
6
 ± 21.61 cells/well compared to 
CD133- cells which numbered 1.48 × 10
6
 ± 18.22 cells/well. In this cell line, 
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4.2.2 CD133+ cells are clonogenic in vitro 
 
Clonogenic assays reflect the stem cell features of a single cell that is resistant to 
anoikis and is able to generate a clonal population [144, 240]. Post-sorted cells, 
cultured in SITA medium containing 0.3% agarose, were layered on the same 
medium with 0.5% agarose. The low percentage of agarose promotes 3 dimensional 
cell growth in semi-solid medium. SITA medium was used to inhibit possible 
cellular differentiation. Colonies were scored after 21 days by standard light 
microscopy. Number of colonies per dish was presented as percentage of the cells 
seeded and is defined as cloning efficiency. 
 
In H345 cells, the CD133- population despite being proloferative in liquid culture did 
not form any colonies in semi-solid medium. Lack of growth of CD133- cells in 
semi-solid medium could possibly be due to the nature of the clonogenic assay. In 
this assay cells are cultured as single cells in the semi-solid medium, limiting cell-
cell interaction, allowing only cells with stem cell nature and clonogenic potential to 
surivive and generate colonies. Whereas, in liquid growth assays, the floating H345 
and H69 cells can directly interact with their adjacent cells providing appropriate 
growth signals via autorcine and paracrine signallings. 
  
Both CD133+ and parent cells were clonogenic with CD133+ cells demonstrating 
2.9 times (P=0.04) more clonogenicity than the parent cells (Figure 24B). The 
cloning efficiency of the CD133+ cells was 5.30 ± 1.12% compared to 1.91 ± 0.17% 
in the unsorted cells. On gross observation, colonies formed by CD133+ or parent 
cells were similar in their morphology. Figure 24A illustrates the clonogenic ability 
of CD133-, CD133+, and parent H345 cells in a tissue culture dish. As illustrated, 
the pink colour of the semi-solid medium containing the non-clonogenic CD133- 
cells was indicative of lack of cellular growth in culture. In contrast, colonies can be 
detected in tissue culture-well containing CD133+ and parent cells. The number of 
colonies formed by CD133+ cells was greater than that formed by parent cells.  
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Similar observations were made in H69 cells (Figure 24C). CD133- cells were 
unable to form colonies whereas both CD133+  (7.90 ± 0.3%) and parent (3.25 ± 
0.6%) cells were clonogenic with CD133+ cells exhibiting greater colony forming 
ability than parent population (P=0.006). Colonies formed by both CD133+ and 
parent cells had similar morphology. In conclusion, supporting the CSC hypothesis, 
in both H345 and H69 cells, CD133+ cells were significantly more clonogenic than 
CD133- cells. The clonogenic efficiency of the CD133+ cells was also significantly 
greater than the parent population indicating that the parent cells contain a population 
of cells with stem cell-like phenotype, however the CD133+ population are enriched 
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Despite high clonogenic efficiency of CD133+ cells, not all CD133+ cells cultured in 
the semi-solid medium formed colonies. Therefore, CD133 expressing cells could be 
a heterogeneous population of cells. Similar observation was made by Eramo et al., 
[79] where in only 5-30% of lung cancer spheres were capable of self-renewing. In 
the present study this hypothesis was assessed by double staining unsorted cells with 
CD133-1-APC and ALDH to evaluate the number of cells co-expressing both stem 
cells markers. As shown in Figure 25, 18 ± 1.01% of H345 cells were CD133+ 
(Figure 25A and A1) and 16 ± 0.78% of cells were ALDH+ (Figure 25B and B1), 
however, only 5.8 ± 0.86% of cells were positive for both markers (Figure 25C and 
C1). Thus, despite similarity in the expression of CD133 antigen, not all CD133+ 
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4.2.3 CD133+ cells express the embryonic stem cell marker, Oct-4, and 
maintain their stem cell-like phenotype over long periods in culture 
 
The presence of Oct-4 in the sorted and unsorted cells was evaluated based on the 
protein levels using western blotting. As shown in Figure 26, a protein band of ~48 
kDa in both CD133+ and parent cells represented the presence of Oct-4 in these cell 
lines whereas no band could be detected in the CD133- cell lysates. β-actin was used 
as loading control. Oct-4, the master switch during differentiation, is essential for 
maintaining the stem cell-like phenotype [255]. Thus, it can be concluded that, in 
contrast to CD133- cells, CD133+ subset are immature cells. Oct-4 protein 
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CSCs are considered self-renewing cells based on their ability to grow for extended 
periods of time without losing their phenotype [78, 79]. CD133+ and CD133- H345 
cell line were cultured in serum-free SITA medium for 30 days. After this period, the 
expression of the stem cell marker, CD133, and the clonogenic potential of these 
cells was evaluated. If CD133+ cells retain stem cell-like nature, prolonged period of 
culturing should not affect its stem cell-like potentials such as its clonogenicity.  
 
Initially, CD133 expression was evaluated on post-sorted cells cultured for 30 days 
in SITA. The expression of CD133 on sorted cells on day 30 was compared with that 
of cells on day 0 (the day of cell isolation). Geometric mean (GM) was used to 
calculate changes in CD133 expression on day 0 and 30. Figure 27 is representative 
flow cytometry histograms showing the expression of CD133 on the parent cells (A1, 
day 0 and B1, day 30), CD133- (A2, day 0 and B2 day 30) and CD133+ (A3, day 0 
and B3 day 30). CD133 expression was compared with its corresponding negative 
control (isotype control). Histograms A4 and B4 are overlay histograms of CD133-, 
CD133+ and parent cells on day 0 and on day 30, respectively.  
 
The GM of CD133+ cells did not significantly change over the period of 30 days 
(A3, GM on day 0 was, 121.35 ± 1.45 and B3, GM on day 30 was, 128.10 ± 1.21), 
indicating that despite a long period of culturing, CD133+ cells retained the CD133 
expression in SITA medium. CD133- cells are not capable of self-renewing 
therefore, as expected, the GM of CD133- cells remained unaltered (A2, GM on day 
0 was, 4.35 ± 1.02 and B2, GM on day 30 was, 4.01 ± 1.63). The difference in the 
CD133 expression between CD133+, CD133-, and parent cells was more apparent on 
the overlay histograms (A4, day 0 and B4, day 30). As demonstrated, on day 0, 
CD133+ cells displayed the highest GM for CD133 expression (121.35 ± 1.45) 
compared to its negative counterpart (4.35 ± 1.02) and the parent cells (32.7 ± 2.86). 
Similarly, on day 30, CD133+ cells displayed the highest GM of CD133 expression 
(128.10 ± 1.21) compared to its negative counterpart (4.01 ± 1.63) and the parent 
populations (30.97 ± 1.32). Therefore, CD133+ cells were able to proliferate for 
prolonged periods of time in serum-free culture without losing the expression of its 
stem cell marker. This data additionally indicates that SITA medium can be 
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employed for the expansion of SCLC CSC-like cells which is essential finding for 
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To further confirm CD133+ H345 cells retained their stem cell-like features over 
prolonged periods of culture, clonogenicity of 30 days post-sorted CD133+, CD133-, 
and parent cells was evaluated. Eramo et al. 2008 [79], demonstrated that CD133+ 
cells isolated from primary lung cancer tissues were able to maintain their stem cell 
phenotype in culture and reproduced the original tumour in vivo. In the present study, 
the stem cell-like phenotype of the cultured CD133+ cells was examined based on 
their colony forming potential in vitro. As shown in Figure 28, despite CD133+ cells 
being cultured in serum-free medium for 1 month, they still retained their aggressive 
phenotype and were able to form colonies with a cloning efficiency of 7.49 ± 0.21%. 
CD133- cells do not retain stem cell-like phenotype and therefore did not form 
colonies in the semi-solid cultures and within 3-5 days post-culturing most of the 
cells appeared apoptotic. Parent cells were clonogenic with efficiency of 2.18 ± 
1.05%. Parent cells comprises of both CD133+ and CD133- cells therefore, it was 
expected that these cells would form colonies. However, the cloning efficiency of 
CD133+ cells were 3.43 times (P=0.006) greater than that of the parent cells. Based 
on these data, CD133+ cells not only retained the expression of their surface marker 
over extended periods of in vitro culturing, but also maintained their aggressive 
phenotype suggesting the possible self-renewing ability of these cells. To confirm 
self-renewing potential of CD133+ cells, serial transplantation of CD133+ cells in 















































CHAPTER 4                                       128 
 
4.2.4 CD133+ cells upon differentiation lose their CD133 expression and 
stem cell-like characteristics 
 
CSCs along with their self-renewal phenotype are able to differentiate to generate 
cells that make up the bulk of the tumour. Presence of serum in culture medium can 
induce differentiation [269]. The differentiation potential of CD133+ H345 cells was 
evaluated by culturing isolated cells for 30 days in serum containing medium (RPMI 
1640 supplemented with 10% (v/v) heat-inactivated FCS, 5 µg/ml L-glutamine, 50 
U/ml penicillin and 50 µg/ml streptomycin) (RPMI complete medium) and analysing 
changes in the expression levels of CD133 on the day 30. Figure 29 is representative 
flow cytometry histograms showing the expression of CD133 on the parent cells (A1, 
days 0, and B1 day 30), CD133- (A2, day 0, and B2, day 30) and CD133+ cells (A3, 
day 0, and B3 day 30). CD133 expression was compared with its corresponding 
negative control (isotype control). Histograms A4 and B4 are overlay figures of 
CD133-, CD133+ and parent cells on day 0 and day 30, respectively.  
 
The GM of CD133- did not significantly change over time (A2, GM on day 0 was, 
4.21 ± 0.61 and B2, GM on day 30 was, 4.72± 0.23) indicating that they were unable 
to generate different progeny of cells and remained a negative population. On the 
other hand, a significant reduction in the GM of CD133+ cells from day 0 (130.04 ± 
1.5) compared to day 30 (53.72 ± 0.94) was observed (P<0.0001). Comparing the 
GM of CD133+ cells with parent population on day 0, CD133+ cells were 
significantly more fluorescent than parent cells (A3, GM of CD133+ cells on day 0 
was, 130.04 ± 1.5, and A1, GM of parent cells on day 0 was, 30.10 ± 1.4, P<0.0001). 
However, on day 30, despite significant difference between the GM of CD133+ and 
parent cells (B3, GM of CD133+ cells on day 30 was, 53.72 ± 0.94, and B1, GM of 
parent cells on day 30 was, 36.13 ± 1.4, P=0.009), the GM of CD133+ cells more 
closely resembled the parent cells than CD133- population, indicating that in the 
presence of serum, CD133+ cells differentiate and generate a mixed progeny similar 
to parent population. To further confirm differentiation potential of CD133+ cells in 
serum, loss of Oct-4 expression and gain of differentiation marker should be 
evaluated. 
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Loss of CD133 expression upon CD133+ differentiation is associated with loss of 
stemness [77, 79]. As shown above, culturing CD133+ cells in serum containing 
medium for 30 days was associated with differentiation of CD133+ cells and 
generation of a mixed progeny. To further evaluate the effect of this culturing 
method on the functional properties of differentiated CD133+ cells, liquid growth 
profile and the clonogenic potential of these cells were assessed. The 30 days post-
sorted CD133+ and CD133- cells (1 × 10
4
 cells/well) were cultured in fresh RPMI 
complete medium and the number of viable cells was counted every 2 days by 
NucleoCounter NC-100 (ChemoMetec, Denmark) over 24 days. In contrast to high 
proliferation of CD133+ cells compared to CD133- cells observed when cultured in 
serum-free SITA medium (Figure 23A), H345 CD133+ cells grown in serum 
containing medium grew at the same rate as the CD133- cells with no significant 
difference in their growth potential (Figure 30A). This observation indicated that in 
the presence of serum, CD133+ cells differentiate which was associated with loss of 
their high proliferation phenotype. This was in line with previous documented data 
that CSCs cultured in serum-containing medium lose their high proliferation 
potential [79]. 
 
The clonogenic potential of 30 days post-sorted CD133+, CD133- H345 and 
unsorted parent cells was evaluated in serum-containing semi-solid medium. CD133- 
cells in the presence of serum were still unable to form colonies which further 
emphasised on their non-CSC phenotype (Figure 30B). In contrast, both CD133+ 
cells and parent cells generated colonies with cloning efficiencies of 7.72 ± 1.26% 
and 8.93 ± 1.08%, respectively. No significant differences between the cloning 
efficiency of the CD133+ and parent populations was observed. Therefore, in line 
with data shown in Figure 29, in the presence of serum, CD133+ cells differentiated 
to generate a mixed progeny similar to the parent cells thus, exhibited a colony 
forming ability similar to the parent population (Figure 30B). To further support this 
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4.2.5 CD133+ cells are tumorigenic in vivo and reproduce the parent 
tumour 
 
The tumour initiation ability of the H345 CD133+ cells was evaluated by 
subcutaneous injection of various numbers of isolated CD133+ and CD133- and 
parent cells (5 × 10
5
, 1 × 10
5
, and 1 × 10
4
) mixed with growth factor reduced 
matrigel (1:1 volume of cells:Matrigel mixed at 4
º
C, total volume of 100 µl) in 
nude/nude mice. Implantation of 1 × 10
4
 CD133+ did not form tumours. However, 
injection of 1 × 10
5
 CD133+ cells consistently resulted in the growth of tumour 
xenografts (Figure 31A) with histological features closely resembling the tumours 
initiated by parent  cells (unsorted cells) as shown by hematoxylin and eosin staining 
(Figure 31B). However, the same number of CD133- or parent cells did not form 
tumours in nude/nude mice. At least 5 × 10
5
 unsorted cells were required to form 
tumours yet, the tumours formed by 5 × 10
5
 parent cells were significantly smaller 
than the same number of cells injected by CD133+ cells (tumour volume of CD133+ 
on day 52 was, 421.73 ± 33.30 mm
3
, and tumour volume of parent cells on day 52 
was, 274.41 ± 24.46 mm
3
, P=0.031). No tumours could be detected in animals 
injected with CD133- cells. Figure 31C is representative of tumour generated in mice 
implanted with CD133-, CD133+ or parent cells. Therefore, in contrast to CD133- 
cells, CD133+ cells were tumorigenic and low numbers of these aggressive cells 
were sufficient to generate a tumour. Based on this observation it can be proposed 
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4.2.6 Metastatic ability of CD133+ cells was evaluated 
 
A growing body of evidence suggest that cancer metastasis occurs due to migration 
of CSCs to distant organs [270, 271] [272]. In patients with SCLC, cells initially 
metastasise to regional followed by distal lymph nodes. Haematogenous spread 
include bone, liver, adrenal glands, and brain [22]. High rate of cancer metastasis in 
SCLC patients is one of the main causes of poor survival rates. Therefore, identifying 
the underlying cause of SCLC metastasis could be essential to improve survival. 
 
The nude/nude mice injected with CD133+ cells showed an enlargement of inguinal 
and axillary lymph nodes. Mice lymph nodes were initially impalpable. One month 
after CD133+ SCLC implantation, animal inguinal and axillary lymph nodes were 
obvious on inspection and palpable (Figure 32). Initially, swelling of the ipsilateral 
inguinal and axillary lymph nodes was detected and over time contralateral lymph 
nodes were also enlarged. On day 52 (last day of experiment) axillary and inguinal 
lymph nodes were measured by calliper. The size of the ipsilateral lymph nodes was 
larger (inguinal lymph node, 120.12 ± 15.87 mm
3
 and axillary lymph node, 100.60 ± 
14 mm
3
) but not significantly different from the contralateral lymph nodes (inguinal 
lymph node, 98.52 ± 16.63 mm
3
 and axillary lymph node, 90.31 ± 18.01 mm
3
). 
Therefore, SCLC metastasis to the lymph nodes was speculated. 
 
Mouse lymph nodes were subject to IHC for detection of the SCLC marker, neural 
cell adhesion molecule (NCAM), for pathological confirmation of metastasis. 
NCAM, a cell-cell adhesion molecule, is detected in almost all SCLC cells [273]. 
Samples were double-stained with CD45, a marker widely expressed on murine 
leucocytes, to distinguish human from murine cells. Primary tumours (tumour 
generated at the site of injection) of the animals that had enlarged lymph nodes were 
used as a positive control for NCAM and spleen of an untreated mouse (not exposed 
to human SCLC cells) was used as a negative control. NCAM (green) was detected 
on the surface of all cells of the primary tumour (Figure 33). This was expected since 
the tumour was generated from H345 CD133+ cells. Interestingly, infiltrating 
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CD45+ cells (red) was observed on the surface of the tumour (Figure 33). As 
expected, almost all of the four lymph nodes, garrisons of immune cells, extracted 
from axillary and inguinal regions, were positive for CD45 (Figure 34). A few 
NCAM+ CD45- cells were detected in the four lymph nodes extracted from animals 
injected with CD133+ cells. Presence of NCAM+ cells could be indicative of SCLC 
metastasis to lymph nodes. However, similar observations were made in mouse 
spleen which was used as negative control (Figure 35) where most cells were CD45+ 
however few NCAM+ CD45- cells were detected. Spleen utilised in this study was 
obtained from animals which were not exposed to human SCLC cells therefore, the 
NCAM+ cells could not have been SCLC cells. Thus, based on these observations it 
could not be concluded that lymphadenopathy in animals subjected to CD133+ 
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4.2.7 CD133+ cells confer resistance to conventional chemotherapeutic 
agent 
 
CD133 expressing cells are the proposed chemoresistant cells and cytotoxic agents 
instead enrich this population by eradicating CD133 non-expressing cells. To 
evaluate this concept in SCLC cells, unsorted (parent) H345 and H69 cells were 
treated with two different concentrations of etoposide (3 and 30 µg/ml). The 
percentage of CD133+ cells was assessed after 72 hours by analysing CD133-1 
expression levels on treated cells by flow cytometry. Untreated cells were used as 
control. Although both cell lines demonstrated a dose-dependent decrease in the total 
number of viable cells, a significant increase in the percentage of CD133+ cells was 
observed in H345 (P=0.043, ANOVA) (Figure 36A) and H69 cells (P=0.039, 
ANOVA) (Figure 36B) suggesting that etoposide was not only ineffective against 
CD133+ cells but instead enriched this population (Table 6). 
 
To confirm that CD133+ cells are chemoresistant, the effect of etoposide on the cell 
viability of H345 and H69 sorted and parent cells was assessed. Both SCLC cell lines 
have been obtained from patients that had originally undergone a period of 
chemotherapy and are therefore relatively resistant to etoposide in culture. Sensitivity 
to etoposide was assessed by MTT assay 72 hours after treatment. As shown in 
Figure 36C, in H345 cell line, all three populations demonstrated resistance to 
etoposide and it was not possible to calculate the IC50 values since etoposide was not 
potent and effective enough to inhibit 50% of cell viability. Among the three 
populations, resistance to etoposide was more apparent in CD133+ cells. Similar 
observation was made in H69 cells, in which all three populations demonstrated 
resistance to etoposide however, this resistance was more apparent in CD133+ 
population (Figure 36D). Therefore, based on this data, CD133 selects for the most 
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4.2.8 CD133+ cells are resistant to apoptosis due to preferential expression 
of the anti-apoptotic Akt/PKB and Bcl-2 proteins 
 
Evasion of programmed cell death is one of the hallmarks of cancers (reviewed in 
[274]). Most cytotoxic agents primarily act by triggering apoptosis. Thus, resistance 
to apoptosis could be a possible mechanism supporting SCLC CSCs survival against 
cytotoxic insults. To evaluate this concept, sorted populations were subject to three 
different concentrations of etoposide (3, 10, and 30 µg/ml) and after 72 hours, the 
percentage of apoptosis using EB/AO and the May-Grunwald-Giemsa staining was 
calculated. Figure 37 is representative images of May-Grunwald-Giemsa (Figure 
37A1-A2) and EB/AO (Figure 37B1-B2) staining in CD133+ and CD133- H345 
cells treated with etoposide 30 µg/ml for 72 hours. In H345 cells, CD133+ and 
CD133- cells responded to etoposide in a dose-dependent manner. However, as 
demonstrated using May-Grunwald-Giemsa staining (Figure 38A), in contrast to 
CD133+ cells, CD133- cells were significantly more sensitive to treatment (at 3 µM, 
P=0.004, at 10 µM, P=0.004, at 30 µM, P=0.02) (Table 7A). This data was further 
supported using EB/AO staining in which CD133- cells were more sensitive to 
etoposide than CD133+ cells (at 3 µM, not significant, at 10 µM, P=0.02, at 30 µM, 
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Similar observations were made in H69 cells; the CD133- cells were significantly 
more responsive to etoposide than CD133+ cells confirmed by staining samples with 
May-Grunwald-Giemsa (at 3 µM, P=0.02, at 10 µM, P=0.004, at 30 µM, P=0.003) 
(Figure 39A, Table 8A) and EB/AO (at 3 µM, P=0.03, at 10 µM, not significant, at 
30 µM, P=0.02) (Figure 39B, Table 8B). Note that, in both cell lines, the percentage 
of apoptosis in untreated CD133+ and CD133- are very similar. Therefore, CD133+ 
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While most studies have proven the chemoresistance phenotype of CSCs, the exact 
mechanisms which enable survival of CD133+ SCLC cells are unclear. Deregulation 
in the Akt/PKB pathway and members of the Bcl-2 survival family in cancer cells 
have been studied extensively and play a provital anti-apoptotic role in various 
malignancies [275, 276]. To address the mechanism by which CD133+ SCLC cells 
confer resistance to etoposide, both CD133- and CD133+ cells were probed by 
western blot for endogenous expression of proteins involved in Akt/PKB and Bcl-2 
survival signalling pathways. CD133+ cells isolated from H345 cell lines, compared 
to matched CD133- counterparts, displayed a higher expression of active Akt 
(phosphorylated at Serine 473) and Bcl-2, indicating that this pathway may 
contribute to the resistance to apoptosis in CD133+ (Figure 40). Total Akt protein 
levels were assessed at the same time to confirm that increased expression of 
phosphorylated Akt in the CD133+ cells was not due to increased in total Akt levels. 
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4.2.9 Human SCLC tissue samples retain high levels of CD133+ cells 
 
The expression of CD133 was evaluated in primary human SCLC tissues by IHC. It 
was unknown if samples were taken from patients who were previously exposed to 
chemotherapy treatment. IHC was performed using a DAKO Envision kit (see 
chapter 2 for more details). Rabbit polyclonal anti-human CD133 (ab16518, Abcam) 
was used for IHC. Figure 41 is representative of a tissue sample taken from a SCLC 
patient. High CD133 staining could be observed in the samples. Based on this 
observation, it could be suggested that the tissue sample was taken from a patient 
who had been previously undergone therapy, however due to lack of information 




























































Data gathered from this chapter demonstrated that the SCLC CD133+ sub-population 
comprises of aggressive cells with augmented proliferative and clonogenic capacity 
in vitro and significantly increased tumour initiation potential in vivo. These cells 
exhibited similar characteristics to normal stem cells including Oct-4 expression, the 
ability to maintain their stem cell-like characteristics over prolonged periods of 
culturing and differentiate in appropriate conditions. On differentiation, the CD133+ 
cells lost CD133 expression and their enhanced growth potential in liquid and semi-
solid medium, and retained a phenotype similar to parent cell line, a population of 
both CD133+ and CD133- cells. Treatment of unsorted SCLC cell lines (H345 and 
H69) with etoposide significantly enriched the CD133+ sub-population, illustrating 
the chemoresistant phenotype of CD133+ cells. The enriched CD133+ cells from 
SCLC cell lines survived chemotherapy relative to unsorted cells and CD133- cells. 
The study for the first time demonstrated that chemoresistance in these cells was 
associated with preferential expression of anti-apoptotic Bcl-2 and activated Akt 
proteins known to support cell survival. Therefore, based on these observations, it 
can be concluded that CD133+ cells within SCLC cells are the possible explanation 
for tumour development and treatment resistance. 
 
In line with previous observations [80], SCLC CD133+ cells exhibited significantly 
greater proliferation in serum-free medium compared to the CD133- cells. 
Contributing factors promoting CSC growth may be attributed to over expression of 
growth factors by the CSCs. In 2008, Levina et al., [82] demonstrated higher 
expression of various cytokines, chemokines, angiogenic and growth factors 
including IL6 (CXCL6), IL8 (CXCL8), bFGF, VEGF, HGF, PDGF-BB, G-CSF, and 
SCGF-β in CSCs than non-CSCs in lung cancer cell lines. These cells also expressed 
higher levels of VEGFR1, FGFR2, CXCR1, and CXCR4 receptors compared to the 
non-CSC sub-population. The author concluded that the growth factors produced by 
CSCs through autocrine and paracrine signalling promote CSC proliferation, tumour 
progression and metastasis. Likewise, increased expression of C-kit and its ligand 
stem cell factor (SCF) on NSCLC CSCs has been proposed to be associated with 
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their proliferation [165]. Proliferation of these cells was inhibited by SCF-
neutralising antibodies or by imatinib, an inhibitor of c-kit. The significant role of 
growth factors on CSC proliferation makes these pathways interesting for targeting 
CSCs. Multiple Ca
2+
 mobilising-neuropeptide through autocrine and paracrine 
growth loops mediate SCLC growth and proliferation [169]. The mechanism 
propelling extensive growth of SCLC CD133+ cells is unknown. It would be 
interesting to evaluate the expression of neuropeptide receptors on these cells 
underlying their enhanced proliferation. 
 
Contradictory data suggest CSCs as quiescent cells. The CD24+ ovarian CSCs were 
slow proliferative than the tumour bulk cells suggesting their quiescent phenotype 
[277]. In breast cancer cell lines, CD44+/CD24−/ESA+ cells were also quiescent 
compared to the tumour bulk [278]. The quiescent phenotype of the CSCs is 
supported by the concept that tissue stem cells may be the origin of CSCs, thus they 
share similar characteristics. Low proliferation of stem cells is a protection 
mechanism to prevent exhausting stem cell proliferative ability and to limit 
accumulation of mutation during frequent cell divisions [279]. However, quiescence 
is not a dogma for stem cells. Slow-cycling LRCs (label-retaining cells) at the +4 
position at the base of the colon crypt are suggested intestine stem cells. These crypt 
based cells are maintained in low number of approximately 4-6 cells that divide once 
a week. However, upon irradiation, these stem cells evaded radiation induced 
apoptosis and demonstrated high proliferation with regeneration of the damaged 
crypt [280]. Similar observations were made by Kim et al. 2008, [98] in lung where 
in bronchoalveolar stem cells (BACS), generally quiescent, actively proliferated in 
response to bronchiolar and alveolar injury.  
 
Tissue stem cells reside in specific areas known as niche which along with the 
neighbouring differentiated cells that secrete and generate a rich microenvironment 
of extracellular matrix and other factors, regulate stem cell quiescence and un-
differentiated state [281]. The importance of these specialised areas in regulating 
stem cell activity can be explained in an experiment where the fate of embryonic 
stem cells (ESCs) was monitored upon implantation into mice. ESCs isolated from 
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blastocyst-stage mouse embryo, when forced in an environment other than their 
niche in vivo these cells can turn into an undesirable differentiated multicellular 
mass. For example, ESC once subcutaneously injected into nude mice led to the 
formation of uncontrolled multicellular tumour mass. In contrast, injection of the 
same stem cells into mouse blastocyst, an environment similar to their native niche, 
resumed normal stem cell behaviour and contributed to the development of healthy 
offspring [281]. Data suggest that CSCs also exist in a similar niche, dubbed “CSC 
niche” which regulates their growth, self-renewal and un-differentiation state 
(reviewed in [282, 283]). Conclusively, stem cells and CSCs located in their niche 
are generally quiescent however their quiescent status depends on the signals that 
they receive from the environment such as signals during tissue injury. Previous data 
from my laboratory shows that SCLC cell lines produce and secrete various 
components of extracellular matrix (ECM) [230, 231, 284]. The generated ECM 
protects these cells from cytotoxic insults induced by etoposide and promotes SCLC 
cellular growth. Therefore, it can be proposed that ECM can serve as CD133+ SCLC 
cell niche and that the growth promoting signals from the interaction of these cells 
with ECM components as well as signals from the environment, such as those from 
the tissue culture medium could possibly explain the increased proliferation of these 
cells in culture.  
 
CSCs are characterised as the clonogenic cells within the tumour bulk. Colony assay 
evaluates the ability of a single cell to survive anchorage-independent growth and its 
stem cell-like nature to generate a cellular progeny. The present study demonstrated 
that CD133+ cells were significantly clonogenic in SITA medium as against the non-
clonogenic CD133- cells, thus, representing the aggressive, stem cell-like sub-
population of SCLC cells. Increased expression of growth factors on lung CSCs not 
only promotes their liquid growth but also is associated with enhanced colony 
formation [82, 165]. Expression of neuropeptides and their receptors as the known 
regulators of SCLC growth and proliferation through autocrine and paracrine signals. 
Waters et al., [65] demonstrated that chemoresistant, aggressive SCLC cell line, 
GLC19 expresses higher levels of neuropeptide receptors compared to 
chemosensitive SCLC cell line, GLC14. Therefore, based on the above data is can be 
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speculated that increased clonogenecity observed in CD133+ SCLC cells is regulated 
by the enhanced expression of the neuropeptides and their receptors (for more details 
see chapter 5). 
 
The expression of CD133 has been another factor proposed as mediator of 
anchorage-independent growth of CSCs. Tumour sphere formation and the 
anchorage-independent growth of Neuroblastoma (NB) CSCs was maintained by 
CD133-related activation of PI3K/AKT pathways [127]. Concluding, in the present 
study, higher CD133 expression of sorted cells, by activating the down stream 
survival signals may have also been associated with their survival and growth in the 
semi-solid medium. In the present study, parent cells also formed colonies. Parent 
cells contain CD133+ and CD133- cells and colony formation can be attributed to 
CD133+ sub-population. Extensive colony forming ability of CD133+ cells 
compared to the parent population could be explained by lower frequency of the 
CD133+ cells in the parent population. Interestingly, the colonies formed by the 
CD133+ and parent cells were similar in shape and size. The observation further 
supports the notion that clonogenic cells within the parent population are the 
CD133+ cells.  
 
Interestingly, despite high clonogenic efficiency, not all CD133+ cells formed 
colonies in the semi-solid medium suggesting heterogeneity within the CD133+ 
population. Similarly, Eramo et al (2008), [79] documented that the number of self-
renewing cells within cancer spheres ranged from 5-30% as measured by colony 
assay and not all CD133+ cells were CSCs. Therefore, to further confirm 
heterogeneity within the SCLC CD133+ cells, sorted population were stained with an 
additional stem cells marker, ALDH, in search of cells co-expressing both markers. 
As shown in Figure 25, only 5.8 ± 0.86% of the population was positive for both 
markers. Taken together, it may be suggested that SCLC CD133+ cells contain a 
subset of cells with similar phenotype but different potentials necessitating the use of 
novel markers or combination of markers to select highly enriched CSC-like cells.  
Heterogeneity in CD133+ fraction has likewise been documented in NSCLC. 
Cisplatin treatment of xenografts of primary NSCLC tumours from patients resulted 
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in remarkable enrichment of the CD133+ cell fraction in the residual tumours. 
However, within the CD133+ fraction the CD133+ ABCG2 and CD133+ CXCR4 
sub-population selectively displayed a clear enrichment after treatment [84]. 
Mammary CSCs are enriched in both CD133+ CD24-/low population and ALDH+ 
sub-fractions. However, co-expression of CD133+/CD24-/low/ALDH+, despite low 
overlap of the two populations (0, 1-1.2%), selected highly aggressive cells in vitro 
and in vivo [75, 83]. Therefore, based on the above data, despite CD133 expression 
in the SCLC cells selected the aggressive and chemoresistant cells, identifying 
makers which would isolate a more purified population of CSC-like cells could 
further aid us to better understand these aggressive cells.  
 
CSCs can proliferate indefinitely in appropriate serum-free cultures without losing 
their stem cell-like nature including clonogenecity and tumorigenicity, indicative of 
their self-renewing potential [77-79]. Thus, it was hypothesised that H345 CD133+ 
cells would exhibit similar stem cell-like characteristics in appropriate conditions. In 
line with data from other malignancies, CD133+ cells cultured in serum-free SITA 
medium retained CD133 expression in culture without losing clonogenicity in semi-
solid medium. In the presence of serum most H345 CD133+ cells lost CD133 
expression and generated a population with heterogeneous levels of CD133 
expression resembling the parent (unsorted) cells. This was accompanied by loss of 
high proliferation in serum containing liquid culture and attenuated enhanced 
clonogenic ability in semi-solid medium. Likewise, Eramo et al., [79] demonstrated 
differentiation of lung CSCs in the presence of serum was associated with loss of 
CD133 expression, gain of differentiation marker including cytokeratins (CKs), and 
inability to grow indefinitely in vitro and form tumours in vivo. Data in this section 
indicate that SCLC CD133+ cells are the stem cell-like population that can be 
maintained and expanded as undifferentiated cells in SITA medium. However, to 
confirm the self-renewing potential of CD133+ SCLC cells it is necessary to evaluate 
their tumorigenicity upon serial transplantation.  
 
Signalling pathways including Sonic hedgehog, Wnt and Notch that regulate tissue 
stem cell self-renewal and fate are common in CSCs (Reviewed in [285, 286]). For 
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example, NSCLC CSCs have elevated Notch pathway transcript expression. 
Suppression of this pathway by either gamma-secretase inhibitor or stable expression 
of shRNA against NOTCH3 resulted in significant decrease in CSCs population, 
reduction in tumour cell proliferation and clonogenicity [287]. In glioma CD133+ 
cells, Hedgehog signalling regulates their “stemness” genes and their self-renewal. 
Lentiviral-mediated silencing of this pathway resulted in the differentiation of the 
CD133+ cells and abolished their tumorigenic potential in vivo [288]. Therefore, 
tissue stem cells and CSCs share similar pathways associated with their self-renewal 
and fate. In the present study it has been shown that CD133+ cells express the 
embryonic stem cell marker, Oct-4 similar to that of mouse pulmonary 
stem/progenitor cells [79]. This observation indicated the stem cell nature of SCLC 
CD133+ cells, further suggesting the role of this sub-population in SCLC 
development in patients. Based on such similarities between tissue stem cells and 
CSCs, it is tempting to conclude that CSCs are generated from stem cells which 
already posses a favourable background. However, as documented by Clarke et al. 
(2006) [289], it is now widely accepted that CSCs may also develop from more 
differentiated cells that have acquired reprogramming hits and therefore regained the 
stem cell phenotype (Figure 42). Better understanding of these pathways could guide 
us to target cells with self-renewing potential and possibly inhibit further cancer 
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A hallmark of CSCs is tumour initiation potential in recipient animals with the 
hypothesis being that neoplastic growth can be initiated by low counts of cells that 
possess stem cell-like phenotype and growth advantage. As expected clonogenic 
CD133+ cells exhibited enhanced tumorigenesis potential in immune-compromised 
mice compared to the CD133- and parent subset. Counts as low as 1 × 10
5
 CD133+ 
cells subcutaneously implanted in nude mice consistently resulted in the growth of 
tumour xenografts whereas the same number of CD133- cells or even higher cell 
number were devoid of tumorigenesis (Figure 31). CD133+ cell xenografts had 
histological features closely resembling the tumours initiated by the parent cells. 
These results further supported that CD133+ cells are the tumour initiating 
undifferentiated cells and that small numbers of these cells are sufficient to generate 
a progeny with cellular heterogeneity similar to that generated by the parent 
population. Non-clonogenic CD133- cells were not tumorigenic in vivo as observed 
within the duration of the experiment. This further emphasised that CD133- cells are 
not the tumour initiating cells, unable to survive anchorage-independent growth and 
devoid of stem-cell like phenotype. Enriched CSC population within the CD133+ 
population was additionally demonstrated when comparing the tumorigenic potential 
of CD133+ cells with that of parent cells. Although parent cells were also 
tumorigenic in the immune-compromised animals, at least 5 fold higher cell number 
compared to CD133+ population was required for tumour development. 
Additionally, tumours formed by parent cells were significantly smaller than the 
neoplasm generated by CD133+ cells when the same number of parent cells as 




was implanted. Thus, the in vivo tumorigenic assay indicates 
CD133+ population are tumour initiation cells in the SCLC cell lines.  
 
According to the established CSC theory, a single CSC should be sufficient to 
develop tumour xenografts. However, at least 1 × 10
5
 CD133+ cells were required 
for tumour initiation in the immune-compromised mice. The conflicting observation 
is in line with the data obtained from colony assay which demonstrated that not all 
SCLC CD133+ were able to form colonies in semi-solid medium. The presence of 
heterogeneity within the CD133+ SCLC (Figure 25) could be a possible explanation 
for high number of CD133+ cells required for tumour initiation. In addition, human 
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cell engraftment in xenotransplant models is limited by the presence of the recipient 
immune system and its environment. The nude/nude mice utilised in the present 
study are immune-deficient athymic animals that lack T cells but produce B cells and 
natural killer (NK) cells. Highly immune-compromised mice such as non-obese 
diabetic/severe combined immunodeficiency (NOD/SCID) mice deficient in both T 
and B cells with impaired natural killer cells would be more suitable for these 
studies. The importance of the strain of the mice used can be exemplified in the study 
conducted by Quintana and colleagues where in the NOD/SCID
Il2rg−/−
, NOD/SCID 
strain lacking the interleukin-2 receptor gamma, ably generated melanoma tumours 
from a single human melanoma cell seeding [290]. Another reason could also be 
associated with the length of the study. It could be that if animals were left longer 
(several months), even lower numbers of CD133+ cells would form a tumour. Thus, 
further purification of CSCs, the use of appropriate mouse strain, and a longer study 
period could result in more successful graft uptake with lower CSCs numbers. 
 
Tumour cell dissemination and metastasis is a relatively early event in SCLC. Loco-
regional and subsequently distant lymph node involvement include epsilateral 
intrapulmonary, hilar and mediasternal nodes, contralateral nodes, and extrathoracic 
scalene and supraclavicular lymph nodes [291]. Distant metastases, generally 
hematogenous, include bone, liver, adrenal glands, and brain. About 18-24% of 
SCLCs at initial diagnosis and 50% of SCLCs during course of disease have CNS 
metastasis [292, 293]. Cancer metastasis is associated with loss of epithelial 
characteristics of the cancer cells and acquisition of migratory phenotype. The 
process referred to as the epithelial to mesenchymal transition (EMT), is an essential 
event in metastasis [294]. In line with this observation, EMT in the self-renewing 
lung neuroendocrine cells led to acquisition of an invasive and metastatic phenotype 
[295]. Interestingly, metastatic cancer cells recapitulated the organisation of their 
primary tumours. The presence of migratory CSC is the proposed explanation for 
such observations. The induction of EMT by transforming growth factor β-1 (TGFβ-
1) enhanced NSCLC CD133+ population with enforced ability to form sphere and 
initiate tumours in NOD/SCID mice [296]. In pancreatic carcinoma, CD133+ 
CXCR4+ CSCs cells were identified in the invasive front of pancreatic tumours. 
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Depletion of this population abrogated the metastatic phenotype of the pancreatic 
tumours suggesting the importance of CSCs in cancer metastasis [297].  
 
Animals injected with CD133+ cells in the present study presented with lymph node 
enlargement. In SCLC patients, metastasis to lymph nodes is often clinically 
observed. Therefore, based on the above data it was hypothesised that lymph node 
enlargement observed in animals was associated with CD133+ cell metastasis. 
Mouse lymph nodes are normally small and usually impalpable. Presenting lymph 
node enlargement could be a result of inflammation or metastasis. Inflammatory 
reactions usually subside after a few days. However, 52 days after subcutaneous 
implantation of SCLC CD133+ cells, episilateral and contralateral lymph nodes 
showed considerable enlargement suggestive of metastasis. Epislateral lymph nodes 
were slightly larger than contralateral nodes indicating sequential seeding of 
metastatic cells.  
 
In the present study, enlarged axillary and inguinal lymph nodes were subject to IHC 
for histological confirmation. Prospective metastatic SCLC cells were subjected to 
NCAM evaluation, a cell adhesion molecule widely expressed on all SCLC cells 
contributing to its invasive behaviour [273, 295]. NCAM, a transmembrane 
glycoprotein, expressed during embryonic development and in adult tissues on neural 
cells, is a marker for cells of neuroendocrine origin [273]. Primary tumour (generated 
by injecting SCLC CD133+ cells) was used as positive control and mouse spleen 
never exposed to human SCLC was used a negative control. Sections were double 
stained with CD45 antibody. CD45 selects mouse leucocyte cells, and since lymph 
nodes are enriched in these cells, it was essential to distinguish these cells from 
prospective human SCLC cells. 
 
Few NCAM+ CD45- cells in all four enlarged lymph nodes excised from the mice 
exposed to CD133+ SCLC cells were detected. However, few NCAM+ CD45- cells 
were also identified in mouse spleen used as negative control. NCAM a well-known 
maker for SCLC cells is also associated with NK cells. The nude/nude mice 
employed in this study, lack T cells but can produce B cells and NK cells. However, 
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the NCAM+ cells within the lymph nodes and the spleen were not NK cells, since 
they were not positive for CD45 antigen. SCLC cells express a range of 
neuropeptides and their corresponding receptors including gastrin releasing peptide 
(GRP) and its receptor GRP-R and vasopressin and its receptor, V1A. It would be 
interesting to evaluate the expression of these receptors as a marker for possible 
SCLC metastasis to lymph nodes. 
 
CSCs are chemoresistant cells. Supporting the CSCs hypothesis and in line with data 
observed in HCC and glioblastoma [80, 139, 141], 3 days after in vitro exposure of 
unsorted H345 and H69 cells to etoposide, the percentage of CD133+ cells 
significantly increased as the concentration of etoposide increased. The result 
suggests that in contrast to eradicated CD133- cells within SCLC cell lines, CD133+ 
cells were enriched on etoposide treatment. To further support the resistant 
phenotype of CD133+ cells, sorted population were subject to etoposide and after 72 
hours the percentage of survival was evaluated by MTT assay. CD133+ cells in 
comparison to the CD133- cells exhibited a profound resistant to etoposide. The 
inhibitory effect of etoposide was not influenced by the growth rate ability of the two 
populations. As show in Figure 23, the growth of CD133+ and CD133- cells were 
similar on the day 3, the time when MTT cell viability assay was conducted. It was 
only around day 18 when the growth rate of the both population significantly 
changed. Parent cells that contained both CD133+ and CD133- population, 
moderately responded to etoposide compared to the sorted populations. These data 
provide direct evidence that chemotherapeutic agents eradicate the bulk of the 
tumour but leave behind CSCs unaffected with resultant chemotherapeutic failure. 
 
Resistance to etoposide may be due to resistance to apoptotic. Therefore, apoptosis 
induced by etoposide on sorted population of H345 and H69 cells was evaluated after 
72 hours exposure. As indicated by EB/AO and the May-Grunwald-Giemsa staining, 
CD133+ cells were profoundly resistant to apoptosis compared to the CD133- cells. 
However, the exact mechanism conferring resistance to apoptosis was unknown.  
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Two major apoptotic signalling pathways include the extrinsic pathway, which acts 
via death receptors, and the intrinsic pathway, which acts via release of 
mitochondrial proteins. Deregulation in both pathways has been demonstrated as 
mechanisms of death evasion in CSCs. The project focused on the intrinsic pathway 
of apoptosis. Activation of intrinsic pathway can be stimulated by anticancer agents, 
growth factor withdrawal, hypoxia, or by induction of oncogenes [298]. The pathway 
is regulated by the release of apoptogenic factors such as cytochrome c from the 
mitochondrial inter-membrane space into the cytosol. Once released, cytochrome c 
forms a complex with Apaf-1/caspase-9-containing apoptosome, triggering caspase-3 
activation with subsequent induction of apoptosis. Members of Bcl-2 protein family 
are essential regulators of mitochondrial integrity. The Bcl-2 family comprises of 
pro- and anti-apoptotic proteins. The anti-apoptotic members include Bcl-2, Bcl-XL 
and Mcl-1, and the pro-apoptotic members include Bax and Bak, as well as BH3 
domain only molecules, for example Bid, Bim, Bik, Noxa and Puma. Bcl-2 members 
induce apoptosis by cleavage of Bid by caspase-8 and Bax-Bak oligomerisation 
causing mitochondrial permeabilization and release of cytochrome c. Bcl-2 members 
can inhibit apoptosis by various methods including by binding of Bcl-2 and Bcl-XL 
to Bcl-2 and Apaf-1 forming a complex with pro-apoptotic proteins Bax and Bak, 
thereby inhibiting its function [298]. Imbalances in the ratio of pro- and anti-
apoptotic proteins of the Bcl-2 family could skew the balance towards cell survival in 
the presence of an apoptotic stimulus. Over expression of Bcl-2 survival protein in 
CSCs has been documented to be associated with their resistance. Increased 
expression of anti-apoptotic proteins Bcl-2 and Mcl-1 was associated with resistance 
to ABT-737, a Bcl-2 inhibitor and down regulation of Mcl-1 partially reversed this 
resistance [299]. In line with these observations, chemoresistance in CD133+ 
glioblastoma cells was associated with significantly higher expression levels of Bcl-2 
and Bcl-XL compared to the CD133- cells [81]. These data suggest that targeting the 
mitochondrial death amplification pathways may be critical in reversing the 
apoptosis resistance phenotype of CSCs. 
 
CSCs can also escape apoptosis by preferential activation of AKT pathway. Akt also 
known as protein kinase B (PKB), is a well-characterized downstream target of the 
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PI3K-Akt-mTOR pathway, and are mediators of cell survival in response to a 
number of stimuli. Preferential activation of this pathway by CSCs in various cancers 
not only augments survival advantage in serum-free and anchorage-independent 
conditions but also, orchestrates evasion of induced apoptosis [80, 300]. Upregulated 
constitutive activity of PI3k/Akt pathway is stimulated by autocrine and paracrine 
growth loops in SCLC cells via β1 integrin mediated interaction with ECM [230, 
231, 246]. Akt/PKB through multiple mechanisms inhibits apoptosis. Akt by 
phosphorylation of pro-apoptotic BAD inhibits this pro-apoptotic member of the Bcl-
2 family to form a non-functional heterodimer with survival factor Bcl-XL, therefore 
resorting Bcl-XL’s anti-apoptotic function. Additionally Akt, by phosphorylation of 
caspase-9 inhibits the catalytic activity of this pro-death protease, thereby blocking 
its function. Finally, Akt by phosphorylation of FKHR, a member of Forkhead 
family of transcription factors, inhibits activation of its target genes such as BIM and 
FAS ligand that are pro-apoptotic proteins [301].  
 
Based on the above data, Akt and Bcl-2 were selected as possible proteins 
deregulated in CD133+ SCLC cells mediating their chemoresistance phenotype. 
Therefore, sorted population of H345 and H69 cells were subject to western blotting 
to evaluate the endogenous expression of proteins involved in Akt/PKB and Bcl-2 
survival signalling pathways. In both cell lines, CD133 expressing cells when 
compared to their CD133- counterpart, exhibited a marked preferential expression of 
active Akt (phosphorylated at Ser473) and higher levels of Bcl-2. Elevated 
expression of phosphoserine-specific Akt in CD133+ SCLC cells was not a result of 
an increase in total Akt. To my knowledge, this is the first study to demonstrate that 
CD133+ SCLC cells are resistant to apoptosis induced by chemotherapy and explain 
the signalling pathway associated with apoptosis resistance in these aggressive cells. 
  
According to the data I have demonstrated in this chapter, SCLC CD133+ cells, 
exhibited characteristics similar to known CSCs. Therefore, it can be concluded that 
CD133+ cells are the CSC-like cells in SCLC cell lines and based on their stem cell-
like, chemoresistant and tumorigenic nature, they are the possible cause of SCLC 
development and recurrence after initial chemoresponse. To strengthen this concept 
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it would be interesting to evaluate the correlation of CD133 expression with SCLC 
patient survival. In the present study tissue sections taken from SCLC patients 
demonstrated high levels of CD133 expression. However, no concluding remarks 
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CHAPTER 5:  
CD133+ cells express high levels of GRP-R and V1A-R which mediate their 




SCLCs are neuroendocrine tumours, characterised by the presence of intra-
cytoplasmic neurosecretory granules, which secrete a wide range of hormones and 
neuropeptides [169, 302]. Some of these include gastrin releasing peptide (GRP), 
arginine vasopressin (AVP), gastrin, neurotensin and cholecystokinin. The finding 
that neuropeptides stimulate SCLC growth in an autocrine fashion was initially 
examined by Cuttitta et al., [190] using a monoclonal antibody to [Lys3]-bombesin 
(2A11). In the absence of serum, the antibody inhibited SCLC cell line colony 
formation and abolished the growth of SCLC xenografts in nude mice. Subsequently, 
it was shown that multiple neuropeptides through autocrine and paracrine 
interactions fuel SCLC growth and proliferation [169]. Treatment of SCLC 
xenografts (NCI-H69) with broad spectrum antagonists such as SP-G, that inhibits 
the growth stimulatory effect of multiple neuropeptides, abolished tumour growth 
[220, 303]. The growth stimulatory effect of neuropeptides has also been 
documented in other cancers including breast, colon, pancreatic and prostate cancers 
[304-307]. Therefore, targeting neuropeptides or their receptors could be an 
interesting strategy for not only SCLC but also other malignancies with 
neuroendocrine phenotype. 
 
Much of the studies on SCLC treatment were focused on the mitogenic roles of GRP 
and AVP. GRP receptor (GRP-R) expression has been detected in various 
neuroendocrine tumours including breast, prostate, colon and lung, conferring 
survival advantage in these cells [65]. Expression of GRP-R is associated with 
malignant transformation of human kidney tissue into renal carcinoma [308]. In 
SCLC patients, detection of GRP-R in peripheral blood has been proposed as a 
useful early diagnostic marker [309]. Likewise, vasopressin and its receptor V1A is a 
well studied neuropeptide associated with SCLC, breast and pancreatic cancer 
survival and proliferation [169, 310]. Similar to GRP, vasopressin mediates SCLC 
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growth through an autocrine and paracrine circuit. In line with previous data 
documented [311], in my laboratory, the expression of V1A receptor was detected in 
four out of four SCLC cell lines [65]. Taken together, overexpression of these 
neuropeptide receptors is shown to be associated with malignant status of neoplastic 
cells.  
 
Waters et al., [65] demonstrated that acquired resistance in SCLC patients was 
associated with increased expression of neuropeptide receptors on the drug resistance 
cells. This was evaluated by quantifying the expression levels of GRP-R by semi-
quantitative RT–PCR in three human SCLC cell lines (GLC14, 16 and 19) 
established from a single patient during longitudinal follow-up [65, 228]. During this 
period, the initial chemosensitive tumour became increasingly chemoresistant. 
Increased expression of GRP-R on the drug resistant cells (GLC16 exhibited 6 fold 
and GLC19 exhibited 11 fold increased GRP-R expression compared to GLC14) was 
associated with increased proliferation and colony formation in the presence of 
neuropeptides [65]. This indicated the neuropeptide dependent growth of resistant 
SCLC cells. Thus, neuropeptide growth factors and their receptors could serve as 
prospective targets for intervention in chemoresistant candidates. 
 
Multiple studies have demonstrated CSCs as resilient cells that are enriched 
following chemotherapy [80, 82, 141, 312]. In line with this concept, Levina et al., 
[82] demonstrated that chemotherapy enriched lung CSCs. The author argued that 
the aggressive phenotype of drug surviving lung CSCs was associated with increased 
expression of various growth factors with survival and proliferation advantage. 
Recently, preliminary data by Flores et al, [172] suggested the involvement of GRP-
R in ex-vivo expansion of brain CSCs. Based on this data combined with the 
knowledge that chemoresistance in SCLC cell lines is associated with increased 
expression of neuropeptide receptors, it was hypothesised that the aggressive 
phenotype of CD133+ SCLC is due to greater expression of GRP-R and V1A-R. 
Understanding the mechanism promoting the growth of these aggressive cells is 
warranted for designing novel therapies. 
 




5.2.1 CD133+ cells express higher levels of GRP and V1A-receptors in H345 
and H69, respectively than their corresponding CD133- cells 
 
H345 cells have relatively high GRP-R expression [313] and H69 cells were 
previously shown in my laboratory to express V1A-R [225]. Therefore, the expression 
levels of GRP-R in isolated H345 cells and V1A-R in isolated H69 cells were 
quantified using q-PCR. Q-PCR provides valuable information regarding the relative 
expression of transcripts in a cell. RNA was extracted from the isolated cells and was 
reverse transcribed to cDNA and subsequently the expression levels of GRP-R and 
V1A-R were quantified by the TaqMan
®
 gene expression assay kit (Applied 
Biosystems, USA). 18S mRNA was used as internal control. CD133+ H345 cells 
expressed significantly higher mRNA levels of GRP-R than the CD133- H345 (fold 
increase in CD133+, 3.4 ± 0.3, and CD133-, 0.84 ± 0.22, P=0.0026) and parent cells 
(1.5 ± 0.18, P=0.0043) (Figure 43A1). Similarly, H69 CD133+ cells demonstrated 
significant higher mRNA levels of V1A-R compared to its corresponding negative 
population (fold increase in CD133+, 4.97 ± 0.15, and CD133-, 0.66 ± 0.38, 
P=0.0005)  and parent (unsorted) cells (2 ± 0.24, P=0.0005) (Figure 43A2). 
Therefore, CD133+ cells retained higher mRNA levels of neuropeptide receptors 
compared to their negative counterpart. 
 
The expression of GRP-R in H345 sorted cells and V1A-R in H69 isolated cells were 
further evaluated for the protein levels by western blotting and data was quantified 
using ImagJ. As illustrated in Figure 43B1, a band of ~65 kDa was indicative of 
GRP-P protein expression. CD133+ H345 cells exhibited 1.58 ± 0.012 times 
(P<0.001) higher GRP-R protein expression compared to the CD133- cells. Lysates 
of G6A cells (CHO cells transfected with GRP-R [171]) was used as a positive 
control. Similar observations were made in H69 sorted cells (Figure 1B2). A band of 
~48 kDa was indicative of V1A-R expression. CD133+ H69 cells exhibited 1.77 ± 
0.01 times (P<0.001) higher V1A-R protein expression compared to the CD133- cells. 
Lysates of V3B cells (CHO cells transfected with V1A-R [171]) was used as positive 
control. Protein expression levels were normalised relative to β-actin levels. 
CHAPTER 5                                                                171 
 
Therefore, neuropeptide receptor expression in CD133+ cells was not only 
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5.2.2 Exogenous GRP and AVP enhance the colony formation of CD133+ 




 mobilising neuropeptides augment SCLC cell lines to form colonies in 
semi-solid medium indicating SCLC growth is regulated by various autocrine and 
paracrine circuits. Therefore, the effects of exogenous GRP and AVP on the 
clonogenicity of the corresponding CD133+ were examined. Sorted CD133+ cells 
were cultured in semi-solid SITA medium in the presence of three different 
concentrations (1, 10, and 100 nM) of GRP for sorted H345 cells and AVP for sorted 
H69 cells. The number of colonies formed was evaluated after 21 days by light 
microscopy. Untreated cells were used as control, representing basal clonogenicity. 
The effect of neuropeptide on CD133+ colony formation was compared with that of 
their corresponding parent cells (unsorted cells). The effect of neuropeptide on 
CD133- H345 and H69 cells could not be evaluated as CD133- cells, despite low 
levels of GRP-R or V1A-R expression, did not respond to the growth stimulatory 
effect of neuropeptides in the semi-solid medium and appeared apoptotic within 3-5 
days post-culture. As shown in Figure 44A increased colony formation in the 
CD133+ H345 cells was observed in a dose-dependent manner in the presence of 
GRP (cloning efficiency at 1 nM, 8.81 ± 1%, at 10 nM, 16.43 ± 0.74% and at 100 
nM, 18.34 ± 1.17%) compared to control (basal cloning efficiency 4.84  ± 1.08%). 
Similar observations were made in the parent H345 cells (cloning efficiency at 1 nM, 
2.67 ± 0.56%, at 10 nM, 6.7 ± 0.83%, at 100 nM, 10.4 ± 1.38%, and control 2 ± 
0.34%). Although a concentration dependent colony growth was also observed in the 
parent cells in the presence of GRP, the effect of this neuropeptide on the 
clonogenicity of CD133+ cells was significantly enhanced. This effect was apparent 
at low concentration of GRP where 1 nM GRP doubled (P=0.048) the clonal growth 
of CD133+ cells whereas the same concentration of GRP did not significantly 
change the clonal growth of parent cells.  
 
The addition of AVP to CD133+ H69 cells enhanced their clonal growth in semi-
solid medium (Figure 44B). Like the effects of GRP on the clonal growth of CD133+ 
H345 cells, the CD133+ H69 cells responded to AVP in a dose-dependent manner 
with significant enhancement of their cloning efficiency (cloning efficiency at 1 nM, 
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11.06 ± 0.93%, at 10 nM, 16.44 ± 1.8% and at 100 nM, 14.50 ± 2.07%) compared to 
untreated cells (basal cloning efficiency 6.51 ± 0.53%). Similar observations were 
made in the parent cells (cloning efficiency at 1 nM 4.06 ± 0.55%, at 10 nM, 8.47 ± 
1.48%, at 100 nM, 5.40 ± 0.6%, and untreated control, 3.40 ± 0.43%). The 
significant effect of AVP on the colony formation of CD133+ cells compared to that 
of parent cells was apparent at low concentration of this neuropeptide where 1 nM 
AVP enhanced the clonogenic efficiency of the CD133+ cells by 2.5 fold (P=0.012) 
whereas the same concentration of this neuropeptide did not significantly effect the 
clonogenicity of parent cells. In both CD133+ and parent H69 cells, 10 nM was the 
maximum concentration of AVP to stimulate colony formation and higher 
concentration of AVP (100 nM) reduced colony formation. Similar observations 
were previously made in my laboratory, demonstrating high concentrations of 
neuropeptide had decreased stimulatory effects [169]. This phenomenon presumably 
could be associated with homologous desensitisation in this long-term assay. Time-
dependent growth desensitisation has also been reported in other cellular systems 
[314, 315]. Therefore, exogenous neuropeptides significantly stimulate clonal growth 






















































The data in this chapter demonstrates that CD133+ SCLC cells transcriptionally and 
translationally express higher levels of neuropeptide receptors, GRP-R and V1A-R. 
Addition of exogenous neuropeptides significantly enhanced the colony formation of 
CD133+ cells, indicating for the first time, the critical role of neuropeptides in 
mediating the autocrine growth of these aggressive cells. 
 
CSCs are the proposed cause underpinning tumour initiation progression and 
chemoresistance due to their aggressive phenotype. In line with this theory, the 
present study demonstrated that CD133+ SCLC cells are proliferative cells with 
higher clonogenicity in vitro compared to the CD133- cells. However, the 
mechanism mediating CD133+ SCLC growth remains unknown.  
 
Levina et al., [82] documented that drug resistant CSCs exhibited significant higher 
expression levels of angiogenic and growth factors (VEGF, bFGF, IL-6, IL-8, HGF, 
PDGF-BB, G-CSF, and SCGF-beta) compared to non-CSC population. The author 
concluded that elevated levels of these factors are associated with high growth 
profile, tumorigenic and metastatic potentials of CSCs. Similar observation was 
made in colorectal cancer cells where in CD133+ cells expressed elevated gastrin 
precursors [316]. Analysis of sixty primary colorectal tumours revealed, increased 
expression of these peptides on the CD133+ cells through activation of Akt 
signalling pathways mediate their proliferation, colony formation and 
chemoresistance. Down-regulation of gastrin peptides in colorectal CD133+ cells 
was associated with loss of tumour initiation in vivo, further supporting the role of 
this peptide in the survival and growth of CSCs [316]. These data indicate the 
importance of growth factors in the regulation of CSCs expansion making them 
promising targets for CSC therapies. 
 
Waters et al., [65] working on GLC cell lines, demonstrated that resistance in SCLC 
cells is in line with increased expression of neuropeptide receptor, GRP-R which 
subsequently was associated with their growth in liquid culture and colony formation 
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in semi-solid medium. This would be similar to the generation of autocrine and 
paracrine growth loops in cancer development in vivo, with malignant cells 
becoming more dependent on neuropeptide growth factors for survival and 
resistance. To further emphasise the importance of growth stimulatory effect of 
neuropeptides, MacKinnon et al., [171], investigated the effect of neuropeptide 
receptors on the growth of CHO cells. Introduction of GRP-R and V1A-R in CHO 
cells led to cellular transformation and was associated with enhanced proliferation, 
colony formation and resistance to etoposide.  
 
Based on the knowledge that drug resistant CSCs express higher levels of growth 
factors and that neuropeptides and their receptors are essential mediators for SCLC 
survival, growth and chemoresistance, in the present study I hypothesise that the 
aggressive phenotype of CD133+ SCLC cells could be associated with their 
increased expression of neuropeptide receptors. The expression of these receptors 
was evaluated transcriptionally and translationally on CD133+ cells using q-PCR and 
western blotting, respectively. As shown in Figure 43, CD133+ H345 cells expressed 
significantly higher levels of GRP-R and CD133+ H69 cells expressed significantly 
higher levels of V1A-R compared to corresponding CD133- and parent cells, 
indicating their greater neuropeptide dependence. Therefore, based on the data 
obtained in this section and in line with previous observations [82, 316], CD133+ 
cells express higher levels of growth factors as a possible mechanism mediating their 
growth and potential tumour initiating capacity.  
 
CD133+ cells in both cell lines demonstrated significant elevated basal colony 
formation compared to their parent cells (Figure 44). This may be explained by 
higher neuropeptide receptor expression on the CD133+ cells. Ferris et al., [317] 
demonstrated that GRP-R is oncogenic when transfected into non-malignant 
NCM460 colon cancer cell line. Since transfected colon cancer cells lines do not 
secrete GRP and in the presence of ligand specific antagonist their growth was not 
influenced, the author concluded that enhanced proliferation in GRP-R transfected 
cells was associated with constitutive activation of its receptors. Despite no evidence 
documented of such constitutive activation for V1A-R, it may be suggested that 
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higher basal clonogenic efficiency observed in the CD133+ cells compared to parent 
cells could be due to constitutive activation of these receptors triggering the growth 
signals. In both cell lines, cloning efficiency in response to neuropeptide was 
increased in the CD133+ population. The observation not only supports the earlier 
data in this chapter (Figure 43) that CD133+ cells express higher levels of these 
receptors, but additionally indicated that they are fully functional and mediate SCLC 
growth through autocrine signalling. However, to confirm the autocrine growth loops 
in CD133+ SCLC cells, it would be interesting to measure GRP or AVP levels in 
cultures. 
 
The finding that CD133+ CSCs express significant amount of neuropeptide receptors 
and that their growth is dependent on their expression would allow us to design 
therapies that would preferentially eliminate these aggressive cells without 
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CHAPTER 6: 




Multiple intracellular calcium mobilising neuropeptides and their receptors are the 
proposed prime regulators of SCLC cell growth. Drugs targeting single mitogenic 
neuropeptides such as the monoclonal antibody 2All which specifically inhibits the 
binding of GRP to its receptor produced a poor clinical outcome [318]. Thus, 
analogues that inhibit the mitogenic effect of multiple neuropeptides are warranted to 
curtain the lethal disease that is fuelled by an extensive neuropeptide network. 
 
Previously, a series of modified substance-P analogues were shown to inhibit the 
effects of a range of neuropeptides on SCLC cells and have demonstrated efficacy in 
animal models [64, 220]. These peptide analogues, termed “broad spectrum 
antagonists” include SP-A and SP-G, via neuropeptide receptors including GRP and 
V1A receptors, act as “biased agonists” [64, 65, 171, 221, 223, 224]. At the receptor, 
they display antagonist activity blocking the neuropeptide induced Ca
2+
 mobilisation 
and agonist activity inducing sustained activation of JNK and ERK. Inhibition of 
Ca
2+
 release along with prolonged activation of ERK and JNK pathways attenuates 
cellular proliferation and augments apoptosis. SP-G has completed a phase 1 clinical 
trial where therapeutic plasma concentrations were achieved with no dose limiting 
toxicity [66].  
 
Development of resistance to conventional chemotherapy in SCLC cells was 
accompanied by an increase in neuropeptide receptor expression as investigated on 
GLC14, 16 and 19, three SCLC cell lines established from one patient during clinical 
follow-up (see chapter 1 for more details on the GLC cell lines) [65, 227, 228]. This 
was accompanied by enhanced response to SP-G where this analogue inhibited the 
growth and colony formation of all three SCLC cell lines but was more effective in 
the most chemoresistant line GLC19 which expressed higher neuropeptide receptor 
compared to the more chemosensitive cell lines GLC14 and GLC16 (Figure 45) [65], 
making SP-G an ideal analogue for treatment of resistant disease. In chapter 5, I have 
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shown that chemoresistant CD133+ SCLC cells exhibit greater expression of 
neuropeptide receptors compared to CD133- cells. SP-G may therefore be more 
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A limiting factor in the effectiveness of SP-G is its short half life (25 minutes) in 
plasma when administered systemically [66]. This is the major factor that has 
resulted in the suspension of further clinical development of the compound. The 
short half life is due to rapid metabolism of this analogue investigated in vitro using 
whole mouse liver homogenates and in vivo after intra-peritoneal injection in mice 
[319, 320]. The hexapeptide structure of SP-G includes D-amino acids and N-
methylated amino acids located at the N-terminus leaving the C-terminal unmodified 
where degradation has shown to occur [321, 322]. The enzyme responsible for SP-G 
degradation is a serine carboxypeptidase with generation two metabolites via initially 
deamidation of the C-terminus to produce Metabolite I (NH2-Arg-DTrp-MePhe-
DTrp-Leu-Met-OH), and subsequently carboxylation producing Metabolite II (NH2-
Arg-DTrp-MePhe-DTrp-Leu-OH) [319]. Identification of more stable analogues of 
SP-G with maintained efficacy may lead to the identification of a new clinical 
candidate for SCLC treatment.  
 
In collaboration with Professor Mark Bradley (Department of Chemistry, Kings 
Building, Edinburgh), a series of analogues were synthesised based on the structure 
of SP-G and SP-A, with the aim to enhance stability and possibly potency. 
Substitution with D-amino acids and N-methylation are well-known devices to aid 
stability [323, 324]. Dimers have inherent advantages as binding is enhanced due to 
entropic considerations. The dimers were based on SP-G structure with various 
linking strategies: Cyclo (Arg-DTrp-NMePhe-DTrp-Leu-Asp), Arg-DTrp-NMePhe-
DTrp-Leu-Linker-Arg-DTrp-NMePhe-DTrp-Leu (Linker = Gly or GABA) and O=C 









8) Arg-DTrp-NMePhe-DTrp-Leu-1,2 Ethylenediamine 
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It is the aim of this chapter to evaluate the efficacy of this new panel of peptides on 




6.2.1 SCLC cell lines are sensitive to peptide-1 
 
The inhibitory effect of the newly designed peptides was evaluated in H345 and H69 
cell lines. Cytotoxicity was determined by MTT accumulation after 72 hours. 
Untreated cells served as control and data is represented as percentage of control. 
The potency of the analogues was compared with that of SP-G. The IC50 values 
(concentration of drug required to reduce cell viability by 50%) of the new analogues 
and SP-G in H345 and H69 are illustrated in Table 9. In both cell lines, peptide-1 
proved to be the most potent analogue compared to SP-G and the newly synthesised 
peptides in inhibiting cell viability. As shown in Figure 46A and B, the efficiency of 
peptide-1 was significantly higher than that of SP-G in H345 cells (IC50 value of 
peptide-1, 3.06 ± 0.41 M and SP-G, 11.87 ± 1.04 M, P=0.0014) and in H69 cells 
(IC50 value of peptide-1, 4.96 ± 0.64 M and SP-G, 15.53 ± 1.99 M, P=0.011). 
Peptide-1 demonstrated ~4 fold increased potency in H345 cells and ~3 fold 
augmented potency in H69 cells compared to SP-G. Thus, this analogue was selected 
for further analysis. Peptides 2, 3, 4, 6, 7, and 8, all less potent than SP-G with IC50 
values above 100 µM were excluded from further analysis. Although peptide-5 
demonstrated an IC50 value less than 100 µM (IC50 value of peptide-5 in H345 cells, 
44.34 ± 3.29 M and in H69 cells, 46.63 ± 2.63 M), the efficiency of this analogue 
in inhibiting cell viability compared to SP-G was lower therefore, it was excluded 











































































CHAPTER 6                                   186 
 
6.2.2 Peptide-1 inhibits intracellular calcium mobilisation  
 
The mobilisation of [Ca
2+
]i stores is one of the earliest events triggered by binding of 
neuropeptides to their receptors and activation of Gαq subunit of G-proteins leading 
to PLC signalling with subsequent production of IP3 (Figure 5) [195, 196]. SP-G 
blocks the Ca
2+
 mobilisation induced by various neuropeptides [171, 224]. In this 
study, the effect of peptide-1 on GRP- and AVP-induced calcium mobilisation was 
examined on cell lines transfected with the human GRP and V1A receptors (G6A and 
V3B cells, respectively [171]). Quiescent G6A and V3B cells were incubated with 
FURA-2AM at 37°C for 20 minutes and the ratiometric fluorescence was monitored 
at 37°C. Figure 47, demonstrates a representative trace of intracellular calcium 
mobilisation in G6A treated with GRP or a combination of GRP and peptide-1. 
 
Initially, the effect of GRP and AVP on the [Ca
2+
]i  mobilisation  in G6A and V3B 
cells were evaluated in the absence of peptide-1. As shown in Figure 48A, in G6A 
cells, GRP produced a concentration-dependent increase in [Ca
2+
]i (EC50 = 1.34 ± 
0.12 nM). Similarly, in V3B cells (Figure 48B) an elevation in [Ca
2+
]i was observed 
in a dose-dependent manner (EC50 = 1.4 ± 0.24 nM). To evaluate the antagonist 
effect of peptide-1 on [Ca
2+
]i mobilisation induced by neuropeptides, samples were 
initially treated with various concentrations of peptide-1 (1-100 µM) for 2 minutes at 
37°C before adding 10 nM GRP for G6A cells or AVP for V3B cells (Figure 48C, 
and D). In G6A and V3B cells, 10 nM neuropeptide produced the maximum 
intracellular calcium mobilisation, thus this concentration was selected for further 
evaluations. In both cell lines, peptide-1 inhibited the response to GRP and AVP in a 
dose-dependent manner with resultant IC50 values of 0.36 ± 0.12 µM in G6A (Figure 
48C) and 1.7 ± 0.34 µM in V3B cells (Figure 48D). Peptide-1 was more efficacious 
in inhibiting the GRP response than the AVP response. Together, these data suggest 
that peptide-1 inhibits [Ca
2+
]i mobilisation induced by GRP as well as AVP with 
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6.2.3 Peptide-1 inhibits SCLC cell proliferation  
 
SP-G inhibits SCLC growth by blocking neuropeptide-induced [Ca
2+
]i mobilisation 
[214]. It was hypothesised that peptide-1 would similarly attenuate SCLC 
proliferation in liquid culture. To evaluate this hypothesis, SCLC cells were cultured 
in serum-free SITA medium, in the presence of SP-G or peptide-1. Untreated 
samples were used as control. Cell number was determined by NucleoCounter NC-
100 for 24 days and data is presented as percentage of control on day 24. As 
illustrated in Figure 49, peptide-1 inhibited H345 and H69 proliferation in a dose-
dependent manner, IC50 in H345 was 3.62 ± 0.66 µM (Figure 49A) and in H69 cells 
was 4.09 ± 0.55 µM (Figure 49B). The efficacy of peptide-1 was significantly greater 
than SP-G (IC50 in H345 cells treated with SP-G was 9.73 ± 1.1 µM and in H69 cells 
treated with SP-G was 10.33 ± 0.81 µM). Thus, peptide-1 was more potent growth 
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6.2.4 Peptide-1 inhibits basal and neuropeptide stimulated colony 
formation 
 
As described in chapter 5, GRP and AVP stimulate clonal growth of H345 and H69 
cells. Previously, at my laboratory, it was demonstrated that SP-G inhibited 
neuropeptide mediated growth with dramatic decrease in clonogenicity of SCLC 
cells in the absence and the presence of exogenously added neuropeptide [64]. The 
present study evaluated the effect of 10 µM peptide-1 on the clonal growth of SCLC 
cells in the absence and the presence of 10 nM GRP and AVP (Figure 50). The 
concentration of peptide-1 and GRP and AVP was selected based on the observation 
that, 10 µM peptide-1 had shown maximum growth inhibitory effect on SCLC cells 
and 10 nM GRP and AVP displayed maximum stimulatory effect on H345 and H69 
cells, respectively. 
 
Peptide-1 inhibited the colony formation of both H345 and H69 cells in the absence 
as well as in the presence of neuropeptides (Figure 50A and B). This analogue 
significantly inhibited the basal colony growth of H345 (cloning efficiency of control 
cells, 2.23 ± 0.27%, and 10 µM peptide-1 treated cells, 1.01 ± 0.12%, P=0.01) and 
H69 cells (cloning efficiency of control cells, 3.35 ± 0.52%, and 10 µM peptide-1 
treated cells, 1.68 ± 0.12%, P=0.01). Additionally, peptide-1 abolished the growth 
stimulatory effect of exogenously added neuropeptides in H345 (cloning efficiency 
of 10 nM GRP, 7.30 ± 1.04%, and 10 nM GRP + 10 µM peptide-1, 3.63 ± 0.26%, 
P=0.02) and H69 cells (cloning efficiency of 10 nM AVP, 9.09 ± 0.39%, and 10 nM 
AVP + 10 µM peptide-1, 4.18 ± 0.67%, P=0.003). Evidently, peptide-1 inhibited the 
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6.2.5 Peptide-1 induces apoptosis   
 
SP-G induces apoptosis in SCLC cells [224]. To determine if the cytotoxicity 
induced by peptide-1 was due to apoptosis, H345 and H69 were treated with two 
different concentrations of SP-G or peptide-1 (1 µM and 10 µM) and after 72 hours, 
apoptosis was determined by cytocentrifuging cells on to glass cover slips and 
staining with May-Grunwald-Giemsa.  
 
Apoptotic cells appeared as shrunken cells with dense nuclei and were quantified by 
light microscopy (Figure 51A). Similar to SP-G, peptide-1 induced apoptosis but 
with greater efficiency than SP-G in both H345 (Figure 51B) and H69 cells (Figure 
51C). 1 µM SP-G did not significantly induce apoptosis in the treated cells compared 
to corresponding controls, whereas the same concentration of peptide-1 significantly 
increased the percentage of apoptotic cells in H345 (percentage of apoptosis in 
control, 13.98 ± 0.8%, and in 1 µM peptide-1 treated cells, 36.73 ± 3.35%, P=0.002) 
and in H69 cells (percentage of apoptosis in control, 17.93 ± 1.52%, and in 1 µM 
peptide-1 treated cells, 34.06 ± 2.61%, P=0.005). At 10 μM, both peptide analogues 
induced apoptosis in treated H345 (percentage of apoptosis in cells treated with 10 
μM SP-G 40.78 ± 3.4% and peptide-1, 68.90 ± 2.53%) and H69 cells (percentage of 
apoptosis in cells treated with 10 μM SP-G 33.60 ± 2.62% and peptide-1, 55.86 ± 
2.4%) cells. However, the efficiency of peptide-1 was significantly greater than SP-G 
in H345 (P=0.003) and H69 cells (P=0.003). Therefore, peptide-1 induces apoptosis 
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6.2.6 Peptide-1 is more stable than SP-G 
 
Stability of peptide-1 and SP-G was studied in vivo using S9 mouse liver preparation. 
Drug metabolism was investigated over a 130 minute time course and aliquots were 
removed at appropriate time points for HPLC analysis. HPLC analysis was kindly 
conducted by Doctor Nikolaos Avlonitis in Professor Mark Bradley’s laboratory, 
Institute of Chemistry, Edinburgh University. Figure 52 demonstrates representative 
Figures of HPLC traces at different time points. Over time, gradual disappearance of 
full length peptide which was accompanied by the appearance of two metabolites 
was observed. By measuring the area under each peak, the amount of non-
metabolised peptide-1 or its metabolites produced were calculated. Data is presented 
as the percentage of non-metabolised analogues present in the sample with time 
compared to time 0. As illustrated in Figure 53, peptide-1 was found to be 
approximately 4.5 fold more metabolically stable than SP-G (P=0.03). The t1/2 (the 
time point when 50% of the analogue is degraded) of SP-G and peptide-1 were 9.32 
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6.2.7 Peptide-1 inhibits H345 xenografts 
 
SP-G inhibits SCLC cell growth in vitro, as well as in vivo [64]. To examine the 
effect of peptide-1 on SCLC xenografts, 15 × 10
6
 H345 cells suspended in growth 
factor reduced Matrigel (1:1 volume of cells:Matrigel mixed at 4
º
C, total volume of 
100 µl) were implanted subcutaneously in the right flank of nude/nude mice. 
Tumours were palpable 3 days post-injection. Drug exposure was initiated on day 7 
and was continued once daily for 5 consecutive days. Peptide-1 was dissolved in 
sterile distilled H2O and administered by subcutaneous injection at a dose of 25 
mg/kg. Etoposide dissolved in sterile distilled H2O and was administered by 
subcutaneous injection at 15 mg/kg. Controls received the same dose schedule of 
vehicle (H2O). Tumours were measured using callipers every 3-4 days for a total of 
33 days.  
 
As illustrated in Figure 54, until day 15 no significant difference between control 
animals (treated with vehicle) and animals receiving peptide-1, etoposide, or 
combination of both drugs was observed. However, from day 20 onwards, a 
significant reduction in tumour volume was observed in animals receiving 
treatment(s) compared to controls (tumour volumes on day 20 for controls were, 
335.21 ± 43.57 mm
3
, for peptide-1 treated animals were, 149.37 ± 47.70 mm
3
, for 
etoposide treated animals were, 187.66 ± 38.68 mm
3
, and for peptide-1 + etoposide 
treated animals were, 160.95 ± 21.46 mm
3
, ANOVA, P=0.026) (tumour volumes on 
day 24 for controls were, 506.65 ± 80.85 mm
3
, for peptide-1 treated animals were, 
204.41 ± 60.79 mm
3
, for etoposide treated animals were, 259.63 ± 71.41 mm
3
, and 
for peptide-1 + etoposide treated animals were, 262.15 ± 34.72 mm
3
, ANOVA, 
P=0.025) (tumour volumes on day 27 for controls were, 875.83 ± 114.59 mm
3
, for 
peptide-1 treated animals were, 228.01 ± 113.61 mm
3
, for etoposide treated animals 
were, 269.85 ± 95.79 mm
3
, and for peptide-1 + etoposide treated animals were, 
343.11 ± 68.86 mm
3
, ANOVA, P=0.003). The inhibitory effect of all three 
treatments was maintained beyond the duration of administration. To be noted, the 
tumour volume of the control animals had reached the maximum permissible size 
authorised by the Home Office license, and were terminated on day 27. Therefore, 
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the administration of peptide-1 alone produced a significant reduction in tumour 
volume for the duration of the study and was as efficacious as etoposide alone. These 
observations indicated that peptide-1 not only attenuated SCLC growth in vitro but 
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6.2.8 Peptide-1 is more effective in CD133+ cells than CD133- cells 
 
As shown above, peptide-1 is a more potent inhibitor of SCLC growth in vitro and in 
vivo and also more stable than SP-G, making it an ideal neuropeptide analogue for 
the treatment of chemoresistant SCLC cells. The inhibitory effect of this analogue 
was evaluated on the CD133+ and CD133- H345 cells and parent cells (Figure 55) 
by MTT assay. CD133+ cells were more responsive to peptide-1 compared to their 
corresponding negative counterpart and parent cells in H345 cell line (IC50 values of 






























































Data in this chapter revealed that the newly designed peptide-1 is a potent inhibitor 
of intracellular calcium mobilisation stimulated by neuropeptides in SCLC cell lines. 
The analogue profoundly inhibited the growth of SCLC cells in liquid and semi-solid 
medium and induced apoptosis. Peptide-1 was ~4 fold and ~3 fold more potent 
inhibitor of H345 an H69 cell viability, respectively and ~3 fold more potent 
inhibitor of SCLC cell growth in both cell lines in liquid culture compared to SP-G. 
Peptide-1 inhibited basal and neuropeptide stimulated colony formation. In addition 
to improved potency of peptide-1, the analogue also showed ~4 fold enhanced 
stability in vitro compared to SP-G. In vitro results suggested that, the analogue 
would also abolish SCLC growth in vivo. In line with the hypothesis, peptide-1 
profoundly inhibited H345 growth in nude/nude mice and was as efficacious as 
etoposide. The knowledge that SP-G is more effective in cells with higher 
neuropeptide receptor expression prompted the speculation that peptide-1 would be 
more effective in the chemoresistant CD133+ cells that over express neuropeptide 
receptors. Supporting this hypothesis, CD133+ SCLC cells exhibited significant 
increased sensitivity to peptide-1 compared to the CD133- sub-population, making it 
an interesting analogue for treatment of chemoresistant SCLC patients. 
 
Despite numerous studies and advances in cytotoxic drug development, SCLC still 
remains as an incurable disease. Recurrence with intractable resistance results in 
fatality.  In the present study it has been proven that, within SCLC cell lines resides a 
sub-population of CD133 expressing cells with stem cell-like phenotype. These cells 
are clonogenic and chemoresistant in vitro, and are more tumorigenic in vivo than the 
CD133- population and could be the possible cause of SCLC chemoresistance and 
recurrence. Therefore, structuring drugs that selectively target these aggressive cells 
could open a new horizon in SCLC management. 
 
SP-G, a broad spectrum neuropeptide antagonist, inhibits the growth stimulatory 
effect of multiple neuropeptides in SCLC cells in vitro and in vivo [64, 220, 226]. 
SP-G, despite novel potential, encounters a major drawback with its instability in 
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plasma making therapy impracticable [66]. This urged the necessity to design 
analogues with added stability. Eight novel analogues were modelled based on the 
structures of either SP-G or SP-A with the aim to increase stability and possible 
potency compared to SP-G. Peptide-1 was the only analogue that exhibited enhanced 
inhibitory effect in H345 and H69 cells and was chosen for further evaluations. 
Peptide-1, DArg-Pro-Lys-Pro-DTrp-Gln-DTrp-Phe-DTrp-DLeu-Leu, consists of 11 
amino acids with chemical structure similar to SP-A, DArg-Pro-Lys-Pro-DTrp-Gln-
DTrp-Phe-DTrp-Leu-Leu-NH2, but has a D-Leucine substitution at position 10. The 
efficiency of this novel analogue was compared with SP-G which has successfully 
completed a phase 1clinical trial [66]. 
 
Multiple neuropeptides stimulate [Ca
2+
]i mobilisation in SCLC cells [64] and SP-G 
blocks the Ca
2+
 mobilisation induced by various neuropeptides [171, 223, 224]. The 
inhibitory effect of peptide-1 on [Ca
2+
]i mobilisation induced by neuropeptide was 
evaluated in CHO cells transfected with GRP and V1A receptors. Previously, in my 
laboratory the stimulatory effect of GRP and AVP and the inhibitory effect of SP-G 
on [Ca
2+
]i mobilisation was evaluated on transfected CHO cells with GRP and V1A 
receptors [171], therefore, in the present study these cells were chosen for evaluation 
of the effect of peptide-1 on [Ca
2+
]i  mobilisation. In line with previous data obtained 
from my laboratory [171], GRP and AVP produced a concentration-dependent 
increase in [Ca
2+
]i in the transfected cells. Peptide-1 functioned as an antagonist for 
Ca
2+
 release and inhibited calcium production in a dose-dependent manner. This 
observation was in line with the antagonist activity observed by SP-G. AVP and 
GRP act through distinct receptors, but activate common signal transduction 
pathways. Peptide-1 inhibited the stimulatory effect of both neuropeptides. This 
could suggest that peptide-1, similar to SP-G, could function as a broad spectrum 
antagonist inhibiting the growth stimulatory effect of multiple neuropeptides. 
However, to confirm this concept the inhibitory affect of peptide-1 on [Ca
2+
]i 
mobilisation stimulated by other neuropeptides including bradykinin, galanin, 
cholecystokinin, and neurotensin should be evaluated. Peptide-1 demonstrated more 
selectivity for GRP receptor than V1A receptor. Thus, the compound may be tailored 
for the treatment of specific tumours with higher GRP-R over expression.  
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Peptide-1 inhibited the growth of SCLC cell lines in liquid culture. The inhibitory 
effect of this compound was ~3 fold higher in H345 and in H69 cells compared to 
SP-G. As expected, peptide-1 also caused a dramatic decrease of the cloning 
efficiency of these cells in the absence of any exogenously added peptide (basal 
colony formation) and in the presence of neuropeptide (GRP or AVP) stimulation. 
These findings suggest that the structural modification of SP-A (substitution of Leu 
with D-Leu at the position 10 of SP-A) did not disrupt the anti-cancer activity of this 
compound and that peptide-1 was significantly more efficacious than SP-G.  
 
Similarly, the structural modification of SP-A to design the novel analogue did not 
effect the pro-apoptotic action of this compound on SCLC cell lines. Similar to SP-
G, peptide-1 induced apoptosis in H345 and H69 cells, with peptide-1 efficacy 
significantly higher than SP-G. Although, mechanism of action of peptide-1 was not 
evaluated in the present study, cytotoxic effects on SCLC cells with a similar 
mechanism as SP-G are speculated.  
 
The most outstanding feature of SP-G is its augmented efficacy in chemoresistant 
SCLC cells due to their higher neuropeptide dependent growth. In the present study 
it was demonstrated that chemoresistant CD133+ sub-population express higher 
levels of GRP-R and V1A-R. Therefore, it was hypothesised that these cells would 
respond better to peptide-1 compared to the CD133- sub-population. In H345 cell 
lines, CD133+ cells were significantly more sensitive to peptide-1 than CD133- 
cells. Increased sensitivity could be associated with enhanced expression of 
neuropeptide receptors. Parent cells displayed a moderate response to peptide-1 this 
could be explained by presence of both CD133+ and CD133- cells, therefore the 
response to peptide-1 would be a value between each single population. 
 
The inhibitory effect of peptide-1 on SCLC growth was also evaluated in vivo. 
Peptide-1 profoundly inhibited the tumour growth, and was as efficacious as 
etoposide, the most commonly employed cytotoxic agent for the treatment of SCLC 
patients. Combined therapy of etoposide and peptide-1 had similar inhibitory effect. I 
have shown that CD133+ population is more resistant to etoposide compared to the 
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CD133- sub-population and are enriched after etoposide exposure however, these 
resistant cells are more sensitive to peptide-1 in contrast to CD133- cells. Therefore, 
hypothetically, treatment of SCLC xenografts with combined therapy of etoposide 
and peptide-1 would eradicate the CD133- as well as CD133+ cells. This would 
serve as a model to demonstrate that elimination of CD133+ cells may be essential to 
prevent tumour recurrence in SCLC patients. In this study, despite inhibitory effect 
of the combined therapy on the SCLC xenograft, it was not possible to draw 
conclusions due to time limitation. The study would need to be continued for a 
longer period so that the inhibitory effect of the combined therapy on tumour 
recurrence could be compared to monotherapies. 
 
The hexapeptide structure of SP-G includes D-amino acid and an N-methylated 
amino acid at the N-terminus leaving the C-terminus region of SP-G unmodified and 
susceptible to degradation [322]. Therefore, attempts have been made to design more 
stable analogues. Peptide-1 was shown to be ~4 fold more stable than SP-G. 
Therefore, the findings in this chapter demonstrate that the newly designed analogue 
is more potent with added stability than SP-G making the compound a promising 
analogue for SCLC clinical trials. 
  
Concluding, peptide-1 is an exciting compound for SCLC therapy. Together, it can 
be proposed that peptide-1 in conjugation with first line therapy or as a second line 
therapy could be beneficial in SCLC patients. Suggested combined therapy with both 
drugs is speculated to not only eradicate the CD133- cells but also SCLC roots, the 
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CHAPTER 7: 
Final conclusions and future directions 
 
SCLC is an aggressive, highly metastatic and fatal malignancy. Despite 
improvements in conventional cytotoxic regimes, cure has remained elusive for most 
SCLC candidates. With the advent of the CSC hypothesis, the pathogenesis of SCLC 
should be revised. This section will include final conclusions of findings of this 
thesis and future aims for the study of CSCs in SCLC. 
 
7.1 Do CSCs exist in SCLC cell lines? 
 
In this study the presence of CSCs was investigated in H345 and H69 human SCLC 
cell lines. Established from metastatic sites of patients that had undergone 
chemotherapy [239, 325], both cell lines displayed resistance to etoposide in vitro in 
accordance with their clinical presentation. Upregulated Bcl-2 and PI3K activation, 
commonly observed in SCLCs, are known causes of chemoresistance and survival 
advantage in these cells [58, 231, 246, 326]. However, the presence of CSCs, 
underpinning resistance was speculated. This was based on the observation that not 
all SCLC cells cultured in semi-solid medium were able to form colonies, reflecting 
tumour cell heterogeneity, and indicating that cells within the neoplasm differ in their 
tumorigenic capacities. 
 
Markers including CD133, Oct-4, and ALDH have been employed for the detection 
of CSCs in pulmonary malignancies [79, 152, 158]. Both SCLC cell lines 
demonstrated CD133 and Oct-4 expression and ALDH enzyme activity suggesting 
that the SCLC cell lines retain a sub-population which expresses CSC makers. 
CD133, the most commonly used marker, has consistently identified the stem cell-
like, chemoresistant and tumorigenic lung cancer cells [79, 82, 84], and was 
therefore chosen for the identification of prospective SCLC CSCs. 
 
CD133+ SCLC cells were proliferative and displayed augmented anchorage-
independent growth. These cells maintained the expression of CD133 antigen and 
clonogenic potentials over prolonged periods in serum-free SITA medium suggesting 
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their possible self-renewing potential. In the presence of serum, they differentiated 
resulting in reduction of CD133 expression and loss of stem like features. 
Additionally, CD133+ cells expressed Oct-4, a well know regulator of stemness 
[158], whereas CD133- cells were devoid of the protein. Implantation of 1 × 10
5 
CD133+ cells consistently resulted in growth of tumour xenografts, in contrast to 
higher numbers of CD133- cells that were not tumorigenic in nude/nude mice. The 
histological features of tumours formed by implantation of CD133+ cells closely 
resembled those developed by parent cells (unsorted cells) as shown by hematoxylin 
and eosin staining, indicating that CD133+ cells could effectively reproduce the 
disease generated by parent cells, further emphasising on its stem cell-like nature. 
These data clearly indicate that CD133 selects for clonogenic, stem cell-like, and 
tumorigenic SCLC cells. 
 
CD133+ cells were enriched upon exposure to etoposide, demonstrating their 
chemoresistant phenotype. Insensitivity to etoposide in CD133+ cells was associated 
with enhanced apoptosis resistance in these cells compared to their negative 
counterpart. Deregulation in Akt and Bcl-2 expression assist cancer cells to evade 
apoptosis. Activated Akt in CD133+ H345 and H69 cells was significantly 
upregulated. Likewise, the anti-apoptotic Bcl-2 showed greater expression in this 
sub-population in the SCLC cell lines. To my knowledge, both proteins were for the 
first time demonstrated to have higher expression in CD133+ SCLC cells, promoting 
chemoresistance. Therefore, CD133 selects for chemoresistant cells in SCLC cell 
lines. 
 
Data obtained from this thesis clearly demonstrates that H345 and H69 cells consist 
of a heterogeneous population of cells with different clonogenic, sensitivity to 
treatment, and tumorigenic capacities. CD133, a well-known CSC marker, selects the 
aggressive SCLC cells from the non-aggressive cells and that CD133 expressing 
population fulfils the CSC criteria. Therefore it can be concluded that human SCLC 
cell lines do retain a sub-population of cells that exhibit CSC-like characteristics and 
that these cells may be the possible SCLC initiators, promoting treatment resistance 
and disease recurrence. 
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7.2 CSC, a myth or a reality? 
 
Despite multiple studies in the last decade which have supported the concept of 
CSCs in leukaemia and solid tumours, some groups disagree with the CSC concept 
and consider these cells as an artifact produced by inductions of an artificial 
environment presented to cells. In the present study, I have illustrated that CD133+ 
cells are clonogenic, chemoresistant, and tumorigenic cells with stem cell-like 
phenotype. Based on the literature, cells expressing CD133 marker with above 
mentioned criteria are considered as CSC-like cells. Ignoring the term cancer stem 
cell and its origin, CD133 as a marker has facilitated the selection of an aggressive 
population of cells within SCLC cell lines, explaining the possible cause of SCLC 
treatment resistance and recurrence. Therefore, the focus of the CSC theory should 
not be on the term “cancer stem cell” but on the fact that this concept has unveiled 
that tumours consist of a heterogeneous population of cells and that not all cells 
within the tumour may exhibit a similar response to therapy. CD133 in the present 
study has shown to be an ideal marker for selecting SCLC aggressive cells which 
could be a great step in better understanding SCLC. 
 
7.3 Animal models and mouse lung CSCs in translational medicine 
 
Animal models serve as a front line for predicting efficacy and monitoring toxicity of 
experimental and conventional drugs. Subcutaneous injections of lung cancer cell 
suspension in the immune-deficient mice were employed in the present study. 
Subcutaneous implants are easy to monitor tumour growth and therapy results 
however, do not mimic the pulmonary environment for the lung cancer cells [327]. 
Additionally, immune-deficient mice are not representative of the human body. An 
immune-competent mouse with an intact immune system may better mimic the 
internal milieu in human. A sporadic mouse SCLC (mSCLC) model has been 
introduced by Meuwissen et al. [103]. To my knowledge, no study has investigated 
the potency of SCLC CSCs in an immune-competent mouse. Characterisation of 
mSCLC CSCs in a syngenic mouse may better reflect their potentials. 
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Mutations commonly found in pathogenesis of human SCLCs are, inactivation of 
Rb1 and Trp53 [18]. MSCLC was obtained by somatic application of Cre-loxP to 
lung epithelial cells leading to deletion of Rb1 and Trp53 genes and the development 
of multiple tumours with histological morphology and clinical features closely 
resembling human SCLC [103]. These cells were highly invasive and expressed 
markers for neuroendocrine differentiation including NCAM, calcitonin-gene related 
peptide, GRP and GRP-R, further supporting its similarity to human SCLC. 
Furthermore, mSCLC cells exhibited high levels of L-myc, N-myc. Amplification of 
Myc gene, N-myc, L-myc or C-myc has been documented in 18-31% of SCLCs [328-
330]. Thus, mSCLC cells not only mimic histological and pathological 
characteristics of human SCLC, but also resemble these cells in their genetic 
aberration. 
 
MSCLC JC9569 and JC9574 cell lines (kind donation by professor Anton Berns) 
were obtained with the aim to evaluate the presence of putative CSCs in these cell 
lines for their in vivo characterisation. Primary data demonstrated that in both 
mSCLC cell lines, cells expressing CD133 and Oct-4 exist, confirmed by western 
blot (Figure 56). Therefore, within JC9569 and JC9574 cells reside a population of 
cells expressing CSCs marker. Characterising CD133+ mSCLC cells, including 
evaluating their clonogenicity, chemosensitivity, and self-renewal and differentiation 
potentials compared to CD133- will allow determining if these cells similar to human 
CD133+ SCLC cells represent the CSC-like sub-population. Additionally, intra-
thoracic pulmonary implants of CD133+ cells from mSCLC cell lines in the 
immune-competent mice will allow studying the tumorigenic potential of the 
prospective mSCLC CSCs in a pathophysiological environment and in the presence 
of an intact immune system. Such study would serve as an ideal preclinical model for 
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7.4 Therapy for SCLC with the aim of eradication of CD133+ cells 
 
If CD133+ cells are the possible cause of SCLC development, understanding the 
mechanisms which regulate their growth and survival is critical. This would help 
designing drugs that would specifically target the aggressive cells with minimal 
effect on the non-cancerous cells. Characterisation of isolated cells demonstrated that 
CD133+ H345 and H69 cells transcriptionally and translationally expressed higher 
GRP and V1A receptors, respectively than their corresponding CD133- counterparts. 
Addition of exogenous GRP and AVP enhanced clonogenic efficiency of the 
CD133+ cells indicating for the first time, the autocrine mediated neuropeptide 
dependent growth of CD133+ SCLC cells, making these growth factor receptors an 
interesting target for therapy. 
 
As multiple neuropeptides mediate SCLC growth, it is essential to evaluate the 
expression of other neuropeptide receptors, including bradykinin, galanin, 
neurotensin, and gastrin, transcriptionally and translationally by qPCR and western 
blotting, respectively on the CD133+ sub-population. This is critical since 
developing analogues which would inhibit the mitogenic effect of single growth 
factor would not provide satisfactory results as seen with monoclonal antibody 2A11. 
If CD133+ SCLC cells demonstrate elevated levels of multiple neuropeptide receptor 
expression, broad spectrum antagonists, such as substance P analogues that inhibit 
the mitogenic effect of multiple neuropeptides would be suitable for the elimination 
of these aggressive cells.  
 
In this thesis, I demonstrated that CD133+ cells despite being resistant to 
chemotherapy were in fact more sensitive to treatment with the new peptide analogue 
peptide-1 that was designed based on the known structure of SP-G.  SP-G has shown 
benefit in animal models and in early clinical trials. Increased sensitivity to peptide-1 
was possibly due to increased expression of neuropeptide receptors by the CD133+ 
cells. The identification of the new analogue that was more potent and more stable in 
vitro and efficacious in vivo than SP-G is an exciting step forward in the 
identification of a potential new therapy for resistant disease. It would also be 
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interesting to evaluate if peptide-1 has anti-tumour effects in other neuroendocrine 
cancers such as prostate, pancreatic, and breast cancers. 
 
The CSC theory states that, cytotoxic agents target tumour bulk leaving behind 
chemoresistant CSCs which are the speculated cause of chemoresistance and disease 
recurrence. Peptide-1 may serve as drug of choice for the treatment of SCLC with its 
ability to target the aggressive CD133+ cells. Co-administration of conventional 
agents along with peptide-1 is expected to eradicate tumour bulk and tumour roots, 
the CD133+ cells. To confirm this concept, it would be interesting to evaluate in 
xenografts models whether the new analogue could prevent the recurrence of 
resistant tumours after chemotherapy. 
 
A major challenge of drug development is the introduction of an analogue with 
minimal potentially undesirable off target effects. CSCs and cells of their origin 
share similar characteristics. Pulmonary neuroendocrine cells (PNECs), subject to 
oncogenic mutations are suggested forerunners of SCLC [103, 104]. Peptide-1 is a 
neuropeptide antagonist as shown by its ability to inhibit intracellular calcium 
mobilisation induced by neuropeptides. The question that rises is will this analogue 
exhibit undesirable inhibitory effect on PNEC? In a normal lung, GRP is produced 
by PNECs with highest number of GRP observed in fetal lung [331]. Normally, GRP 
expressing PNEC are infrequent after birth. Therefore, it can be speculated that in 
patients exposed to peptide-1, CD133+ SCLC cells will be the main target of this 
analogue. Thus, peptide-1 fulfils the essential criteria of an ideal drug for the 
treatment of SCLC including efficiency on the aggressive, stem cell-like CD133+ 
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7.5 Future studies to strengthen the concept of CSC-like cells within SCLC 
cell lines 
 
1. In the present study, CD133+ cells maintained colony forming ability in 
prolonged periods of culturing, indicating their possible self-renewing 
potential. However, the self-renewing capacity of these cells was not 
confirmed. A gold-standard assay reflecting CD133+ self-renewal and 
differentiation potential is serial transplantation of these cells in animal 
models. A cancer cell which is able to retain its cancer initiating potential 
over serial transplantation probably possesses self-renewing capacity to be 
able to proliferate indefinitely without differentiating. This assay could be 
performed by subcutaneously implanting CD133+ cells (1 × 10
5 
cells) in 
nude/nude mice. After tumour development, CD133+ cells within the 
developed tumour would be isolated using FACS and transplanted in another 
nude/nude mice with matching age and sex. This procedure should be 
continued in 4-5 animals to confirm the self-renewing potential of CD133+ 
SCLC cells. 
 
2. Knockdown studies have revealed the importance of CD133 expression on 
cells with stem cell-like phenotype [77, 127]. Knockdown of this gene in 
neuroblastoma has been associated with loss of clonogenicity and 
tumorigenicity and in colorectal cancer led to increased sensitivity of 
CD133+ cells to chemotherapy. It would be interesting to evaluate 
knockdown of CD133 using shRNA in CD133+ isolated SCLC cells and its 
effect on clonogenicity, sensitivity to etoposide, and tumorigenicity. This 
would confirm if CD133 truly selects the aggressive SCLC cells. 
 
3. CSC theory states that only a small subset of cells are the cause of tumour 
development [289], however, in the present study a relatively high percentage 
of H345 (~18%) and H69 (~20%) cells were positive for CD133 antigen. 
SCLC cell lines utilised in the present study were established from patients 
exposed to chemotherapy. Therefore, a high percentage of CD133 expression 
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could be due to the enrichment of this chemoresistant population within the 
SCLC cell lines. Additionally, I have also shown that not all CD133+ cells 
are clonogenic, indicative of heterogeneity within CD133 expressing cells. 
Therefore, a combination of CD133 with another stem cell marker such as 
ALDH may be a more accurate method for detection of pure CSCs in SCLC 
cells. To confirm this concept the characteristics of cells expressing either 
CD133 or ALDH could be compared with that of cells positive for both 
marker (CD133+ ALDH+). 
 
4. Stem cells and CSCs share various similar signalling pathways including 
Notch and Wnt which are important regulatory factors in both cell types. The 
main aim of CSC studies is to develop effective therapeutic strategies that 
selectively target human malignancies. The challenge is to identify the 
differences between stem cells and CSCs. Microarray and genome wide 
techniques could be utilised to detect possible genetic and epigenetic 
differences between these two cell types. Additionally, these techniques 
would familiarise us with trends in genetic and epigenetic “blueprints” for 
CSCs to better understand the true signature of these cells. 
 
5. Studies have implicated the importance of CD133 as a prognostic maker for 
NSCLC [85, 118]. Evaluation of CD133 expression in tissue section of SCLC 
patients by IHC would allow determining the potential prognostic value of 
CD133 expression in SCLC patients.  
 
Chemotherapy forms the cornerstone for SCLC management. However, advances in 
chemo-radiation have reached a plateau. Findings in this study that SCLC cells 
contain a sub-population of aggressive cells that evade apoptosis and are tumorigenic 
in animals, distinct from other cancer cells implicates that therapeutic strategies 
should consider tumours as a heterogeneous cellular mass initiated and propagated 
selectively by these cancer stem cell-like cells. From this view, targeted therapy of 
CSCs should be the focus for cancer management. In this regards, peptide-1 which 
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demonstrated greater efficacy to CD133+ SCLC cells may be provital in the 





































1. Ginsberg, M.S., R.K. Grewal, and R.T. Heelan, Lung cancer. Radiol Clin 
North Am, 2007. 45(1): p. 21-43. 
2. Harkness, E.F., et al., Changing trends in incidence of lung cancer by 
histologic type in Scotland. Int J Cancer, 2002. 102(2): p. 179-83. 
3. Janssen-Heijnen, M.L. and J.W. Coebergh, The changing epidemiology of 
lung cancer in Europe. Lung Cancer, 2003. 41(3): p. 245-58. 
4. Ettinger, D.S., Overview and state of the art in the management of lung 
cancer. Oncology (Williston Park), 2004. 18(7 Suppl 4): p. 3-9. 
5. Franceschi, S. and E. Bidoli, The epidemiology of lung cancer. Ann Oncol, 
1999. 10 Suppl 5: p. S3-6. 
6. Murray, N. and A.T. Turrisi, 3rd, A review of first-line treatment for small-
cell lung cancer. J Thorac Oncol, 2006. 1(3): p. 270-8. 
7. Hann, C.L. and C.M. Rudin, Management of small-cell lung cancer: 
incremental changes but hope for the future. Oncology (Williston Park), 
2008. 22(13): p. 1486-92. 
8. Govindan, R., et al., Changing epidemiology of small-cell lung cancer in the 
United States over the last 30 years: analysis of the surveillance, 
epidemiologic, and end results database. J Clin Oncol, 2006. 24(28): p. 4539-
44. 
9. Puglisi, M., et al., Treatment options for small cell lung cancer - do we have 
more choice? Br J Cancer. 102(4): p. 629-38. 
10. Ferlay, J., D.M. Parkin, and E. Steliarova-Foucher, Estimates of cancer 
incidence and mortality in Europe in 2008. Eur J Cancer. 46(4): p. 765-81. 
11. Ettinger, D.S. and J. Aisner, Changing face of small-cell lung cancer: real 
and artifact. J Clin Oncol, 2006. 24(28): p. 4526-7. 
12. Riaz, S.P., et al., Trends in incidence of small cell lung cancer and all lung 
cancer. Lung Cancer. 75(3): p. 280-4. 
13. Toh, C.-K., et al., Differences between small-cell lung cancer and non-small-
cell lung cancer among tobacco smokers. Lung cancer (Amsterdam, 
Netherlands), 2007. 56(2): p. 161-166. 
14. Karim-Kos, H.E., et al., Recent trends of cancer in Europe: a combined 
approach of incidence, survival and mortality for 17 cancer sites since the 
1990s. Eur J Cancer, 2008. 44(10): p. 1345-89. 
15. Alberg, A.J. and J.M. Samet, Epidemiology of lung cancer. Chest, 2003. 
123(1 Suppl): p. 21S-49S. 
16. Hibi, K., et al., Three distinct regions involved in 3p deletion in human lung 
cancer. Oncogene, 1992. 7(3): p. 445-9. 
17. Kok, K., S.L. Naylor, and C.H. Buys, Deletions of the short arm of 
chromosome 3 in solid tumors and the search for suppressor genes. Adv 
Cancer Res, 1997. 71: p. 27-92. 
18. Miura, I., et al., Chromosome alterations in human small cell lung cancer: 
frequent involvement of 5q. Cancer Res, 1992. 52(5): p. 1322-8. 
19. D'Amico, D., et al., High frequency of somatically acquired p53 mutations in 
small-cell lung cancer cell lines and tumors. Oncogene, 1992. 7(2): p. 339-
46. 
References                                                                                                                218 
 
20. Harbour, J.W., et al., Abnormalities in structure and expression of the human 
retinoblastoma gene in SCLC. Science, 1988. 241(4863): p. 353-7. 
21. Travis, W.D., Advances in neuroendocrine lung tumors. Ann Oncol. 21 
Suppl 7: p. vii65-71. 
22. Chong, S., et al., Neuroendocrine tumors of the lung: clinical, pathologic, 
and imaging findings. Radiographics, 2006. 26(1): p. 41-57; discussion 57-8. 
23. Gandhi, L. and B.E. Johnson, Paraneoplastic syndromes associated with 
small cell lung cancer. J Natl Compr Canc Netw, 2006. 4(6): p. 631-8. 
24. Dalmau, J. and M.R. Rosenfeld, Paraneoplastic syndromes of the CNS. 
Lancet Neurol, 2008. 7(4): p. 327-40. 
25. Zelen, M., Keynote address on biostatistics and data retrieval. Cancer 
Chemother Rep 3, 1973. 4(2): p. 31-42. 
26. Suzuki, S., [Lambert-Eaton myasthenic syndrome (LEMS)]. Brain Nerve. 
62(4): p. 419-26. 
27. Laurent, F., M. Montaudon, and O. Corneloup, CT and MRI of Lung Cancer. 
Respiration, 2006. 73(2): p. 133-42. 
28. Gustafsson, B.I., et al., Bronchopulmonary neuroendocrine tumors. Cancer, 
2008. 113(1): p. 5-21. 
29. Argiris, A. and J.R. Murren, Staging and clinical prognostic factors for 
small-cell lung cancer. Cancer J, 2001. 7(5): p. 437-47. 
30. Haddadin, S. and M.C. Perry, History of small-cell lung cancer. Clin Lung 
Cancer. 12(2): p. 87-93. 
31. Shepherd, F.A., et al., The International Association for the Study of Lung 
Cancer lung cancer staging project: proposals regarding the clinical staging 
of small cell lung cancer in the forthcoming (seventh) edition of the tumor, 
node, metastasis classification for lung cancer. J Thorac Oncol, 2007. 2(12): 
p. 1067-77. 
32. Carmichael, J., et al., Chemosensitivity testing of human lung cancer cell 
lines using the MTT assay. Br J Cancer, 1988. 57(6): p. 540-7. 
33. Green, R.A., et al., Alkylating agents in bronchogenic carcinoma. Am J Med, 
1969. 46(4): p. 516-25. 
34. Lowenbraun, S., et al., The superiority of combination chemotherapy over 
single agent chemotherapy in small cell lung carcinoma. Cancer, 1979. 44(2): 
p. 406-13. 
35. Roth, B.J., et al., Randomized study of cyclophosphamide, doxorubicin, and 
vincristine versus etoposide and cisplatin versus alternation of these two 
regimens in extensive small-cell lung cancer: a phase III trial of the 
Southeastern Cancer Study Group. J Clin Oncol, 1992. 10(2): p. 282-91. 
36. Sundstrom, S., et al., Cisplatin and etoposide regimen is superior to 
cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung 
cancer: results from a randomized phase III trial with 5 years' follow-up. J 
Clin Oncol, 2002. 20(24): p. 4665-72. 
37. Mavroudis, D., et al., A multicenter randomized clinical trial comparing 
paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line 
treatment in patients with small-cell lung cancer. Ann Oncol, 2001. 12(4): p. 
463-70. 
References                                                                                                                219 
 
38. Clark, R. and D.C. Ihde, Small-cell lung cancer: treatment progress and 
prospects. Oncology (Williston Park), 1998. 12(5): p. 647-58; discussion 
661-3. 
39. von Pawel, J., et al., Topotecan versus cyclophosphamide, doxorubicin, and 
vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol, 
1999. 17(2): p. 658-67. 
40. Albain, K.S., et al., Predictors of survival following relapse or progression of 
small cell lung cancer. Southwest Oncology Group Study 8605 report and 
analysis of recurrent disease data base. Cancer, 1993. 72(4): p. 1184-91. 
41. Kim, Y.H. and M. Mishima, Second-line chemotherapy for small-cell lung 
cancer (SCLC). Cancer Treat Rev. 37(2): p. 143-50. 
42. Kollmannsberger, C., et al., Topotecan - A novel topoisomerase I inhibitor: 
pharmacology and clinical experience. Oncology, 1999. 56(1): p. 1-12. 
43. Sugimoto, Y., et al., Decreased expression of DNA topoisomerase I in 
camptothecin-resistant tumor cell lines as determined by a monoclonal 
antibody. Cancer Res, 1990. 50(21): p. 6925-30. 
44. Noda, K., et al., Irinotecan plus cisplatin compared with etoposide plus 
cisplatin for extensive small-cell lung cancer. N Engl J Med, 2002. 346(2): p. 
85-91. 
45. Crossin, K.L. and D.H. Carney, Microtubule stabilization by taxol inhibits 
initiation of DNA synthesis by thrombin and by epidermal growth factor. 
Cell, 1981. 27(2 Pt 1): p. 341-50. 
46. Kirschling, R.J., et al., Paclitaxel and G-CSF in previously untreated patients 
with extensive stage small-cell lung cancer: a phase II study of the North 
Central Cancer Treatment Group. Am J Clin Oncol, 1999. 22(5): p. 517-22. 
47. Onoda, S., et al., Phase II trial of amrubicin for treatment of refractory or 
relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 
0301. J Clin Oncol, 2006. 24(34): p. 5448-53. 
48. Kaira, K., et al., A phase II study of amrubicin, a synthetic 9-
aminoanthracycline, in patients with previously treated lung cancer. Lung 
Cancer. 69(1): p. 99-104. 
49. Pignon, J.P., et al., A meta-analysis of thoracic radiotherapy for small-cell 
lung cancer. N Engl J Med, 1992. 327(23): p. 1618-24. 
50. Warde, P. and D. Payne, Does thoracic irradiation improve survival and 
local control in limited-stage small-cell carcinoma of the lung? A meta-
analysis. J Clin Oncol, 1992. 10(6): p. 890-5. 
51. Paumier, A. and C. Le Pechoux, Radiotherapy in small-cell lung cancer: 
where should it go? Lung Cancer. 69(2): p. 133-40. 
52. Takada, M., et al., Phase III study of concurrent versus sequential thoracic 
radiotherapy in combination with cisplatin and etoposide for limited-stage 
small-cell lung cancer: results of the Japan Clinical Oncology Group Study 
9104. J Clin Oncol, 2002. 20(14): p. 3054-60. 
53. Turrisi, A.T., 3rd, et al., Twice-daily compared with once-daily thoracic 
radiotherapy in limited small-cell lung cancer treated concurrently with 
cisplatin and etoposide. N Engl J Med, 1999. 340(4): p. 265-71. 
54. Jeremic, B., et al., Role of radiation therapy in the combined-modality 
treatment of patients with extensive disease small-cell lung cancer: A 
randomized study. J Clin Oncol, 1999. 17(7): p. 2092-9. 
References                                                                                                                220 
 
55. Arriagada, R., et al., Prophylactic cranial irradiation for patients with small-
cell lung cancer in complete remission. J Natl Cancer Inst, 1995. 87(3): p. 
183-90. 
56. Auperin, A., et al., Prophylactic cranial irradiation for patients with small-
cell lung cancer in complete remission. Prophylactic Cranial Irradiation 
Overview Collaborative Group. N Engl J Med, 1999. 341(7): p. 476-84. 
57. Slotman, B., et al., Prophylactic cranial irradiation in extensive small-cell 
lung cancer. N Engl J Med, 2007. 357(7): p. 664-72. 
58. Jiang, S.X., et al., Expression of bcl-2 oncogene protein is prevalent in small 
cell lung carcinomas. J Pathol, 1995. 177(2): p. 135-8. 
59. Shoemaker, A.R., et al., Activity of the Bcl-2 family inhibitor ABT-263 in a 
panel of small cell lung cancer xenograft models. Clin Cancer Res, 2008. 
14(11): p. 3268-77. 
60. Stauffer, S.R., Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein 
interaction: proof-of-concept of an in vivo chemopotentiator ABT-737. Curr 
Top Med Chem, 2007. 7(10): p. 961-5. 
61. Gandhi, L., et al., Phase I study of Navitoclax (ABT-263), a novel Bcl-2 
family inhibitor, in patients with small-cell lung cancer and other solid 
tumors. J Clin Oncol. 29(7): p. 909-16. 
62. Tarhini, A., et al., Phase II Study of Everolimus (RAD001) in Previously 
Treated Small Cell Lung Cancer. Clinical Cancer Research. 16(23): p. 5900-
5907. 
63. Pandya, K.J., et al., A randomized, phase II trial of two dose levels of 
temsirolimus (CCI-779) in patients with extensive-stage small-cell lung 
cancer who have responding or stable disease after induction chemotherapy: 
a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol, 
2007. 2(11): p. 1036-41. 
64. Sethi, T., et al., Growth of small cell lung cancer cells: stimulation by 
multiple neuropeptides and inhibition by broad spectrum antagonists in vitro 
and in vivo. Cancer Res, 1992. 52(9 Suppl): p. 2737s-2742s. 
65. Waters, C.M., et al., Increased gastrin-releasing peptide (GRP) receptor 
expression in tumour cells confers sensitivity to [Arg6,D-Trp7,9,NmePhe8]-
substance P (6-11)-induced growth inhibition. Br J Cancer, 2003. 88(11): p. 
1808-16. 
66. Clive, S., et al., Forearm blood flow and local responses to peptide 
vasodilators: a novel pharmacodynamic measure in the phase I trial of 
antagonist G, a neuropeptide growth factor antagonist. Clin Cancer Res, 
2001. 7(10): p. 3071-8. 
67. Murray, N., R. Salgia, and F.V. Fossella, Targeted molecules in small cell 
lung cancer. Semin Oncol, 2004. 31(1 Suppl 1): p. 106-11. 
68. Dy, G.K., et al., A phase II trial of imatinib (ST1571) in patients with c-kit 
expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. 
Ann Oncol, 2005. 16(11): p. 1811-6. 
69. Krug, L.M., et al., Imatinib mesylate lacks activity in small cell lung 
carcinoma expressing c-kit protein: a phase II clinical trial. Cancer, 2005. 
103(10): p. 2128-31. 
References                                                                                                                221 
 
70. Peck, R.A., et al., Phase I and pharmacokinetic study of the novel MDR1 and 
MRP1 inhibitor biricodar administered alone and in combination with 
doxorubicin. J Clin Oncol, 2001. 19(12): p. 3130-41. 
71. Heppner, G.H. and B.E. Miller, Tumor heterogeneity: biological implications 
and therapeutic consequences. Cancer Metastasis Rev, 1983. 2(1): p. 5-23. 
72. Southam, C.M. and A. Brunschwig, Quantitative studies of 
autotransplantation of human cancer. Preliminary report. Cancer, 1961. 
14(5): p. 971-978. 
73. Visvader, J.E. and G.J. Lindeman, Cancer stem cells in solid tumours: 
accumulating evidence and unresolved questions. Nat Rev Cancer, 2008. 
8(10): p. 755-68. 
74. Bonnet, D. and J.E. Dick, Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nat Med, 1997. 
3(7): p. 730-7. 
75. Al-Hajj, M., et al., Prospective identification of tumorigenic breast cancer 
cells. Proc Natl Acad Sci U S A, 2003. 100(7): p. 3983-8. 
76. O/'Brien, C.A., et al., A human colon cancer cell capable of initiating tumour 
growth in immunodeficient mice. Nature, 2007. 445(7123): p. 106-110. 
77. Ricci-Vitiani, L., et al., Identification and expansion of human colon-cancer-
initiating cells. Nature, 2007. 445(7123): p. 111-5. 
78. Singh, S.K., et al., Identification of a cancer stem cell in human brain tumors. 
Cancer Res, 2003. 63(18): p. 5821-8. 
79. Eramo, A., et al., Identification and expansion of the tumorigenic lung cancer 
stem cell population. Cell Death Differ, 2008. 15(3): p. 504-14. 
80. Ma, S., et al., CD133+ HCC cancer stem cells confer chemoresistance by 
preferential expression of the Akt/PKB survival pathway. Oncogene, 2008. 
27(12): p. 1749-58. 
81. Liu, G., et al., Analysis of gene expression and chemoresistance of CD133+ 
cancer stem cells in glioblastoma. Mol Cancer, 2006. 5: p. 67. 
82. Levina, V., et al., Drug-selected human lung cancer stem cells: cytokine 
network, tumorigenic and metastatic properties. PLoS One, 2008. 3(8): p. 
e3077. 
83. Ginestier, C., et al., ALDH1 is a marker of normal and malignant human 
mammary stem cells and a predictor of poor clinical outcome. Cell Stem 
Cell, 2007. 1(5): p. 555-67. 
84. Bertolini, G., et al., Highly tumorigenic lung cancer CD133+ cells display 
stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci 
U S A, 2009. 106(38): p. 16281-6. 
85. Shien, K., et al., Prognostic impact of cancer stem cell-related markers in 
non-small cell lung cancer patients treated with induction 
chemoradiotherapy. Lung Cancer, (0). 
86. Baker, S.J., et al., Suppression of human colorectal carcinoma cell growth by 
wild-type p53. Science, 1990. 249(4971): p. 912-5. 
87. Iwasaki, H. and K. Akashi, Myeloid lineage commitment from the 
hematopoietic stem cell. Immunity, 2007. 26(6): p. 726-40. 
88. Kotton, D.N. and A. Fine, Lung stem cells. Cell Tissue Res, 2008. 331(1): p. 
145-56. 
References                                                                                                                222 
 
89. Giangreco, A., et al., Stem cells are dispensable for lung homeostasis but 
restore airways after injury. Proc Natl Acad Sci U S A, 2009. 106(23): p. 
9286-91. 
90. Rawlins, E.L., Lung epithelial progenitor cells: lessons from development. 
Proc Am Thorac Soc, 2008. 5(6): p. 675-81. 
91. Knight, D.A. and S.T. Holgate, The airway epithelium: structural and 
functional properties in health and disease. Respirology, 2003. 8(4): p. 432-
46. 
92. Stripp, B.R. and S.D. Reynolds, Maintenance and repair of the bronchiolar 
epithelium. Proc Am Thorac Soc, 2008. 5(3): p. 328-33. 
93. Van Winkle, L.S., et al., Cellular response in naphthalene-induced Clara cell 
injury and bronchiolar epithelial repair in mice. Am J Physiol, 1995. 269(6 
Pt 1): p. L800-18. 
94. Hong, K.U., et al., In vivo differentiation potential of tracheal basal cells: 
evidence for multipotent and unipotent subpopulations. Am J Physiol Lung 
Cell Mol Physiol, 2004. 286(4): p. L643-9. 
95. Reynolds, S.D., et al., Neuroepithelial bodies of pulmonary airways serve as 
a reservoir of progenitor cells capable of epithelial regeneration. Am J 
Pathol, 2000. 156(1): p. 269-78. 
96. Rawlins, E.L. and B.L. Hogan, Epithelial stem cells of the lung: privileged 
few or opportunities for many? Development, 2006. 133(13): p. 2455-65. 
97. Giangreco, A., S.D. Reynolds, and B.R. Stripp, Terminal bronchioles harbor 
a unique airway stem cell population that localizes to the bronchoalveolar 
duct junction. Am J Pathol, 2002. 161(1): p. 173-82. 
98. Kim, C.F., et al., Identification of bronchioalveolar stem cells in normal lung 
and lung cancer. Cell, 2005. 121(6): p. 823-35. 
99. Rawlins, E.L., et al., The role of Scgb1a1+ Clara cells in the long-term 
maintenance and repair of lung airway, but not alveolar, epithelium. Cell 
Stem Cell, 2009. 4(6): p. 525-34. 
100. Malkinson, A.M., Molecular comparison of human and mouse pulmonary 
adenocarcinomas. Exp Lung Res, 1998. 24(4): p. 541-55. 
101. Jackson, E.L., et al., Analysis of lung tumor initiation and progression using 
conditional expression of oncogenic K-ras. Genes Dev, 2001. 15(24): p. 
3243-8. 
102. Ventura, J.J., et al., p38alpha MAP kinase is essential in lung stem and 
progenitor cell proliferation and differentiation. Nat Genet, 2007. 39(6): p. 
750-8. 
103. Meuwissen, R., et al., Induction of small cell lung cancer by somatic 
inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer 
Cell, 2003. 4(3): p. 181-9. 
104. Wistuba, II, A.F. Gazdar, and J.D. Minna, Molecular genetics of small cell 
lung carcinoma. Semin Oncol, 2001. 28(2 Suppl 4): p. 3-13. 
105. Minna, J.D., J.M. Kurie, and T. Jacks, A big step in the study of small cell 
lung cancer. Cancer Cell, 2003. 4(3): p. 163-6. 
106. Wikenheiser-Brokamp, K.A., Rb family proteins differentially regulate 
distinct cell lineages during epithelial development. Development, 2004. 
131(17): p. 4299-310. 
References                                                                                                                223 
 
107. Watkins, D.N., et al., Hedgehog signalling within airway epithelial 
progenitors and in small-cell lung cancer. Nature, 2003. 422(6929): p. 313-7. 
108. Ericson, J., et al., Two critical periods of Sonic Hedgehog signaling required 
for the specification of motor neuron identity. Cell, 1996. 87(4): p. 661-73. 
109. Ball, D.W., Achaete-scute homolog-1 and Notch in lung neuroendocrine 
development and cancer. Cancer Lett, 2004. 204(2): p. 159-69. 
110. Yin, A.H., et al., AC133, a novel marker for human hematopoietic stem and 
progenitor cells. Blood, 1997. 90(12): p. 5002-12. 
111. Corbeil, D., et al., The human AC133 hematopoietic stem cell antigen is also 
expressed in epithelial cells and targeted to plasma membrane protrusions. J 
Biol Chem, 2000. 275(8): p. 5512-20. 
112. Corbeil, D., et al., Selective localization of the polytopic membrane protein 
prominin in microvilli of epithelial cells - a combination of apical sorting and 
retention in plasma membrane protrusions. J Cell Sci, 1999. 112 ( Pt 7): p. 
1023-33. 
113. Piechaczek, C., Cd133. J Biol Regul Homeost Agents, 2001. 15(1): p. 101-2. 
114. Miraglia, S., et al., A novel five-transmembrane hematopoietic stem cell 
antigen: isolation, characterization, and molecular cloning. Blood, 1997. 
90(12): p. 5013-21. 
115. Potgens, A.J., et al., Monoclonal antibody CD133-2 (AC141) against 
hematopoietic stem cell antigen CD133 shows crossreactivity with 
cytokeratin 18. J Histochem Cytochem, 2002. 50(8): p. 1131-4. 
116. Gordon, P.R., et al., Large-scale isolation of CD133+ progenitor cells from 
G-CSF mobilized peripheral blood stem cells. Bone Marrow Transplant, 
2003. 31(1): p. 17-22. 
117. Alessandri, G., et al., Isolation and culture of human muscle-derived stem 
cells able to differentiate into myogenic and neurogenic cell lineages. Lancet, 
2004. 364(9448): p. 1872-83. 
118. Woo, T., et al., Prognostic value of CD133 expression in stage I lung 
adenocarcinomas. Int J Clin Exp Pathol. 4(1): p. 32-42. 
119. Horst, D., et al., Prognostic significance of the cancer stem cell markers 
CD133, CD44, and CD166 in colorectal cancer. Cancer Invest, 2009. 27(8): 
p. 844-50. 
120. Zeppernick, F., et al., Stem cell marker CD133 affects clinical outcome in 
glioma patients. Clin Cancer Res, 2008. 14(1): p. 123-9. 
121. Yu, J.W., et al., Expressions and clinical significances of CD133 protein and 
CD133 mRNA in primary lesion of gastric adenocacinoma. J Exp Clin 
Cancer Res. 29: p. 141. 
122. Fargeas, C.A., et al., Prominin-1 (CD133): from progenitor cells to human 
diseases. Future Lipidology, 2006. 1(2): p. 213-225. 
123. Bauer, N., et al., New insights into the cell biology of hematopoietic 
progenitors by studying prominin-1 (CD133). Cells Tissues Organs, 2008. 
188(1-2): p. 127-38. 
124. Freund, D., et al., Polarization of human hematopoietic progenitors during 
contact with multipotent mesenchymal stromal cells: effects on proliferation 
and clonogenicity. Stem Cells Dev, 2006. 15(6): p. 815-29. 
125. Pine, S.R., et al., Microenvironmental modulation of asymmetric cell division 
in human lung cancer cells. Proc Natl Acad Sci U S A. 107(5): p. 2195-200. 
References                                                                                                                224 
 
126. Marzesco, A.M., et al., Release of extracellular membrane particles carrying 
the stem cell marker prominin-1 (CD133) from neural progenitors and other 
epithelial cells. J Cell Sci, 2005. 118(Pt 13): p. 2849-58. 
127. Takenobu, H., et al., CD133 suppresses neuroblastoma cell differentiation 
via signal pathway modification. Oncogene. 30(1): p. 97-105. 
128. de Wynter, E.A., et al., CD34+AC133+ cells isolated from cord blood are 
highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating 
cells and dendritic cell progenitors. Stem Cells, 1998. 16(6): p. 387-96. 
129. Gehling, U.M., et al., In vitro differentiation of endothelial cells from AC133-
positive progenitor cells. Blood, 2000. 95(10): p. 3106-3112. 
130. Padovan, C.S., et al., Expression of neuronal markers in differentiated 
marrow stromal cells and CD133+ stem-like cells. Cell Transplant, 2003. 
12(8): p. 839-48. 
131. Koehl, U., et al., Autologous transplantation of CD133 selected 
hematopoietic progenitor cells in a pediatric patient with relapsed leukemia. 
Bone Marrow Transplant, 2002. 29(11): p. 927-30. 
132. Bussolati, B., et al., Isolation of renal progenitor cells from adult human 
kidney. Am J Pathol, 2005. 166(2): p. 545-55. 
133. Belicchi, M., et al., Human skin-derived stem cells migrate throughout 
forebrain and differentiate into astrocytes after injection into adult mouse 
brain. J Neurosci Res, 2004. 77(4): p. 475-86. 
134. Richardson, G.D., et al., CD133, a novel marker for human prostatic 
epithelial stem cells. J Cell Sci, 2004. 117(Pt 16): p. 3539-45. 
135. Collins, A.T., et al., Prospective identification of tumorigenic prostate cancer 
stem cells. Cancer Res, 2005. 65(23): p. 10946-51. 
136. O'Brien, C.A., et al., A human colon cancer cell capable of initiating tumour 
growth in immunodeficient mice. Nature, 2007. 445(7123): p. 106-10. 
137. Elsaba, T.M., et al., The stem cell marker CD133 associates with enhanced 
colony formation and cell motility in colorectal cancer. PLoS One. 5(5): p. 
e10714. 
138. Li, C.Y., et al., Higher percentage of CD133+ cells is associated with poor 
prognosis in colon carcinoma patients with stage IIIB. J Transl Med, 2009. 7: 
p. 56. 
139. Bao, S., et al., Glioma stem cells promote radioresistance by preferential 
activation of the DNA damage response. Nature, 2006. 444(7120): p. 756-60. 
140. Ma, S., et al., Identification and characterization of tumorigenic liver cancer 
stem/progenitor cells. Gastroenterology, 2007. 132(7): p. 2542-56. 
141. Tan, S., et al., Selective enrichment of hepatocellular cancer stem cells by 
chemotherapy. J Int Med Res, 2009. 37(4): p. 1046-56. 
142. Yang, Z., et al., Transient mTOR inhibition facilitates continuous growth of 
liver tumors by modulating the maintenance of CD133+ cell populations. 
PLoS One. 6(12): p. e28405. 
143. Song, W., et al., Expression and clinical significance of the stem cell marker 
CD133 in hepatocellular carcinoma. Int J Clin Pract, 2008. 62(8): p. 1212-8. 
144. Carney, D.N., et al., Demonstration of the stem cell nature of clonogenic 
tumor cells from lung cancer patients. Stem Cells, 1982. 1(3): p. 149-64. 
References                                                                                                                225 
 
145. Goodell, M.A., et al., Isolation and functional properties of murine 
hematopoietic stem cells that are replicating in vivo. J Exp Med, 1996. 
183(4): p. 1797-806. 
146. Patel, M., et al., ALDH1A1 and ALDH3A1 expression in lung cancers: 
correlation with histologic type and potential precursors. Lung Cancer, 2008. 
59(3): p. 340-9. 
147. Marchitti, S.A., et al., Non-P450 aldehyde oxidizing enzymes: the aldehyde 
dehydrogenase superfamily. Expert Opin Drug Metab Toxicol, 2008. 4(6): p. 
697-720. 
148. Black, W.J., et al., Human aldehyde dehydrogenase genes: alternatively 
spliced transcriptional variants and their suggested nomenclature. 
Pharmacogenet Genomics, 2009. 19(11): p. 893-902. 
149. Vasiliou, V. and A. Pappa, Polymorphisms of human aldehyde 
dehydrogenases. Consequences for drug metabolism and disease. 
Pharmacology, 2000. 61(3): p. 192-8. 
150. Gudas, L.J. and J.A. Wagner, Retinoids regulate stem cell differentiation. J 
Cell Physiol. 226(2): p. 322-30. 
151. Ma, I. and A.L. Allan, The role of human aldehyde dehydrogenase in normal 
and cancer stem cells. Stem Cell Rev. 7(2): p. 292-306. 
152. Jiang, F., et al., Aldehyde dehydrogenase 1 is a tumor stem cell-associated 
marker in lung cancer. Mol Cancer Res, 2009. 7(3): p. 330-8. 
153. Moreb, J.S., et al., ALDH isozymes downregulation affects cell growth, cell 
motility and gene expression in lung cancer cells. Mol Cancer, 2008. 7: p. 87. 
154. Koelling, T.M., et al., Development and characterization of a 
cyclophosphamide-resistant subline of acute myeloid leukemia in the Lewis x 
Brown Norway hybrid rat. Blood, 1990. 76(6): p. 1209-13. 
155. Niwa, H., J. Miyazaki, and A.G. Smith, Quantitative expression of Oct-3/4 
defines differentiation, dedifferentiation or self-renewal of ES cells. Nat 
Genet, 2000. 24(4): p. 372-6. 
156. Gidekel, S., et al., Oct-3/4 is a dose-dependent oncogenic fate determinant. 
Cancer Cell, 2003. 4(5): p. 361-70. 
157. Atlasi, Y., et al., OCT-4, an embryonic stem cell marker, is highly expressed 
in bladder cancer. Int J Cancer, 2007. 120(7): p. 1598-602. 
158. Chen, Y.C., et al., Oct-4 expression maintained cancer stem-like properties in 
lung cancer-derived CD133-positive cells. PLoS One, 2008. 3(7): p. e2637. 
159. Ponti, D., et al., Isolation and in vitro propagation of tumorigenic breast 
cancer cells with stem/progenitor cell properties. Cancer Res, 2005. 65(13): 
p. 5506-11. 
160. Bar, E.E., et al., Cyclopamine-mediated hedgehog pathway inhibition 
depletes stem-like cancer cells in glioblastoma. Stem Cells, 2007. 25(10): p. 
2524-33. 
161. Peacock, C.D., et al., Hedgehog signaling maintains a tumor stem cell 
compartment in multiple myeloma. Proc Natl Acad Sci U S A, 2007. 104(10): 
p. 4048-53. 
162. Zhao, C., et al., Hedgehog signalling is essential for maintenance of cancer 
stem cells in myeloid leukaemia. Nature, 2009. 458(7239): p. 776-9. 
References                                                                                                                226 
 
163. Fan, X., et al., Notch pathway inhibition depletes stem-like cells and blocks 
engraftment in embryonal brain tumors. Cancer Res, 2006. 66(15): p. 7445-
52. 
164. Rasheed, Z.A., et al., Concise review: Emerging concepts in clinical 
targeting of cancer stem cells. Stem Cells. 29(6): p. 883-7. 
165. Levina, V., et al., Elimination of human lung cancer stem cells through 
targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res. 
70(1): p. 338-46. 
166. Todaro, M., et al., IL-4-mediated drug resistance in colon cancer stem cells. 
Cell Cycle, 2008. 7(3): p. 309-13. 
167. Gupta, P.B., et al., Identification of selective inhibitors of cancer stem cells by 
high-throughput screening. Cell, 2009. 138(4): p. 645-59. 
168. Matsui, W., et al., Anti-tumour activity of interferon-alpha in multiple 
myeloma: role of interleukin 6 and tumor cell differentiation. Br J Haematol, 
2003. 121(2): p. 251-8. 
169. Sethi, T. and E. Rozengurt, Multiple neuropeptides stimulate clonal growth of 
small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, 
galanin, and neurotensin. Cancer Res, 1991. 51(13): p. 3621-3. 
170. Rozengurt, E., Neuropeptides as cellular growth factors: role of multiple 
signalling pathways. Eur J Clin Invest, 1991. 21(2): p. 123-34. 
171. MacKinnon, A.C., et al., Expression of V1A and GRP receptors leads to 
cellular transformation and increased sensitivity to substance-P analogue-
induced growth inhibition. Br J Cancer, 2005. 92(3): p. 522-31. 
172. Flores, D.G., et al., Cancer stem cells and the biology of brain tumors. Curr 
Stem Cell Res Ther, 2009. 4(4): p. 306-13. 
173. Rozengurt, E., Signal transduction pathways in the mitogenic response to G 
protein-coupled neuropeptide receptor agonists. J Cell Physiol, 1998. 177(4): 
p. 507-17. 
174. Palczewski, K., et al., Crystal structure of rhodopsin: A G protein-coupled 
receptor. Science, 2000. 289(5480): p. 739-45. 
175. Ji, T.H., M. Grossmann, and I. Ji, G protein-coupled receptors. I. Diversity of 
receptor-ligand interactions. J Biol Chem, 1998. 273(28): p. 17299-302. 
176. De Lean, A., J.M. Stadel, and R.J. Lefkowitz, A ternary complex model 
explains the agonist-specific binding properties of the adenylate cyclase-
coupled beta-adrenergic receptor. Journal of Biological Chemistry, 1980. 
255(15): p. 7108-7117. 
177. Seifert, R. and K. Wenzel-Seifert, Constitutive activity of G-protein-coupled 
receptors: cause of disease and common property of wild-type receptors. 
Naunyn Schmiedebergs Arch Pharmacol, 2002. 366(5): p. 381-416. 
178. Hermans, E., Biochemical and pharmacological control of the multiplicity of 
coupling at G-protein-coupled receptors. Pharmacol Ther, 2003. 99(1): p. 25-
44. 
179. Hepler, J.R. and A.G. Gilman, G proteins. Trends Biochem Sci, 1992. 
17(10): p. 383-7. 
180. Wettschureck, N. and S. Offermanns, Mammalian G proteins and their cell 
type specific functions. Physiol Rev, 2005. 85(4): p. 1159-204. 
181. Hamm, H.E., The many faces of G protein signaling. J Biol Chem, 1998. 
273(2): p. 669-72. 
References                                                                                                                227 
 
182. Farfel, Z., H.R. Bourne, and T. Iiri, The expanding spectrum of G protein 
diseases. N Engl J Med, 1999. 340(13): p. 1012-20. 
183. Lyons, J., et al., Two G protein oncogenes in human endocrine tumors. 
Science, 1990. 249(4969): p. 655-9. 
184. Chan, A.M., et al., Expression cDNA cloning of a transforming gene 
encoding the wild-type G alpha 12 gene product. Mol Cell Biol, 1993. 13(2): 
p. 762-8. 
185. Erspamer, V., et al., Occurrence of bombesin and alytesin in extracts of the 
skin of three European discoglossid frogs and pharmacological actions of 
bombesin on extravascular smooth muscle. Br J Pharmacol, 1972. 45(2): p. 
333-48. 
186. Spindel, E.R., et al., Cloning and characterization of cDNAs encoding human 
gastrin-releasing peptide. Proceedings of the National Academy of Sciences, 
1984. 81(18): p. 5699-5703. 
187. Kroog, G.S., R.T. Jensen, and J.F. Battey, Mammalian bombesin receptors. 
Med Res Rev, 1995. 15(5): p. 389-417. 
188. Wang, D., H. Yeger, and E. Cutz, Expression of gastrin-releasing peptide 
receptor gene in developing lung. Am J Respir Cell Mol Biol, 1996. 14(5): p. 
409-16. 
189. Gudermann, T. and S. Roelle, Calcium-dependent growth regulation of small 
cell lung cancer cells by neuropeptides. Endocr Relat Cancer, 2006. 13(4): p. 
1069-84. 
190. Cuttitta, F., et al., Bombesin-like peptides can function as autocrine growth 
factors in human small-cell lung cancer. Nature, 1985. 316(6031): p. 823-6. 
191. Cornelio, D., R. Roesler, and G. Schwartsmann, Gastrin-releasing peptide 
receptor as a molecular target in experimental anticancer therapy. Annals of 
Oncology, 2007. 18(9): p. 1457-1466. 
192. Thibonnier, M., et al., Molecular pharmacology of human vasopressin 
receptors. Adv Exp Med Biol, 1998. 449: p. 251-76. 
193. Zingg, H.H., Vasopressin and oxytocin receptors. Baillieres Clin Endocrinol 
Metab, 1996. 10(1): p. 75-96. 
194. Wittau, N., et al., The galanin receptor type 2 initiates multiple signaling 
pathways in small cell lung cancer cells by coupling to G(q), G(i) and G(12) 
proteins. Oncogene, 2000. 19(37): p. 4199-209. 
195. Mikoshiba, K., The InsP3 receptor and intracellular Ca2+ signaling. Curr 
Opin Neurobiol, 1997. 7(3): p. 339-45. 
196. Exton, J.H., Regulation of phosphoinositide phospholipases by hormones, 
neurotransmitters, and other agonists linked to G proteins. Annu Rev 
Pharmacol Toxicol, 1996. 36: p. 481-509. 
197. Noh, D.Y., S.H. Shin, and S.G. Rhee, Phosphoinositide-specific 
phospholipase C and mitogenic signaling. Biochim Biophys Acta, 1995. 
1242(2): p. 99-113. 
198. Paolucci, L. and E. Rozengurt, Protein kinase D in small cell lung cancer 
cells: rapid activation through protein kinase C. Cancer Res, 1999. 59(3): p. 
572-7. 
199. Hedin, K.E., et al., Gi proteins use a novel beta gamma- and Ras-independent 
pathway to activate extracellular signal-regulated kinase and mobilize AP-1 
References                                                                                                                228 
 
transcription factors in Jurkat T lymphocytes. J Biol Chem, 1999. 274(28): p. 
19992-20001. 
200. Jaffe, A.B. and A. Hall, Rho GTPases in transformation and metastasis. Adv 
Cancer Res, 2002. 84: p. 57-80. 
201. Woll, P.J. and E. Rozengurt, Multiple neuropeptides mobilise calcium in 
small cell lung cancer: effects of vasopressin, bradykinin, cholecystokinin, 
galanin and neurotensin. Biochem Biophys Res Commun, 1989. 164(1): p. 
66-73. 
202. Schuller, H.M., M. Orloff, and G.K. Reznik, Antiproliferative effects of the 
Ca2+/calmodulin antagonist B859-35 and the Ca(2+)-channel blocker 
verapamil on human lung cancer cell lines. Carcinogenesis, 1991. 12(12): p. 
2301-3. 
203. Schuller, H.M., Carbon dioxide potentiates the mitogenic effects of nicotine 
and its carcinogenic derivative, NNK, in normal and neoplastic 
neuroendocrine lung cells via stimulation of autocrine and protein kinase C-
dependent mitogenic pathways. Neurotoxicology, 1994. 15(4): p. 877-86. 
204. Carney, D.N., Clinical implications of the biology of small cell lung cancer. 
Eur J Respir Dis Suppl, 1987. 149: p. 5-9. 
205. Weber, S., et al., Gastrin releasing peptide is a selective mitogen for small 
cell lung carcinoma in vitro. J Clin Invest, 1985. 75(1): p. 306-9. 
206. Alexander, R.W., et al., Effects of bombesin on growth of human small cell 
lung carcinoma in vivo. Cancer Res, 1988. 48(6): p. 1439-41. 
207. North, W.G., et al., Human neurophysins as potential tumor markers for 
small cell carcinoma of the lung: application of specific radioimmunoassays. 
J Clin Endocrinol Metab, 1980. 51(4): p. 892-6. 
208. North, W.G., et al., Expression of all known vasopressin receptor subtypes by 
small cell tumors implies a multifaceted role for this neuropeptide. Cancer 
Res, 1998. 58(9): p. 1866-71. 
209. Coulson, J.M., et al., Detection of small cell lung cancer by RT-PCR for 
neuropeptides, neuropeptide receptors, or a splice variant of the neuron 
restrictive silencer factor. Methods Mol Med, 2003. 75: p. 335-52. 
210. Chaudhry, A., et al., Phase I and Imaging Trial of a Monoclonal Antibody 
Directed against Gastrin-releasing Peptide in Patients with Lung Cancer. 
Clinical Cancer Research, 1999. 5(11): p. 3385-3393. 
211. Mahmoud, S., et al., [Psi 13,14] bombesin analogues inhibit growth of small 
cell lung cancerin vitro and in vivo. Cancer Res, 1991. 51(7): p. 1798-802. 
212. Datar, P., et al., Substance P: structure, function, and therapeutics. Curr Top 
Med Chem, 2004. 4(1): p. 75-103. 
213. Woll, P.J. and E. Rozengurt, A neuropeptide antagonist that inhibits the 
growth of small cell lung cancer in vitro. Cancer Res, 1990. 50(13): p. 3968-
73. 
214. Woll, P.J. and E. Rozengurt, [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, 
a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth 
of human small cell lung cancer cells in vitro. Proc Natl Acad Sci U S A, 
1988. 85(6): p. 1859-63. 
215. Hruby, V.J., F. al-Obeidi, and W. Kazmierski, Emerging approaches in the 
molecular design of receptor-selective peptide ligands: conformational, 
References                                                                                                                229 
 
topographical and dynamic considerations. Biochem J, 1990. 268(2): p. 249-
62. 
216. Keire, D.A., et al., The lipid-associated 3D structure of SPA, a broad-
spectrum neuropeptide antagonist with anticancer properties. Biophys J, 
2006. 91(12): p. 4478-89. 
217. Seckl, M.J., T. Higgins, and E. Rozengurt, [D-Arg1,D-
Trp5,7,9,Leu11]Substance P coordinately and reversibly inhibits bombesin- 
and vasopressin-induced signal transduction pathways in Swiss 3T3 cells. J 
Biol Chem, 1996. 271(46): p. 29453-60. 
218. Woll, P.J. and E. Rozengurt, Two classes of antagonist interact with 
receptors for the mitogenic neuropeptides bombesin, bradykinin, and 
vasopressin. Growth Factors, 1988. 1(1): p. 75-83. 
219. Sethi, T. and E. Rozengurt, Galanin stimulates Ca2+ mobilization, inositol 
phosphate accumulation, and clonal growth in small cell lung cancer cells. 
Cancer Res, 1991. 51(6): p. 1674-9. 
220. Langdon, S., et al., Broad spectrum neuropeptide antagonists inhibit the 
growth of small cell lung cancer in vivo. Cancer Res, 1992. 52(16): p. 4554-
7. 
221. MacKinnon, A.C., et al., [Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) 
activates JNK and induces apoptosis in small cell lung cancer cells via an 
oxidant-dependent mechanism. Br J Cancer, 1999. 80(7): p. 1026-34. 
222. Mousli, M., et al., G protein activation: a receptor-independent mode of 
action for cationic amphiphilic neuropeptides and venom peptides. Trends in 
Pharmacological Sciences, 1990. 11(9): p. 358-362. 
223. Jarpe, M.B., et al., [D-Arg1,D-Phe5,D-Trp7,9,Leu11]Substance P acts as a 
biased agonist toward neuropeptide and chemokine receptors. J Biol Chem, 
1998. 273(5): p. 3097-104. 
224. MacKinnon, A.C., et al., Bombesin and substance P analogues differentially 
regulate G-protein coupling to the bombesin receptor. Direct evidence for 
biased agonism. J Biol Chem, 2001. 276(30): p. 28083-91. 
225. MacKinnon, A.C., et al., Targeting V1A-vasopressin receptors with [Arg6, 
D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop 
novel anti-cancer therapies. Br J Pharmacol, 2009. 156(1): p. 36-47. 
226. MacKinnon, A.C., et al., [Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-
11) (antagonist G) induces AP-1 transcription and sensitizes cells to 
chemotherapy. Br J Cancer, 2000. 83(7): p. 941-8. 
227. Berendsen, H.H., et al., Characterization of Three Small Cell Lung Cancer 
Cell Lines Established from One Patient during Longitudinal Follow-up. 
Cancer Research, 1988. 48(23): p. 6891-6899. 
228. de Vries, E.G.E., et al., Resistance Mechanisms in Three Human Small Cell 
Lung Cancer Cell Lines Established from One Patient during Clinical 
Follow-up. Cancer Research, 1989. 49(15): p. 4175-4178. 
229. Ricci-Vitiani, L., et al., Influence of local environment on the differentiation 
of neural stem cells engrafted onto the injured spinal cord. Neurol Res, 2006. 
28(5): p. 488-92. 
230. Hodkinson, P.S., et al., ECM overrides DNA damage-induced cell cycle 
arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-
References                                                                                                                230 
 
dependent activation of PI3-kinase. Cell Death Differ, 2006. 13(10): p. 1776-
88. 
231. Moore, S.M., et al., The presence of a constitutively active phosphoinositide 
3-kinase in small cell lung cancer cells mediates anchorage-independent 
proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer 
Res, 1998. 58(22): p. 5239-47. 
232. Spatzenegger, M. and W. Jaeger, Clinical importance of hepatic cytochrome 
P450 in drug metabolism. Drug Metab Rev, 1995. 27(3): p. 397-417. 
233. Wiegand, H.J., et al., Toxicology of engineered nanomaterials - introduction. 
Toxicol Lett, 2009. 186(3): p. 147. 
234. Grynkiewicz, G., M. Poenie, and R.Y. Tsien, A new generation of Ca2+ 
indicators with greatly improved fluorescence properties. J Biol Chem, 1985. 
260(6): p. 3440-50. 
235. Takahashi, A., et al., Measurement of intracellular calcium. Physiol Rev, 
1999. 79(4): p. 1089-125. 
236. Jiang, T., et al., Achaete-scute complex homologue 1 regulates tumor-
initiating capacity in human small cell lung cancer. Cancer Res, 2009. 69(3): 
p. 845-54. 
237. Yu, X., et al., CD133, Stem Cells, and Cancer Stem Cells: Myth or Reality? 
Curr Colorectal Cancer Rep. 7(4): p. 253-259. 
238. Greve, B., et al., Flow cytometry in cancer stem cell analysis and separation. 
Cytometry A. 
239. Carney, D.N., et al., Establishment and identification of small cell lung 
cancer cell lines having classic and variant features. Cancer Res, 1985. 
45(6): p. 2913-23. 
240. Franken, N.A., et al., Clonogenic assay of cells in vitro. Nat Protoc, 2006. 
1(5): p. 2315-9. 
241. Carney, D.N., A.F. Gazdar, and J.D. Minna, Positive correlation between 
histological tumor involvement and generation of tumor cell colonies in 
agarose in specimens taken directly from patients with small-cell carcinoma 
of the lung. Cancer Res, 1980. 40(6): p. 1820-3. 
242. Freedman, V.H. and S.I. Shin, Cellular tumorigenicity in nude mice: 
correlation with cell growth in semi-solid medium. Cell, 1974. 3(4): p. 355-9. 
243. Herman, I.M., Actin isoforms. Curr Opin Cell Biol, 1993. 5(1): p. 48-55. 
244. Salnikov, A.V., et al., CD133 is indicative for a resistance phenotype but 
does not represent a prognostic marker for survival of non-small cell lung 
cancer patients. Int J Cancer. 126(4): p. 950-8. 
245. Lucas, J.N. and D. Pinkel, Orientation measurements of microsphere 
doublets and metaphase chromosomes in flow. Cytometry, 1986. 7(6): p. 575-
81. 
246. Hodkinson, P.S., A.C. Mackinnon, and T. Sethi, Extracellular matrix 
regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol, 
2007. 83(11-12): p. 733-41. 
247. Sartorius, U.A. and P.H. Krammer, Upregulation of Bcl-2 is involved in the 
mediation of chemotherapy resistance in human small cell lung cancer cell 
lines. Int J Cancer, 2002. 97(5): p. 584-92. 
248. Luo, J., B.D. Manning, and L.C. Cantley, Targeting the PI3K-Akt pathway in 
human cancer: rationale and promise. Cancer Cell, 2003. 4(4): p. 257-62. 
References                                                                                                                231 
 
249. Hsia, T.C., et al., Relationship between chemotherapy response of small cell 
lung cancer and P-glycoprotein or multidrug resistance-related protein 
expression. Lung, 2002. 180(3): p. 173-9. 
250. Jain, N., et al., Mechanisms of resistance of human small cell lung cancer 
lines selected in VP-16 and cisplatin. Cancer, 1996. 77(9): p. 1797-808. 
251. Wojtalla, A. and A. Arcaro, Targeting phosphoinositide 3-kinase signalling 
in lung cancer. Crit Rev Oncol Hematol. 80(2): p. 278-90. 
252. Keely, P.J., et al., Cdc42 and Rac1 induce integrin-mediated cell motility and 
invasiveness through PI(3)K. Nature, 1997. 390(6660): p. 632-6. 
253. Chen, W., et al., Anti-human CD133 monoclonal antibody that could inhibit 
the proliferation of colorectal cancer cells. Hybridoma (Larchmt). 29(4): p. 
305-10. 
254. Cortes-Dericks, L., et al., High expression of octamer-binding transcription 
factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates 
involvement in the initiation of lung adenocarcinoma resulting in shorter 
disease-free intervals. Eur J Cardiothorac Surg. 41(6): p. e173-81. 
255. Pan, G.J., et al., Stem cell pluripotency and transcription factor Oct4. Cell 
Res, 2002. 12(5-6): p. 321-9. 
256. Kennedy, J.A., et al., Comment on "Tumor growth need not be driven by rare 
cancer stem cells". Science, 2007. 318(5857): p. 1722; author reply 1722. 
257. Eyler, C.E. and J.N. Rich, Survival of the fittest: cancer stem cells in 
therapeutic resistance and angiogenesis. J Clin Oncol, 2008. 26(17): p. 2839-
45. 
258. Lee, H.E., et al., An increase in cancer stem cell population after primary 
systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer. 
104(11): p. 1730-1738. 
259. Corti, S., et al., Isolation and characterization of murine neural 
stem/progenitor cells based on Prominin-1 expression. Exp Neurol, 2007. 
205(2): p. 547-62. 
260. Clement, V., et al., Limits of CD133 as a marker of glioma self-renewing 
cells. Int J Cancer, 2009. 125(1): p. 244-8. 
261. Dean, M., T. Fojo, and S. Bates, Tumour stem cells and drug resistance. Nat 
Rev Cancer, 2005. 5(4): p. 275-84. 
262. Vermeulen, L., et al., Cancer stem cells--old concepts, new insights. Cell 
Death Differ, 2008. 15(6): p. 947-58. 
263. Neuzil, J., et al., Tumour-initiating cells vs. cancer 'stem' cells and CD133: 
what's in the name? Biochem Biophys Res Commun, 2007. 355(4): p. 855-9. 
264. Pallini, R., et al., Cancer stem cell analysis and clinical outcome in patients 
with glioblastoma multiforme. Clin Cancer Res, 2008. 14(24): p. 8205-12. 
265. Nichols, J., et al., Formation of pluripotent stem cells in the mammalian 
embryo depends on the POU transcription factor Oct4. Cell, 1998. 95(3): p. 
379-91. 
266. Graham, S.M., et al., Primitive, quiescent, Philadelphia-positive stem cells 
from patients with chronic myeloid leukemia are insensitive to STI571 in 
vitro. Blood, 2002. 99(1): p. 319-25. 
267. Dean, M., ABC transporters, drug resistance, and cancer stem cells. J 
Mammary Gland Biol Neoplasia, 2009. 14(1): p. 3-9. 
References                                                                                                                232 
 
268. Bepler, G., et al., Establishment, growth properties, and morphological 
characteristics of permanent human small cell lung cancer cell lines. J 
Cancer Res Clin Oncol, 1987. 113(1): p. 31-40. 
269. Yokoyama, M., et al., Influence of fetal calf serum on differentiation of 
mesenchymal stem cells to chondrocytes during expansion. J Biosci Bioeng, 
2008. 106(1): p. 46-50. 
270. Ke, C.-C., et al., High pluripotent status and metastatic ability of CD133 
positive cells in primary papillary thyroid cancer. J NUCL MED MEETING 
ABSTRACTS. 51(2_MeetingAbstracts): p. 1128-. 
271. Maeda, S., et al., CD133 expression is correlated with lymph node metastasis 
and vascular endothelial growth factor-C expression in pancreatic cancer. Br 
J Cancer, 2008. 98(8): p. 1389-97. 
272. Dalerba, P. and M.F. Clarke, Cancer stem cells and tumor metastasis: first 
steps into uncharted territory. Cell Stem Cell, 2007. 1(3): p. 241-2. 
273. Rygaard, K., et al., Expression of cadherin and NCAM in human small cell 
lung cancer cell lines and xenografts. Br J Cancer, 1992. 65(4): p. 573-7. 
274. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 
100(1): p. 57-70. 
275. Fischer, B., M. Marinov, and A. Arcaro, Targeting receptor tyrosine kinase 
signalling in small cell lung cancer (SCLC): what have we learned so far? 
Cancer Treat Rev, 2007. 33(4): p. 391-406. 
276. Nicholson, K.M. and N.G. Anderson, The protein kinase B/Akt signalling 
pathway in human malignancy. Cell Signal, 2002. 14(5): p. 381-95. 
277. Gao, M.Q., et al., CD24+ cells from hierarchically organized ovarian cancer 
are enriched in cancer stem cells. Oncogene. 29(18): p. 2672-80. 
278. Fillmore, C.M. and C. Kuperwasser, Human breast cancer cell lines contain 
stem-like cells that self-renew, give rise to phenotypically diverse progeny 
and survive chemotherapy. Breast Cancer Res, 2008. 10(2): p. R25. 
279. Coller, H.A., L. Sang, and J.M. Roberts, A new description of cellular 
quiescence. PLoS Biol, 2006. 4(3): p. e83. 
280. Potten, C.S., Stem cells in gastrointestinal epithelium: numbers, 
characteristics and death. Philos Trans R Soc Lond B Biol Sci, 1998. 
353(1370): p. 821-30. 
281. Fuchs, E., T. Tumbar, and G. Guasch, Socializing with the neighbors: stem 
cells and their niche. Cell, 2004. 116(6): p. 769-78. 
282. Borovski, T., et al., Cancer stem cell niche: the place to be. Cancer Res. 
71(3): p. 634-9. 
283. Boral, D. and D. Nie, Cancer stem cells and niche mircoenvironments. Front 
Biosci (Elite Ed). 4: p. 2502-14. 
284. Sethi, T., et al., Extracellular matrix proteins protect small cell lung cancer 
cells against apoptosis: a mechanism for small cell lung cancer growth and 
drug resistance in vivo. Nat Med, 1999. 5(6): p. 662-8. 
285. Garcia Campelo, M.R., et al., Stem cell and lung cancer development: 
blaming the Wnt, Hh and Notch signalling pathway. Clin Transl Oncol. 
13(2): p. 77-83. 
286. Collins, B.J., W. Kleeberger, and D.W. Ball, Notch in lung development and 
lung cancer. Semin Cancer Biol, 2004. 14(5): p. 357-64. 
References                                                                                                                233 
 
287. Sullivan, J.P., et al., Aldehyde dehydrogenase activity selects for lung 
adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 
70(23): p. 9937-48. 
288. Clement, V., et al., HEDGEHOG-GLI1 signaling regulates human glioma 
growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol, 2007. 
17(2): p. 165-72. 
289. Clarke, M.F., et al., Cancer stem cells--perspectives on current status and 
future directions: AACR Workshop on cancer stem cells. Cancer Res, 2006. 
66(19): p. 9339-44. 
290. Quintana, E., et al., Efficient tumour formation by single human melanoma 
cells. Nature, 2008. 456(7222): p. 593-8. 
291. Wolf, C., et al., Metastasis to the appendix: sonographic appearance and 
review of the literature. J Ultrasound Med, 1999. 18(1): p. 23-5. 
292. Pol, M., et al., MRI in detection of brain metastases at initial staging of 
small-cell lung cancer. Neuroradiology, 1996. 38(3): p. 207-210. 
293. Komaki, R., J.D. Cox, and W. Whitson, Risk of brain metastasis from small 
cell carcinoma of the lung related to length of survival and prophylactic 
irradiation. Cancer Treat Rep, 1981. 65(9-10): p. 811-4. 
294. Brabletz, T., et al., Opinion: migrating cancer stem cells - an integrated 
concept of malignant tumour progression. Nat Rev Cancer, 2005. 5(9): p. 
744-9. 
295. Gilchrist, A.J., et al., Cell adhesion-mediated transformation of a human 
SCLC cell line is associated with the development of a normal phenotype. 
Exp Cell Res, 2002. 276(1): p. 63-78. 
296. Pirozzi, G., et al., Epithelial to mesenchymal transition by TGFbeta-1 
induction increases stemness characteristics in primary non small cell lung 
cancer cell line. PLoS One. 6(6): p. e21548. 
297. Hermann, P.C., et al., Distinct populations of cancer stem cells determine 
tumor growth and metastatic activity in human pancreatic cancer. Cell Stem 
Cell, 2007. 1(3): p. 313-23. 
298. Fulda, S. and S. Pervaiz, Apoptosis signaling in cancer stem cells. Int J 
Biochem Cell Biol. 42(1): p. 31-8. 
299. Tagscherer, K.E., et al., Apoptosis-based treatment of glioblastomas with 
ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. 
Oncogene, 2008. 27(52): p. 6646-56. 
300. Wang, Y.K., et al., Activation of Akt and MAPK pathways enhances the 
tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis. 31(8): 
p. 1376-80. 
301. Vivanco, I. and C.L. Sawyers, The phosphatidylinositol 3-Kinase AKT 
pathway in human cancer. Nat Rev Cancer, 2002. 2(7): p. 489-501. 
302. Sorenson, G.D., et al., Hormone production by cultures of small-cell 
carcinoma of the lung. Cancer, 1981. 47(6): p. 1289-96. 
303. Seckl, M. and E. Rozengurt, Substance P analogues act as broad-spectrum 
neuropeptide antagonists. Letters in Peptide Science, 1998. 5(2): p. 199-204. 
304. Reubi, J.C., et al., Y(1)-mediated effect of neuropeptide Y in cancer: breast 
carcinomas as targets. Cancer Res, 2001. 61(11): p. 4636-41. 
305. Rozengurt, E. and J.H. Walsh, Gastrin, CCK, signaling, and cancer. Annu 
Rev Physiol, 2001. 63: p. 49-76. 
References                                                                                                                234 
 
306. Ryder, N.M., et al., G protein-coupled receptor signaling in human ductal 
pancreatic cancer cells: neurotensin responsiveness and mitogenic 
stimulation. J Cell Physiol, 2001. 186(1): p. 53-64. 
307. Rozengurt, E., Neuropeptides as growth factors for normal and cancerous 
cells. Trends Endocrinol Metab, 2002. 13(3): p. 128-34. 
308. Pansky, A., et al., Gastrin releasing peptide-preferring bombesin receptors 
mediate growth of human renal cell carcinoma. J Am Soc Nephrol, 2000. 
11(8): p. 1409-18. 
309. Taneja, T.K. and S.K. Sharma, Markers of small cell lung cancer. World J 
Surg Oncol, 2004. 2: p. 10. 
310. Folny, V., et al., Pancreatic vasopressin V1b receptors: characterization in 
In-R1-G9 cells and localization in human pancreas. Am J Physiol Endocrinol 
Metab, 2003. 285(3): p. E566-76. 
311. Ocejo-Garcia, M., et al., Use of RT-PCR to detect co-expression of 
neuropeptides and their receptors in lung cancer. Lung Cancer, 2001. 33(1): 
p. 1-9. 
312. Kim, J.J. and I.F. Tannock, Repopulation of cancer cells during therapy: an 
important cause of treatment failure. Nat Rev Cancer, 2005. 5(7): p. 516-25. 
313. Corjay, M.H., et al., Two distinct bombesin receptor subtypes are expressed 
and functional in human lung carcinoma cells. J Biol Chem, 1991. 266(28): 
p. 18771-9. 
314. Millar, J.B. and E. Rozengurt, Heterologous desensitization of bombesin-
induced mitogenesis by prolonged exposure to vasopressin: a post-receptor 
signal transduction block. Proc Natl Acad Sci U S A, 1989. 86(9): p. 3204-8. 
315. Millar, J.B. and E. Rozengurt, Chronic desensitization to bombesin by 
progressive down-regulation of bombesin receptors in Swiss 3T3 cells. 
Distinction from acute desensitization. J Biol Chem, 1990. 265(20): p. 12052-
8. 
316. Ferrand, A., et al., Expression of gastrin precursors by CD133-positive 
colorectal cancer cells is crucial for tumour growth. Biochim Biophys Acta, 
2009. 1793(3): p. 477-88. 
317. Ferris, H.A., et al., Constitutive activation of the gastrin-releasing peptide 
receptor expressed by the nonmalignant human colon epithelial cell line 
NCM460. J Clin Invest, 1997. 100(10): p. 2530-7. 
318. Chaudhry, A., et al., Phase I and imaging trial of a monoclonal antibody 
directed against gastrin-releasing peptide in patients with lung cancer. Clin 
Cancer Res, 1999. 5(11): p. 3385-93. 
319. Jones, D.A., et al., Metabolism of the anticancer peptide H-Arg-D-Trp-
NmePhe-D-Trp-Leu-Met-NH2. Peptides, 1995. 16(5): p. 777-83. 
320. Cummings, J., et al., Pharmacokinetics, metabolism and tumour disposition 
of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and 
xenograft bearing mice. Ann Oncol, 1996. 7(3): p. 291-6. 
321. Sandberg, B.E., et al., Synthesis and biological properties of enzyme-resistant 
analogues of substance P. Eur J Biochem, 1981. 114(2): p. 329-37. 
322. Cummings, J., et al., Stability and in vitro metabolism of the mitogenic 
neuropeptide antagonists [D-Arg1,D-Phe5, D-Trp7,9, Leu11]-substance P 
and [Arg6, D-Trp7,9, MePhe8]-substance P (6-11) characterized by high-
References                                                                                                                235 
 
performance liquid chromatography. J Pharm Biomed Anal, 1994. 12(6): p. 
811-9. 
323. Powell, M.F., et al., Peptide stability in drug development. II. Effect of single 
amino acid substitution and glycosylation on peptide reactivity in human 
serum. Pharm Res, 1993. 10(9): p. 1268-73. 
324. Chatterjee, J., et al., N-methylation of peptides: a new perspective in 
medicinal chemistry. Acc Chem Res, 2008. 41(10): p. 1331-42. 
325. Gazdar, A.F., et al., Characterization of variant subclasses of cell lines 
derived from small cell lung cancer having distinctive biochemical, 
morphological, and growth properties. Cancer Res, 1985. 45(6): p. 2924-30. 
326. Krystal, G.W., G. Sulanke, and J. Litz, Inhibition of phosphatidylinositol 3-
kinase-Akt signaling blocks growth, promotes apoptosis, and enhances 
sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther, 
2002. 1(11): p. 913-22. 
327. Hoffman, R.M., Orthotopic metastatic mouse models for anticancer drug 
discovery and evaluation: a bridge to the clinic. Invest New Drugs, 1999. 
17(4): p. 343-59. 
328. Krystal, G., et al., Multiple mechanisms for transcriptional regulation of the 
myc gene family in small-cell lung cancer. Mol Cell Biol, 1988. 8(8): p. 
3373-81. 
329. Richardson, G.E. and B.E. Johnson, The biology of lung cancer. Semin 
Oncol, 1993. 20(2): p. 105-27. 
330. Funa, K., et al., Increased expression of N-myc in human small cell lung 
cancer biopsies predicts lack of response to chemotherapy and poor 
prognosis. Am J Clin Pathol, 1987. 88(2): p. 216-20. 
331. Degan, S., et al., Gastrin-releasing peptide, immune responses, and lung 
disease. Ann N Y Acad Sci, 2008. 1144: p. 136-47. 
 
 
